<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>b46996biexv2w1.htm
<DESCRIPTION>EX-2.1 AGREEMENT AND PLAN OF MERGER
<TEXT>
<HTML>
<HEAD>
<TITLE>Ex-2.1 Agreement and Plan of Merger</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="right">
<FONT size="2">EXHIBIT&nbsp;2.1
</FONT>
</DIV>

<P align="center">
<B><FONT size="2">AGREEMENT AND PLAN OF MERGER</FONT></B>

<DIV align="center">
<B><FONT size="2">BY AND AMONG</FONT></B>
</DIV>

<DIV align="center">
<B><FONT size="2">IDEC PHARMACEUTICALS CORPORATION,</FONT></B>
</DIV>

<DIV align="center">
<B><FONT size="2">BRIDGES MERGER CORPORATION</FONT></B>
</DIV>

<DIV align="center">
<B><FONT size="2">AND</FONT></B>
</DIV>

<DIV align="center">
<B><FONT size="2">BIOGEN, INC.</FONT></B>
</DIV>

<DIV align="center">
<B><FONT size="2">DATED AS OF JUNE&nbsp;20, 2003</FONT></B>
</DIV>

<DIV>&nbsp;</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P align="center">
<B><FONT size="2">AGREEMENT AND PLAN OF MERGER</FONT></B>

<P align="center">
<B><FONT size="2">TABLE OF CONTENTS</FONT></B>

<CENTER>
<TABLE width="80%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="16%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="72%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE I THE MERGER</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">1</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">The Merger
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Closing
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.3
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Effective Time
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.4
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Effects of The Merger
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.5
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Purposes of the Surviving Corporation
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.6
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Organizational Documents of the Surviving
    Corporation
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.7
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Directors and Officers of the Surviving
    Corporation
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.8
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">IDEC Charter Amendment
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;1.9
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Alternative Structure
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE II EFFECTS OF THE MERGER; EXCHANGE OF
    CERTIFICATES</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">3</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;2.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Effect on Capital Stock
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;2.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Exchange of Shares and Certificates
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">4</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE III REPRESENTATIONS AND
    WARRANTIES</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">6</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;3.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Representations and Warranties of Biogen
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">6</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;3.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Representations and Warranties of IDEC and Merger
    Sub
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">20</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE IV COVENANTS RELATING TO CONDUCT OF
    BUSINESS</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">33</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;4.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Conduct of Business
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">33</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;4.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">No Solicitation
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">38</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE V ADDITIONAL AGREEMENTS</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">40</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Preparation of SEC Documents; Stockholders&#146;
    Meetings
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">40</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Accountant&#146;s Letters
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">42</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.3
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Access to Information; Confidentiality
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">42</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.4
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Reasonable Efforts
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">43</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.5
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Indemnification and Insurance
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">44</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.6
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Fees and Expenses
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">44</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.7
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Public Announcements
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">44</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.8
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Listing
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">45</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.9
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Tax-Free Reorganization Treatment
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">45</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.10
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Post-Agreement Operations
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">45</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.11
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Conveyance Taxes
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">45</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.12
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Equity Awards and Employee Benefits
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">45</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.13
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Consents of Accountants
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">47</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.14
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">IDEC Board
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">47</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.15
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Affiliate Legends
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">47</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.16
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Notification of Certain Matters
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">48</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.17
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Section&nbsp;16 Matters
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">48</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.18
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Rights Plans; State Takeover Laws
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">48</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="center"><FONT size="2">i
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<CENTER>
<TABLE width="80%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="16%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="72%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.19
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Reservation of IDEC Common Stock
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">48</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;5.20
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Actions with Respect to the New IDEC Stock Plan
    and the New IDEC Annual Bonus Plan
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">49</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE VI CONDITIONS PRECEDENT</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">49</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;6.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Conditions to Each Party&#146;s Obligation to
    Effect The Merger
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">49</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;6.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Conditions to Obligations of Biogen
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">50</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;6.3
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Conditions to Obligations of IDEC and Merger Sub
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">50</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE VII TERMINATION, AMENDMENT AND
    WAIVER</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">51</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;7.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Termination
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">51</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;7.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Effect of Termination
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">53</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;7.3
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Payments
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">53</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;7.4
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Amendment
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">55</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;7.5
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Extension; Waiver
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">55</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD colspan="4" align="left" valign="top">
    <B><FONT size="2">ARTICLE VIII GENERAL PROVISIONS</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><B><FONT size="2">55</FONT></B></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.1
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Nonsurvival of Representations and Warranties
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">55</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.2
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Notices
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">55</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.3
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Definitions
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">56</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.4
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Terms Defined Elsewhere
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">59</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.5
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Interpretation
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">62</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.6
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Counterparts
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">62</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.7
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Entire Agreement; No Third-Party Beneficiaries
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">62</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.8
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Governing Law
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">63</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.9
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Assignment
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">63</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.10
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Consent to Jurisdiction
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">63</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.11
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Headings, etc.&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">63</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.12
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Severability
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">63</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.13
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Failure or Indulgence Not Waiver; Remedies
    Cumulative
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">63</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.14
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Waiver of Jury Trial
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">63</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SECTION&nbsp;8.15
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Specific Performance
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">64</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">EXHIBIT A
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">FORM OF IDEC CERTIFICATE OF AMENDMENT
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">A-1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="center"><FONT size="2">ii
</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P align="center">
<B><FONT size="2">AGREEMENT AND PLAN OF MERGER</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">THIS AGREEMENT AND PLAN OF MERGER (this
<I>&#147;Agreement&#148;</I>) is made and entered into as of
June&nbsp;20, 2003, by and among IDEC PHARMACEUTICALS
CORPORATION, a Delaware corporation <I>(&#147;IDEC&#148;),</I>
BRIDGES MERGER CORPORATION, a Massachusetts corporation and a
direct wholly owned subsidiary of IDEC <I>(&#147;Merger
Sub&#148;),</I> and BIOGEN, INC., a Massachusetts corporation
<I>(&#147;Biogen&#148;).</I>
</FONT>

<P align="center">
<FONT size="2">WITNESSETH:
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">WHEREAS, the respective Boards of Directors of
IDEC, Merger Sub and Biogen have deemed it advisable and in the
best interests of their respective corporations and stockholders
that IDEC and Biogen engage in a business combination in a
merger of equals in order to advance their respective long-term
strategic business interests;&nbsp;and
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">WHEREAS, in furtherance thereof, the Boards of
Directors of each of IDEC, Merger Sub and Biogen have approved
this Agreement and the merger of Merger Sub with and into Biogen
with Biogen continuing as the surviving corporation (the
<I>&#147;Merger&#148;</I>), upon the terms and subject to the
conditions set forth in this Agreement and in accordance with
the provisions of the Massachusetts Business Corporation Law
(the <I>&#147;MBCL&#148;</I>);&nbsp;and
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">WHEREAS, the Board of Directors of Biogen has
determined to recommend to its stockholders the approval and
adoption of this Agreement and the Merger; and
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">WHEREAS, the Board of Directors of IDEC has
determined to recommend to its stockholders approval of the IDEC
Charter Amendment (as defined in <I>Section&nbsp;1.8</I>) and
the issuance of shares of IDEC Common Stock (as defined in
<I>Section&nbsp;2.1(a)</I>) in connection with the Merger (the
<I>&#147;Share Issuance&#148;</I>);&nbsp;and
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">WHEREAS, IDEC, as the sole stockholder of Merger
Sub, has approved this Agreement and the Merger;&nbsp;and
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">WHEREAS, for United States federal income tax
purposes, it is intended that the Merger shall qualify as a
reorganization within the meaning of Section&nbsp;368(a) of the
Internal Revenue Code of 1986, as amended (the
<I>&#147;Code&#148;</I>), and this Agreement is intended to be,
and is hereby, adopted as a plan of reorganization within the
meaning of Section&nbsp;368 of the Code.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">NOW, THEREFORE, in consideration of the foregoing
and the representations, warranties, covenants and agreements
set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged,
the parties agree as follows:
</FONT>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;I</FONT></B>

<P align="center">
<B><FONT size="2">THE MERGER</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The
Merger.</I> Upon the terms and subject to the conditions set
forth in this Agreement, and in accordance with the MBCL, at the
Effective Time (as defined in <I>Section&nbsp;1.3</I>), Merger
Sub shall be merged with and into Biogen, the separate corporate
existence of Merger Sub shall cease and Biogen shall continue as
the surviving corporation in the Merger (the <I>&#147;Surviving
Corporation&#148;</I>) and shall succeed to and assume all the
property, rights, privileges, powers and franchises of Merger
Sub in accordance with the MBCL.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Closing.</I>
The closing of the Merger (the <I>&#147;Closing&#148;</I>) shall
take place at 10:00&nbsp;a.m., Boston time, on a date to be
specified by the parties, which shall be no later than the
second business day after satisfaction or waiver of all of the
conditions set forth in <I>Article&nbsp;VI</I> (other than
delivery of items to be delivered at the Closing and other than
those conditions that by their nature are to be satisfied at the
Closing, it being understood that the occurrence of the Closing
shall remain subject to the delivery of such
</FONT>

<P align="center"><FONT size="2">1
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="left">
<FONT size="2">items and the satisfaction or waiver of such
conditions at the Closing) at the offices of Skadden, Arps,
Slate, Meagher&nbsp;&#38; Flom LLP, One Beacon Street, Boston,
Massachusetts, unless another time, date or place is agreed to
in writing by the parties hereto. The date on which the Closing
occurs is referred to herein as the <I>&#147;Closing
Date.&#148;</I>
</FONT>
</DIV>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Effective
Time.</I> Subject to the terms and conditions of this Agreement,
as soon as practicable on the Closing Date, the parties shall
cause the Merger to be consummated by filing articles of merger
executed in accordance with the relevant provisions of the MBCL
(the <I>&#147;Articles of Merger&#148;</I>) with the Secretary
of State of the Commonwealth of Massachusetts (the
<I>&#147;Secretary of State&#148;</I>) and shall make all other
filings or recordings required under the MBCL. The Merger shall
become effective at such time as the Articles of Merger are duly
filed with the Secretary of State, or at such subsequent date or
time as IDEC and Biogen shall agree and specify in the Articles
of Merger. The time at which the Merger becomes effective is
referred to herein as the <I>&#147;Effective Time.&#148;</I>
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Effects
of The Merger.</I> At the Effective Time, the Merger shall have
the effects set forth in this Agreement and in the applicable
provisions of the MBCL.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Purposes
of the Surviving Corporation.</I> The purposes of the Surviving
Corporation shall be as set forth in Article&nbsp;2 of the
articles of organization of the Surviving Corporation.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Organizational
Documents of the Surviving Corporation.</I> At the Effective
Time, the Biogen Charter (as defined in
<I>Section&nbsp;3.1(a)(ii)</I>) shall be amended and restated in
its entirety to be identical to the articles of organization of
Merger Sub, as in effect immediately prior to the Effective
Time, until thereafter amended in accordance with the MBCL and
as provided in such articles of organization; <I>provided,
however,</I> that at the Effective Time, Article&nbsp;I of the
articles of organization of the Surviving Corporation shall be
amended and restated in its entirety to read as follows:
&#147;The name of the corporation is Biogen, Inc.&#148; After
the Effective Time, the authorized capital stock of the
Surviving Corporation shall consist of 1,000&nbsp;shares of
common stock, par value $.01&nbsp;per share. At the Effective
Time, the Biogen By-Laws (as defined in
<I>Section&nbsp;3.1(a)(ii)</I>) shall be amended and restated in
their entirety to be identical to the by-laws of Merger Sub, as
in effect immediately prior to the Effective Time, until
thereafter amended in accordance with the MBCL and as provided
in such by-laws.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Directors
and Officers of the Surviving Corporation.</I> The initial
directors of the Surviving Corporation shall be the IDEC
Designated Directors (as defined in <I>Section&nbsp;5.14</I>)
and the Biogen Designated Directors (as defined in
<I>Section&nbsp;5.14</I>), until their respective successors are
duly elected or appointed and qualified. The initial officers of
the Surviving Corporation shall be the officers of Biogen
immediately prior to the Effective Time, until their respective
successors are duly appointed.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>IDEC
Charter Amendment.</I> Immediately prior to the Effective Time,
and subject to the terms and conditions of this Agreement and
receipt of IDEC Stockholder Approval (as defined in
<I>Section&nbsp;3.2(c)(iii)</I>), pursuant to the applicable
provisions of Delaware General Corporation Law, IDEC shall cause
the IDEC Charter (as defined in <I>Section&nbsp;3.2(a)(ii)</I>)
to be amended (the <I>&#147;IDEC Charter Amendment&#148;</I>) to
(i)&nbsp;change the name of IDEC to &#147;BIOGEN IDEC,
INC.&#148; and (ii)&nbsp;increase the number of authorized
shares of IDEC Common Stock to one billion (1,000,000,000)
shares, by filing a Certificate of Amendment substantially in
the form of <I>Exhibit&nbsp;A</I> hereto (the <I>&#147;IDEC
Certificate of Amendment&#148;</I>) with the Secretary of State
of the State of Delaware in accordance with applicable
provisions of the Delaware General Corporation Law.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Alternative
Structure.</I> Biogen and IDEC may mutually agree to revise the
structure of the Merger provided for herein at any time prior to
receipt of either Biogen Stockholder Approval (as defined in
<I>Section&nbsp;3.1(c)(iii)</I>) or IDEC Stockholder Approval,
or at any time thereafter if, with appropriate disclosure, any
required further approval of the revised structure is obtained
from the stockholders of Biogen and IDEC, as applicable;
<I>provided, however,</I> that under any such revised structure
the Merger would qualify as a reorganization within the meaning
of Section&nbsp;368(a) of the Code. Biogen and IDEC agree to
consider in good faith the request of the other party to revise
the structure of the Merger from that set forth herein.
</FONT>

<P align="center"><FONT size="2">2
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;II</FONT></B>

<P align="center">
<B><FONT size="2">EFFECTS OF THE MERGER; EXCHANGE OF
CERTIFICATES</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Effect
on Capital Stock.</I> Subject to the terms and conditions of
this Agreement, at the Effective Time, by virtue of the Merger
and without any action on the part of IDEC, Merger Sub, Biogen
or the holders of any shares of common stock, par value
$0.01&nbsp;per share, of Biogen (together with any associated
Biogen Rights (as defined in <I>Section&nbsp;3.1(b)(i)</I>),
<I>&#147;Biogen Common Stock&#148;</I>):
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Conversion of Biogen Common
    Stock.</I> Each share of Biogen Common Stock issued and
    outstanding immediately prior to the Effective Time, other than
    any shares of Biogen Common Stock to be canceled pursuant to
    <I>Section&nbsp;2.1(c)</I> or, subject to
    <I>Section&nbsp;2.1(g)</I>, held by a Dissenting Holder (as
    defined in <I>Section&nbsp;2.1(g)(i)</I>), shall be
    automatically converted into the right to receive 1.150 (the
    <I>&#147;Exchange Ratio&#148;</I>) fully paid and nonassessable
    shares of common stock, par value $0.0005&nbsp;per share
    <I>(&#147;IDEC Common Stock&#148;),</I> of IDEC (together with
    any associated IDEC Rights (as defined in
    <I>Section&nbsp;3.2(b)(i)</I>), the <I>&#147;Merger
    Consideration&#148;</I>)) upon surrender of the Certificate (as
    defined in <I>Section&nbsp;2.2(b)</I>) which immediately prior
    to the Effective Time represented such share of Biogen Common
    Stock in the manner provided in <I>Section&nbsp;2.2(b)</I> (or,
    in the case of a lost, stolen or destroyed certificate,
    <I>Section&nbsp;2.2(i)</I>). As a result of the Merger, at the
    Effective Time, each holder of a Certificate shall cease to have
    any rights with respect thereto, except (i)&nbsp;the right to
    receive the Merger Consideration payable in respect of the
    shares of Biogen Common Stock represented by such Certificate
    immediately prior to the Effective Time, any cash in lieu of
    fractional shares payable pursuant to <I>Section&nbsp;2.1(e)</I>
    and any dividends or other distributions payable pursuant to
    <I>Section&nbsp;2.2(c)</I>, all to be issued or paid, without
    interest, in consideration therefor upon the surrender of such
    Certificate in accordance with <I>Section&nbsp;2.2(b)</I> or
    (ii)&nbsp;in the case of a Dissenting Holder, the rights set
    forth in <I>Section&nbsp;2.1(g).</I>
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Capital Stock of Merger Sub.</I> Each
    issued and outstanding share of common stock, par value
    $0.01&nbsp;per share, of Merger Sub shall be converted into one
    fully paid and nonassessable share of common stock, par value
    $0.01&nbsp;per share, of the Surviving Corporation.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Cancellation of Treasury Shares.</I>
    Each share of Biogen Common Stock held in the treasury of
    Biogen, if any, shall automatically be extinguished without any
    conversion, and no consideration shall be delivered in respect
    thereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>Biogen Options and Employee Stock
    Purchase Plans.</I> At the Effective Time, (i)&nbsp;all options
    to purchase Biogen Common Stock (each, a <I>&#147;Biogen
    Option&#148;</I>) issued and outstanding under each Biogen Stock
    Plan (as defined in <I>Section&nbsp;3.1(b)(i)</I>) shall be
    assumed by IDEC in accordance with <I>Section&nbsp;5.12(a)</I>
    and (ii)&nbsp;all rights outstanding under Biogen&#146;s 1983
    Employee Stock Purchase Plan, as amended and restated, and the
    1994 International Employee Stock Purchase Plan, as amended and
    restated (collectively, the <I>&#147;Biogen Purchase
    Plans&#148;</I>), shall be treated as set forth in
    <I>Section&nbsp;5.12(b).</I>
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>Fractional Shares.</I> No fraction of
    a share of IDEC Common Stock will be issued by virtue of the
    Merger, but in lieu thereof each holder of shares of Biogen
    Common Stock who would otherwise be entitled to a fraction of a
    share of IDEC Common Stock (after aggregating all fractional
    shares of IDEC Common Stock that otherwise would be received by
    such holder) shall, upon surrender of such holder&#146;s
    Certificate(s), receive from IDEC an amount of cash (rounded to
    the nearest whole cent), without interest, equal to the product
    of: (i)&nbsp;such fraction, multiplied by (ii)&nbsp;the average
    closing price of one share of IDEC Common Stock for the ten
    (10)&nbsp;most recent trading days that IDEC Common Stock has
    traded ending on the trading day one day prior to the Effective
    Time, as reported on the Nasdaq National Market.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>Adjustments to Exchange Ratio.</I>
    The Exchange Ratio shall be adjusted to reflect fully the
    appropriate effect of any stock split, reverse stock split,
    stock dividend (including any dividend or distribution of
    securities convertible into IDEC Common Stock or Biogen Common
    Stock), reorganization, recapitalization, reclassification or
    other like change with respect to IDEC Common
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">3
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Stock or Biogen Common Stock having a record date
    on or after the date hereof and prior to the Effective Time.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(g)&nbsp;<I>Dissenter&#146;s Rights.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;No conversion under
    <I>Section&nbsp;2.1(a)</I> hereof shall occur with respect to
    the shares of Biogen Common Stock held by a Dissenting Holder;
    <I>provided, however,</I> that each share of Biogen Common Stock
    outstanding immediately prior to the Effective Time and held by
    a Dissenting Holder who shall, after the Effective Time,
    withdraw his demand for appraisal or lose his right of
    appraisal, in either case pursuant to the applicable provisions
    of the MBCL, shall be deemed to be converted, as of the
    Effective Time, into the Merger Consideration as set forth in
    <I>Section&nbsp;2.1(a)</I> hereof. The term <I>&#147;Dissenting
    Holder&#148;</I> shall mean a holder of Biogen Common Stock who
    has demanded appraisal rights in compliance with the applicable
    provisions of the MBCL concerning the right of such holder to
    dissent from the Merger and demand appraisal of such
    holder&#146;s shares of Biogen Common Stock.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;Any Dissenting Holder (A)&nbsp;who
    (1)&nbsp;files with Biogen a written objection to the Merger
    before the Biogen Stockholders&#146; Meeting (as defined in
    <I>Section&nbsp;5.1(b)</I>) and (2)&nbsp;states in such
    objection that he intends to demand payment for his shares if
    the Merger is consummated and (B)&nbsp;whose shares are not
    voted in favor of the Merger shall be entitled to demand payment
    from Biogen for his shares of Biogen Common Stock and an
    appraisal of the value thereof, in accordance with the
    provisions of Sections&nbsp;86 through 98 of the MBCL.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange
of Shares and Certificates.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Exchange Agent.</I> At or prior to
    the Effective Time, IDEC shall engage an institution reasonably
    satisfactory to Biogen to act as exchange agent in connection
    with the Merger (the <I>&#147;Exchange Agent&#148;</I>),
    pursuant to an agreement reasonably satisfactory to Biogen. At
    the Effective Time, IDEC shall deposit with the Exchange Agent,
    in trust for the benefit of the holders of shares of Biogen
    Common Stock immediately prior to the Effective Time,
    certificates representing the shares of IDEC Common Stock
    issuable pursuant to <I>Section&nbsp;2.1(a)</I>. In addition,
    IDEC shall make available by depositing with the Exchange Agent,
    as necessary from time to time after the Effective Time as
    needed, cash in an amount sufficient to make the payments in
    lieu of fractional shares pursuant to <I>Section&nbsp;2.1(e)</I>
    and any dividends or distributions to which holders of shares of
    Biogen Common Stock may be entitled pursuant to
    <I>Section&nbsp;2.2(c)</I>. All cash and IDEC Common Stock
    deposited with the Exchange Agent shall hereinafter be referred
    to as the <I>&#147;Exchange Fund.&#148;</I>
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Exchange Procedures.</I> Promptly
    after the Effective Time, IDEC shall cause the Exchange Agent to
    mail to each holder of record of a certificate or certificates
    which immediately prior to the Effective Time represented
    outstanding shares of Biogen Common Stock (the
    <I>&#147;Certificates&#148;</I>), which at the Effective Time
    were converted into the right to receive the Merger
    Consideration pursuant to <I>Section&nbsp;2.1</I> hereof,
    (i)&nbsp;a letter of transmittal (which shall specify that
    delivery shall be effected, and risk of loss and title to the
    Certificates shall pass only upon delivery of the Certificates
    to the Exchange Agent and shall be in such form and have such
    other provisions as IDEC may reasonably specify) and
    (ii)&nbsp;instructions for use in effecting the surrender of the
    Certificates in exchange for certificates representing whole
    shares of IDEC Common Stock, cash in lieu of any fractional
    shares pursuant to <I>Section&nbsp;2.1(e)</I> and any dividends
    or other distributions payable pursuant to
    <I>Section&nbsp;2.2(c)</I>. Upon surrender of Certificates for
    cancellation to the Exchange Agent or to such other agent or
    agents as may be appointed by IDEC, together with such letter of
    transmittal, duly completed and validly executed in accordance
    with the instructions thereto, and such other documents as may
    reasonably be required by the Exchange Agent, the holder of such
    Certificates shall be entitled to receive in exchange therefor a
    certificate representing that number of whole shares of IDEC
    Common Stock (after taking into account all Certificates
    surrendered by such holder) to which such holder is entitled
    pursuant to <I>Section&nbsp;2.1</I> (which shall be
    uncertificated book entry form unless a physical certificate is
    requested), payment in lieu of fractional shares which such
    holder is entitled to receive pursuant to
    <I>Section&nbsp;2.1(e)</I> and any dividends or distributions
    payable pursuant to <I>Section&nbsp;2.2(c)</I>, and
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">4
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">the Certificates so surrendered shall forthwith
    be canceled. In the event of a transfer of ownership of Biogen
    Common Stock which is not registered in the transfer records of
    Biogen, a certificate representing the proper number of shares
    of IDEC Common Stock may be issued to a Person (as defined in
    <I>Section&nbsp;8.3(o)</I>) other than the Person in whose name
    the Certificate so surrendered is registered, if such
    Certificate shall be properly endorsed or otherwise be in proper
    form for transfer and the Person requesting such issuance shall
    pay any transfer or other taxes required by reason of the
    issuance of shares of IDEC Common Stock to a Person other than
    the registered holder of such Certificate or establish to the
    satisfaction of IDEC that such tax has been paid or is not
    applicable. Until surrendered as contemplated by this
    <I>Section&nbsp;2.2(b)</I>, each Certificate shall be deemed at
    any time after the Effective Time to represent only the right to
    receive the Merger Consideration (and any amounts to be paid
    pursuant to <I>Section&nbsp;2.1(e)</I> or
    <I>Section&nbsp;2.2(c)</I>) upon such surrender. No interest
    shall be paid or shall accrue on any amount payable pursuant to
    <I>Section&nbsp;2.1(e)</I> or <I>Section&nbsp;2.2(c)</I>.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Distributions with Respect to
    Unexchanged Shares.</I> No dividends or other distributions with
    respect to IDEC Common Stock with a record date after the
    Effective Time shall be paid to the holder of any unsurrendered
    Certificate with respect to the shares of IDEC Common Stock
    represented thereby, and no cash payment in lieu of fractional
    shares shall be paid to any such holder pursuant to
    <I>Section&nbsp;2.1(e)</I> hereof, until such Certificate has
    been surrendered in accordance with this <I>Article&nbsp;II</I>.
    Subject to Applicable Law (as defined in
    <I>Section&nbsp;3.1(g)(i)</I>), following surrender of any such
    Certificate, there shall be paid to the recordholder thereof,
    without interest, (i)&nbsp;promptly after such surrender, the
    number of whole shares of IDEC Common Stock issuable in exchange
    therefor pursuant to this <I>Article&nbsp;II,</I> together with
    any cash payable in lieu of a fractional share of IDEC Common
    Stock to which such holder is entitled pursuant to
    <I>Section&nbsp;2.1(e)</I> and the amount of dividends or other
    distributions with a record date after the Effective Time
    theretofore paid with respect to such whole shares of IDEC
    Common Stock, and (ii)&nbsp;at the appropriate payment date, the
    amount of dividends or other distributions with a record date
    after the Effective Time and a payment date subsequent to such
    surrender payable with respect to such whole shares of IDEC
    Common Stock.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>No Further Ownership Rights in Biogen
    Common Stock.</I> All shares of IDEC Common Stock issued upon
    the surrender for exchange of Certificates in accordance with
    the terms of this <I>Article&nbsp;II</I> and any cash paid
    pursuant to <I>Section&nbsp;2.1(e)</I> or
    <I>Section&nbsp;2.2(c)</I> shall be deemed to have been issued
    (and paid) in full satisfaction of all rights pertaining to the
    shares of Biogen Common Stock previously represented by such
    Certificates. At the Effective Time, the stock transfer books of
    Biogen shall be closed and there shall be no further
    registration of transfers on the stock transfer books of the
    Surviving Corporation of the shares of Biogen Common Stock which
    were outstanding immediately prior to the Effective Time. If,
    after the Effective Time, Certificates are presented to the
    Surviving Corporation or the Exchange Agent for any reason, they
    shall be canceled and exchanged as provided in this
    <I>Article&nbsp;II</I>.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>Termination of Exchange Fund.</I> Any
    portion of the Exchange Fund which remains undistributed to the
    holders of Certificates one year after the Effective Time shall
    be delivered to IDEC, upon demand, and any holders of
    Certificates who have not theretofore complied with this
    <I>Article&nbsp;II</I> shall thereafter look only to IDEC for
    payment of their claim for the Merger Consideration, any cash in
    lieu of fractional shares of IDEC Common Stock pursuant to
    <I>Section&nbsp;2.1(e)</I> and any dividends or distributions
    pursuant to <I>Section&nbsp;2.2(c)</I>.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>No Liability.</I> None of IDEC,
    Merger Sub, Biogen or the Exchange Agent shall be liable to any
    Person in respect of any shares of IDEC Common Stock (or
    dividends or distributions with respect thereto) or cash from
    the Exchange Fund delivered to a public official pursuant to any
    applicable abandoned property, escheat or similar law. If any
    Certificate shall not have been surrendered prior to seven years
    after the Effective Time, or immediately prior to such earlier
    date on which any shares of IDEC Common Stock, any cash in lieu
    of fractional shares of IDEC Common Stock or any dividends or
    distributions with respect to IDEC Common Stock issuable in
    respect of
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">5
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">such Certificate would otherwise escheat to or
    become the property of any Governmental Entity (as defined in
    <I>Section&nbsp;3.1(c)(v)</I>), any such shares, cash, dividends
    or distributions in respect of such Certificate shall, to the
    extent permitted by Applicable Law, become the property of the
    Surviving Corporation, free and clear of all claims or interest
    of any Person previously entitled thereto.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(g)&nbsp;<I>Investment of Exchange Fund.</I> The
    Exchange Agent shall invest any cash included in the Exchange
    Fund as directed by IDEC on a daily basis <I>provided</I> that
    no such investment or loss thereon shall affect the amounts
    payable to former stockholders of Biogen after the Effective
    Time pursuant to this <I>Article&nbsp;II</I>. Any interest and
    other income resulting from such investment shall become a part
    of the Exchange Fund, and any amounts in excess of the amounts
    payable pursuant to this <I>Article&nbsp;II</I> shall promptly
    be paid to IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(h)&nbsp;<I>Withholding Rights.</I> IDEC or the
    Exchange Agent shall be entitled to deduct and withhold from any
    consideration payable pursuant to this Agreement to any Person
    who was a holder of Biogen Common Stock immediately prior to the
    Effective Time such amounts as IDEC or the Exchange Agent may be
    required to deduct and withhold with respect to the making of
    such payment under the Code, or any provision of federal, state,
    local or foreign tax law. To the extent that amounts are so
    withheld by IDEC or the Exchange Agent, such withheld amounts
    shall be treated for all purposes of this Agreement as having
    been paid to the Person to whom such consideration would
    otherwise have been paid.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>Lost, Stolen or Destroyed
    Certificates.</I> In the event any Certificates shall have been
    lost, stolen or destroyed, the Exchange Agent shall issue in
    exchange for such lost, stolen or destroyed Certificates, upon
    the making of an affidavit of that fact by the holder thereof,
    such shares of IDEC Common Stock as may be required pursuant to
    <I>Section&nbsp;2.1(a)</I>, cash for fractional shares pursuant
    to <I>Section&nbsp;2.1(e)</I> and any dividends or distributions
    payable pursuant to <I>Section&nbsp;2.2(c)</I>; <I>provided,
    however,</I> that IDEC may, in its discretion and as a condition
    precedent to the issuance thereof, require the owner of such
    lost, stolen or destroyed Certificates to deliver an agreement
    of indemnification in form reasonably satisfactory to IDEC, or a
    bond in such sum as IDEC may reasonably direct as indemnity,
    against any claim that may be made against IDEC or the Exchange
    Agent in respect of the Certificates alleged to have been lost,
    stolen or destroyed.
    </FONT></TD>
</TR>

</TABLE>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;III</FONT></B>

<P align="center">
<B><FONT size="2">REPRESENTATIONS AND WARRANTIES</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations
and Warranties of Biogen.</I> Except as set forth in the
disclosure schedule dated as of the date of this Agreement and
executed and delivered by Biogen to IDEC concurrently with or
prior to the execution and delivery by Biogen of this Agreement
(the <I>&#147;Biogen Disclosure Schedule&#148;</I>), Biogen
represents and warrants to IDEC and Merger Sub as set forth
below. Each exception set forth in the Biogen Disclosure
Schedule, and any other information included in the Biogen
Disclosure Schedule, is identified by reference to, or has been
grouped under a heading referring to, a specific individual
subsection of this Agreement and shall be deemed to be disclosed
solely for purposes of such subsection, except to the extent
that disclosure in one subsection of the Biogen Disclosure
Schedule is specifically referred to in another subsection of
the Biogen Disclosure Schedule by appropriate cross-reference.
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Organization, Standing and Corporate
    Power; Charter Documents; Subsidiaries.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>Organization, Standing and Corporate
    Power.</I> Biogen and each of its Subsidiaries (as defined in
    <I>Section&nbsp;8.3(p)</I>) is a corporation or other legal
    entity duly organized, validly existing and in good standing
    (with respect to jurisdictions which recognize such concept)
    under the laws of the jurisdiction in which it is incorporated
    or otherwise organized, and has the requisite corporate (or
    similar) power and authority to carry on its business as
    currently conducted, except for those jurisdictions in which the
    failure to be so organized, existing or in good standing would
    not, individually or in the aggregate, reasonably be likely to
    have a Material Adverse Effect (as
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">6
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">defined in <I>Section&nbsp;8.3(l)</I>) on Biogen.
    Each of Biogen and its Subsidiaries is duly qualified or
    licensed to do business and is in good standing (with respect to
    jurisdictions which recognize such concept) in each jurisdiction
    in which the nature of its business or the ownership, leasing or
    operation of its properties makes such qualification or
    licensing necessary, except for those jurisdictions where the
    failure to be so qualified or licensed or to be in good standing
    would not, individually or in the aggregate, reasonably be
    likely to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;<I>Charter Documents.</I> Biogen has
    delivered or made available to IDEC prior to the execution of
    this Agreement complete and correct copies of (A)&nbsp;the
    Articles of Organization of Biogen (including any certificates
    of designation), as amended and currently in effect (the
    <I>&#147;Biogen Charter&#148;</I>), and the by-laws of Biogen,
    as amended and currently in effect (the <I>&#147;Biogen
    By-Laws,&#148;</I> and, together with the Biogen Charter, the
    <I>&#147;Biogen Organizational Documents&#148;</I>), and
    (B)&nbsp;the certificate of incorporation and by-laws or like
    organizational documents of each of the Biogen Significant
    Subsidiaries (as defined in <I>Section&nbsp;3.1(a)(iii)</I>), as
    amended and currently in effect (collectively, the
    <I>&#147;Biogen Subsidiary Organizational Documents&#148;</I>),
    and each such instrument is in full force and effect. Biogen is
    not in violation of the Biogen Organizational Documents and no
    Biogen Significant Subsidiary is in violation of its Biogen
    Subsidiary Organizational Documents, except, in the case of such
    Biogen Significant Subsidiary, as would not reasonably be likely
    to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)<I>&nbsp;Subsidiaries.</I>
    <I>Section&nbsp;3.1(a)(iii)</I> of the Biogen Disclosure
    Schedule lists all the Subsidiaries of Biogen which as of the
    date of this Agreement are significant subsidiaries (as defined
    in Rule&nbsp;102 of Regulation&nbsp;S-X of the
    U.S.&nbsp;Securities and Exchange Commission (the
    <I>&#147;SEC&#148;</I>)) (the <I>&#147;Biogen Significant
    Subsidiaries&#148;</I>). All the outstanding shares of capital
    stock of, or other equity interests in, each Biogen Significant
    Subsidiary have been validly issued and are fully paid and
    nonassessable and are owned directly or indirectly by Biogen,
    free and clear of all pledges, claims, liens, charges,
    encumbrances and security interests of any kind or nature
    whatsoever (collectively, <I>&#147;Liens&#148;</I>) and free of
    any other restriction (including any restriction on the right to
    vote, sell or otherwise dispose of such capital stock or other
    ownership interests).
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Capital Structure.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;The authorized capital stock of Biogen
    consists of 375,000,000&nbsp;shares of Biogen Common Stock, and
    20,000,000&nbsp;shares of preferred stock, par value
    $0.01&nbsp;per share <I>(&#147;Biogen Preferred
    Stock&#148;).</I> At the close of business on May&nbsp;31, 2003,
    (A)&nbsp;148,964,583&nbsp;shares of Biogen Common Stock were
    issued and outstanding; (B)&nbsp;2,234,719&nbsp;shares of Biogen
    Common Stock were held by Biogen in its treasury; (C)&nbsp;no
    shares of Biogen Preferred Stock were issued and outstanding;
    (D)&nbsp;192,220&nbsp;shares of Biogen Common Stock were
    reserved for issuance pursuant to the Biogen Purchase Plans;
    (E)&nbsp;27,716,417&nbsp;shares of Biogen Common Stock were
    reserved for issuance pursuant to the Biogen 1982 Incentive
    Stock Option Plan, as amended and restated through
    December&nbsp;13, 2002, effective December&nbsp;31, 2002, the
    Biogen 1985 Non-Qualified Stock Option Plan, as amended and
    restated through April&nbsp;11, 2003, the Biogen 1987 Scientific
    Board Stock Option Plan, as amended and restated through
    February&nbsp;7, 2003, and the Biogen 2003 Omnibus Equity Plan
    (such plans, collectively, the <I>&#147;Biogen Stock
    Plans&#148;</I>), complete and correct copies of which, in each
    case as amended, have been filed as exhibits to the Biogen SEC
    Documents (as defined in <I>Section&nbsp;3.1(d)(i)</I>) prior to
    the date of this Agreement or delivered to IDEC; and
    (F)&nbsp;250,000&nbsp;shares of Biogen Preferred Stock were
    designated as Series&nbsp;A-1 Junior Participating Preferred
    Stock, par value $0.01&nbsp;per share, and were reserved for
    issuance upon the exercise of preferred share purchase rights
    (the <I>&#147;Biogen Rights&#148;</I>) issued pursuant to the
    Biogen Rights Agreement dated May&nbsp;8, 1999 between Biogen
    and State Street Bank and Trust Company (as successor in
    interest to First National Bank of Boston), as amended by the
    Amendment and Agreement to Rights Agreement dated as of
    May&nbsp;31, 2002 between Biogen, State Street Bank and Trust
    Company, as the old rights agent, and EquiServe Trust Company,
    N.A., as the new rights agent, and the Second Agreement and
    Amendment to Rights Agreement
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">7
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">dated as of June&nbsp;20, 2003, between Biogen
    and EquiServe Trust Company, N.A. (the <I>&#147;Biogen Rights
    Agreement&#148;</I>).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;As of the close of business on
    May&nbsp;31, 2003, 18,852,124&nbsp;shares of Biogen Common Stock
    were subject to issuance pursuant to outstanding Biogen Options
    under the Biogen Stock Plans. All shares of Biogen Common Stock
    subject to issuance under the Biogen Stock Plans and the Biogen
    Purchase Plans, upon issuance on the terms and conditions
    specified in the instruments pursuant to which they are
    issuable, will be duly authorized, validly issued, fully paid
    and nonassessable. There are no commitments or agreements of any
    character to which Biogen is bound obligating Biogen to
    accelerate the vesting of any Biogen Option as a result of the
    Merger (whether alone or upon the occurrence of any additional
    or subsequent events). There are no outstanding or authorized
    stock appreciation, phantom stock, profit participation or other
    similar rights with respect to Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;No bonds, debentures, notes or other
    evidences of indebtedness having the right to vote on any
    matters on which stockholders may vote <I>(&#147;Voting
    Debt&#148;) </I>of Biogen are issued or outstanding as of the
    date hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;Except as otherwise set forth in this
    <I>Section&nbsp;3.1(b)</I>, as of May&nbsp;31, 2003, there are
    no securities, options, warrants, calls, rights, commitments,
    agreements, arrangements or undertakings of any kind to which
    Biogen or any of its Subsidiaries is a party or by which any of
    them is bound obligating Biogen or any of its Subsidiaries to
    issue, deliver or sell, or cause to be issued, delivered or
    sold, additional shares of capital stock, Voting Debt or other
    voting securities of Biogen or any of its Subsidiaries, or
    obligating Biogen or any of its Subsidiaries to issue, grant,
    extend or enter into any such security, option, warrant, call,
    right, commitment, agreement, arrangement or undertaking. All
    outstanding shares of Biogen Common Stock, all outstanding
    Biogen Options, and all outstanding shares of capital stock of
    each Subsidiary of Biogen have been issued and granted in
    compliance in all material respects with (A)&nbsp;all applicable
    securities laws and all other Applicable Law and (B)&nbsp;all
    requirements set forth in applicable material Contracts (as
    defined in <I>Section&nbsp;8.3(d)</I>).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;Since May&nbsp;31, 2003 and through the
    date hereof, other than (A) issuances of Biogen Common Stock
    pursuant to the exercise of Biogen Options granted under Biogen
    Stock Plans and outstanding as of May&nbsp;31, 2003,
    (B)&nbsp;issuances of Biogen Common Stock pursuant to the Biogen
    Purchase Plans, (C)&nbsp;repurchases of Biogen Common Stock from
    employees of Biogen following their termination pursuant to the
    terms of their pre-existing stock option or purchase agreements,
    (D)&nbsp;issuances of Biogen Common Stock (consisting of
    newly-issued shares or shares in treasury) as contributions of
    Biogen Common Stock to defined contribution plans sponsored by
    Biogen <I>(&#147;Biogen Defined Contribution Plans&#148;)</I>
    and (E)&nbsp;grants of Biogen Options under Biogen Stock Plans
    in the ordinary course of business consistent with past
    practice, there has been no change in (1) the outstanding
    capital stock of Biogen, (2)&nbsp;the number of Biogen Options
    outstanding, or (3)&nbsp;the number of other options, warrants
    or other rights to purchase Biogen capital stock.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;Neither Biogen nor any Subsidiary of
    Biogen is a party to any currently effective agreement
    restricting the purchase or transfer of, relating to the voting
    of, requiring registration of, or granting any preemptive or
    antidilutive rights with respect to, any capital stock of Biogen
    or any of its Subsidiaries or any securities of the type
    referred to in <I>Section&nbsp;3.1(b)(iv)</I> hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;Other than its Subsidiaries, as of the
    date hereof, Biogen does not directly or indirectly beneficially
    own any securities or other beneficial ownership interests in
    any other entity except for non-controlling investments made in
    the ordinary course of business consistent with past practice in
    entities which are not individually or in the aggregate material
    to Biogen and its Subsidiaries taken as a whole.
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">8
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Authority; Board Approval; Voting
    Requirements; No Conflict; Required Filings and Consents.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>Authority.</I> Biogen has all
    requisite corporate power and authority to enter into this
    Agreement and to consummate the transactions contemplated
    hereby. The execution and delivery of this Agreement by Biogen,
    and the consummation by Biogen of the transactions contemplated
    hereby, have been duly authorized by all necessary corporate
    action on the part of Biogen, and no other corporate proceedings
    on the part of Biogen and no stockholder votes are necessary to
    authorize this Agreement or to consummate the transactions
    contemplated hereby, other than with respect to approval of this
    Agreement and the Merger, the Biogen Stockholder Approval. This
    Agreement has been duly executed and delivered by Biogen.
    Assuming the due authorization, execution and delivery of this
    Agreement by IDEC and Merger Sub, this Agreement constitutes the
    legal, valid and binding obligation of Biogen enforceable
    against Biogen in accordance with its terms, subject to
    applicable bankruptcy, insolvency, reorganization, moratorium or
    other laws relating to or affecting the rights and remedies of
    creditors generally and to general principles of equity
    (regardless of whether considered in a proceeding in equity or
    at law).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)<I>&nbsp;Board Approval.</I> The Board of
    Directors of Biogen has (A) determined that this Agreement and
    the Merger are advisable and fair to and in the best interest of
    Biogen and its stockholders, (B)&nbsp;approved and adopted this
    Agreement, the Merger and the other transactions contemplated
    hereby, which adoption has not been rescinded or modified,
    (C)&nbsp;resolved (subject to <I>Section&nbsp;4.2(d)</I>) to
    recommend this Agreement and the Merger to its stockholders for
    approval and (D)&nbsp;directed that this Agreement and the
    Merger be submitted to its stockholders for consideration in
    accordance with this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)<I>&nbsp;Voting Requirements.</I> The
    affirmative vote in favor of approval of this Agreement and the
    Merger by the holders of a majority of the outstanding shares of
    Biogen Common Stock entitled to vote thereon at a duly convened
    and held Biogen Stockholders&#146; Meeting (the <I>&#147;Biogen
    Stockholder Approval&#148;</I>) is the only vote of the holders
    of any class or series of Biogen&#146;s capital stock necessary
    to approve and adopt this Agreement, the Merger and the other
    transactions contemplated hereby.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)<I>&nbsp;No Conflict.</I> The execution and
    delivery of this Agreement by Biogen does not, and the
    consummation by Biogen of the transactions contemplated hereby
    and compliance by Biogen with the provisions of this Agreement
    will not, conflict with, or result in any violation of, or
    default (with or without notice or lapse of time, or both)
    under, require any consent, waiver or approval under, give rise
    to any right of termination or other right, or the cancellation
    or acceleration of any right or obligation or loss of a benefit
    under, or result in the creation of any Lien upon any of the
    properties or assets of Biogen or any of its Subsidiaries or any
    restriction on the conduct of Biogen&#146;s business or
    operations under, (A)&nbsp;the Biogen Organizational Documents
    or the Biogen Subsidiary Organizational Documents, (B)&nbsp;any
    Contract, permit, concession, franchise, license or
    authorization applicable to Biogen or any of its Subsidiaries or
    their respective properties or assets, or (C)&nbsp;subject to
    the governmental filings and other matters referred to in
    <I>Section&nbsp;3.1(c)(v)</I>, any judgment, order, decree,
    statute, law, ordinance, rule or regulation applicable to Biogen
    or any of its Subsidiaries or their respective properties or
    assets, other than, in the case of clauses&nbsp;(B)&nbsp;and
    (C), any such conflicts, violations, defaults, rights, losses,
    restrictions or Liens, or failure to obtain consents, waivers or
    approvals, which, individually or in the aggregate, would not
    reasonably be likely to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;<I>Required Filings or Consents.</I> No
    consent, approval, order or authorization of, action by or in
    respect of, or registration, declaration or filing with, any
    federal, state, local or foreign government, any court,
    administrative, regulatory or other governmental agency,
    commission or authority or any non-governmental self-regulatory
    agency, commission or authority (a <I>&#147;Governmental
    Entity&#148;</I>) is required to be made or obtained by or with
    respect to Biogen or any of its
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">9
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Subsidiaries in connection with the execution and
    delivery of this Agreement by Biogen or the consummation by
    Biogen of the transactions contemplated hereby, except for:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(A)&nbsp;the filing of a pre-merger notification
    and report form by Biogen under the Hart-Scott-Rodino
    Antitrust&nbsp;Improvements Act of 1976, as amended (the
    <I>&#147;HSR Act&#148;</I>), and any applicable filings or
    notifications under the antitrust, competition or similar laws
    of any foreign jurisdiction;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(B)&nbsp;the filing with the SEC of:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="13%"></TD>
    <TD width="87%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(1)&nbsp;a proxy statement relating to the Biogen
    Stockholders&#146; Meeting (such proxy statement, together with
    the proxy statement relating to the IDEC Stockholders&#146;
    Meeting (as defined in <I>Section&nbsp;5.1(b)</I>), in each case
    as amended or supplemented from time to time, the <I>&#147;Joint
    Proxy Statement&#148;</I>);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(2)&nbsp;such reports under Section&nbsp;13(a),
    13(d), 15(d) or 16(a) of the Securities Exchange Act of 1934, as
    amended (the <I>&#147;Exchange Act&#148;</I>), as may be
    required in connection with this Agreement and the transactions
    contemplated hereby;
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(C)&nbsp;the filing of the Articles of Merger
    with the Secretary of State and appropriate documents with the
    relevant authorities of other states in which Biogen is
    qualified to do business and such filings with state securities
    or other &#147;blue sky&#148; laws;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(D)&nbsp;such consents, approvals, orders or
    authorizations, the failure of which to be made or obtained,
    individually or in the aggregate, would not reasonably be likely
    to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>SEC Documents; Financial
    Statements.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;Biogen has filed with the SEC all
    registration statements, prospectuses, reports, schedules,
    forms, statements, certifications and other documents (including
    exhibits and all other information incorporated by reference
    therein) required to be so filed by Biogen since January&nbsp;1,
    2001 (excluding the Joint Proxy Statement, the <I>&#147;Biogen
    SEC Documents&#148;</I>). As of their respective dates, the
    Biogen SEC Documents complied in all material respects with the
    requirements of the Securities Act of 1933, as amended (the
    <I>&#147;Securities Act&#148;</I>), or the Exchange Act, as the
    case may be, and the rules and regulations of the SEC
    promulgated thereunder applicable to such Biogen SEC Documents,
    and none of the Biogen SEC Documents, when filed, contained any
    untrue statement of a material fact or omitted to state a
    material fact required to be stated therein or necessary in
    order to make the statements therein, in light of the
    circumstances under which they were made, not misleading, except
    to the extent corrected by a subsequently filed Biogen SEC
    Document filed with the SEC prior to the date hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;The financial statements of Biogen
    included in the Biogen SEC Documents, including each Biogen SEC
    Document filed after the date hereof until the Effective Time,
    comply, as of their respective dates of filing with the SEC, in
    all material respects with applicable accounting requirements
    and the published rules and regulations of the SEC with respect
    thereto, have been prepared in accordance with United States
    generally accepted accounting principles
    <I>(&#147;GAAP&#148;)</I> (except, in the case of unaudited
    statements, as permitted by Form&nbsp;10-Q or 8-K of the SEC)
    applied on a consistent basis during the periods involved
    (except as may be indicated in the notes thereto) and fairly
    present the consolidated financial position of Biogen and its
    consolidated Subsidiaries as of the dates thereof and the
    consolidated results of their operations and cash flows for the
    periods then ended (subject, in the case of unaudited
    statements, to normal year-end audit adjustments which are not
    material).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;Except as reflected or reserved
    against in the balance sheet of Biogen dated March&nbsp;31, 2003
    included in the Form&nbsp;10-Q filed by Biogen with the SEC on
    April&nbsp;17, 2003 (including the notes thereto, the
    <I>&#147;Biogen Balance Sheet&#148;</I>), neither Biogen nor any
    of its Subsidiaries has any liabilities (absolute, accrued,
    contingent or otherwise) which are required by GAAP to be set
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">10
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">forth on a consolidated balance sheet of Biogen
    and its consolidated Subsidiaries or in the notes thereto, other
    than (A) liabilities and obligations incurred since
    March&nbsp;31, 2003 in the ordinary course of business
    consistent with past practice which would not reasonably be
    likely to have a Material Adverse Effect on Biogen and
    (B)&nbsp;liabilities and obligations incurred in connection with
    this Agreement or the transactions contemplated hereby.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;Neither Biogen nor any of its
    Subsidiaries is a party to, or has any commitment to become a
    party to, any joint venture, partnership or any similar contract
    or arrangement (including without limitation any contract or
    arrangement relating to any transaction or relationship between
    or among Biogen and any of its Subsidiaries, on the one hand,
    and any unconsolidated Affiliate (as defined in
    <I>Section&nbsp;8.3(a)</I>), including without limitation any
    structured finance, special purpose or limited purpose entity or
    Person, on the other hand), where the result, purpose or
    intended effect of such contract or arrangement is to avoid
    disclosure of any material transaction involving, or material
    liabilities of, Biogen or any of its Subsidiaries in
    Biogen&#146;s or its Subsidiaries&#146; published financial
    statements.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>Information Supplied.</I> None of the
    information supplied or to be supplied by or on behalf of Biogen
    for inclusion or incorporation by reference in (i)&nbsp;the
    registration statement on Form&nbsp;S-4 to be filed with the SEC
    by IDEC in connection with the issuance of IDEC Common Stock in
    the Merger (including any amendments or supplements, the
    <I>&#147;Form&nbsp;S-4&#148;</I>) will, at the time the
    Form&nbsp;S-4 becomes effective under the Securities Act,
    contain any untrue statement of a material fact or omit to state
    any material fact required to be stated therein or necessary to
    make the statements therein not misleading or (ii)&nbsp;the
    Joint Proxy Statement will, at the date it is first mailed to
    Biogen&#146;s stockholders or at the time of the Biogen
    Stockholders&#146; Meeting, contain any untrue statement of a
    material fact or omit to state any material fact required to be
    stated therein or necessary in order to make the statements
    therein, in light of the circumstances under which they are
    made, not misleading. The Joint Proxy Statement and the
    Form&nbsp;S-4 will comply as to form in all material respects
    with the requirements of the Securities Act and the Exchange Act
    and the rules and regulations thereunder, except that no
    representation or warranty is made by Biogen with respect to
    information or statements with respect to IDEC or its
    Subsidiaries made or incorporated by reference therein supplied
    by or on behalf of IDEC for inclusion or incorporation by
    reference in the Joint Proxy Statement or the Form&nbsp;S-4.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>Absence of Certain Changes or
    Events.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;Since December&nbsp;31, 2002 through the
    date hereof, except as and to the extent disclosed in the Biogen
    SEC Documents filed prior to the date of this Agreement:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(A)&nbsp;Biogen and its Subsidiaries have
    conducted their business only in the ordinary course consistent
    with past practice;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(B)&nbsp;there has not been any split,
    combination or reclassification of any of Biogen&#146;s capital
    stock or any declaration, setting aside or payment of any
    dividend on, or other distribution (whether in cash, stock or
    property) in respect of, in lieu of, or in substitution for,
    shares of Biogen&#146;s capital stock;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(C)&nbsp;except as required by a change in GAAP,
    there has not been any change in accounting methods, principles
    or practices by Biogen;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(D)&nbsp;there has not been any action taken by
    Biogen or any of its Subsidiaries that, if taken during the
    period from the date of this Agreement through the Effective
    Time, would constitute a breach of <I>Section&nbsp;4.1(b)</I>,
    other than actions in connection with entering into this
    Agreement.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;Since December&nbsp;31, 2002 through
    the date hereof, there have not been any changes, circumstances
    or events that, individually or in the aggregate, have had, or
    would reasonably be likely to have, a Material Adverse Effect on
    Biogen.
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">11
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(g)&nbsp;<I>Compliance with Applicable Laws;
    Permits; Litigation.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;Biogen, its Subsidiaries and employees
    hold all permits, licenses, easements, variances, exemptions,
    orders, consents, registrations and approvals of all
    Governmental Entities (including all authorizations under the
    Federal Food, Drug and Cosmetic Act of 1938, as amended (the
    <I>&#147;FDCA&#148;</I>), and the regulations of the
    U.S.&nbsp;Food and Drug Administration (the
    <I>&#147;FDA&#148;</I>) promulgated thereunder) which are
    required for the operation of the businesses of Biogen and its
    Subsidiaries in the manner described in the Biogen SEC Documents
    filed prior to the date hereof or as they are being conducted as
    of the date hereof (the <I>&#147;Biogen Permits&#148;</I>), and
    all Biogen Permits are in full force and effect, except where
    the failure to have, or the suspension or cancellation of, or
    the failure to be valid or in full force and effect of, any such
    Biogen Permits individually or in the aggregate would not
    reasonably be likely to have a Material Adverse Effect on
    Biogen. As of the date hereof, Biogen and its Subsidiaries are
    in compliance with the terms of the Biogen Permits and all
    applicable laws, statutes, orders, rules, regulations, policies
    or guidelines promulgated, or judgments, decisions or orders
    entered by any Governmental Entity (all such laws, statutes,
    orders, rules, regulations, policies, guidelines, judgments,
    decisions and orders, collectively, <I>&#147;Applicable
    Laws&#148;</I>) relating to Biogen and its Subsidiaries or their
    respective business or properties, except where the failure to
    be in compliance with the terms of the Biogen Permits or such
    Applicable Laws individually or in the aggregate would not
    reasonably be likely to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;As of the date hereof, except as and to
    the extent disclosed in the Biogen SEC Documents filed prior to
    the date of this Agreement, including the notes to the financial
    statements included therein, no action, demand, suit,
    proceeding, requirement or investigation by any Governmental
    Entity and no suit, action, mediation, arbitration or proceeding
    by any Person, against or affecting Biogen or any of its
    Subsidiaries or any of their respective properties, including
    Intellectual Property (as defined in
    <I>Section&nbsp;8.3(j)</I>), is pending or, to the Knowledge (as
    defined in <I>Section&nbsp;8.3(k)</I>) of Biogen, threatened
    which individually or in the aggregate would reasonably be
    likely to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;As of the date hereof, neither Biogen
    nor any of its Subsidiaries is subject to any outstanding order,
    injunction or decree which, individually or in the aggregate,
    has had or would reasonably be likely to have a Material Adverse
    Effect on Biogen.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(h)&nbsp;<I>Labor and Other Employment
    Matters.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;As of the date hereof, except as would
    not, individually or in the aggregate, reasonably be likely to
    have a Material Adverse Effect on Biogen, (a)&nbsp;no work
    stoppage, slowdown, lockout, labor strike, material arbitrations
    or other material labor disputes against Biogen or any of its
    Subsidiaries are pending or, to the Knowledge of Biogen,
    threatened, (b)&nbsp;no unfair labor practice charges,
    grievances or complaints are pending or, to the Knowledge of
    Biogen, threatened against Biogen or any of its Subsidiaries,
    (c)&nbsp;neither Biogen nor any of its Subsidiaries is
    delinquent in payments to any of its employees for any wages,
    salaries, commissions, bonuses or other direct compensation for
    any services performed for it or amounts required to be
    reimbursed to such employees, (d)&nbsp;Biogen and each of its
    Subsidiaries are in compliance with all Applicable Laws
    respecting labor and employment, including, but not limited to,
    terms and conditions of employment, workers&#146; compensation,
    occupational safety and health requirements, plant closings,
    wages and hours, employment discrimination, disability rights or
    benefits, equal opportunity, affirmative action, employee
    benefits, severance payments, labor relations, employee leave
    issues and unemployment insurance and related matters,
    (e)&nbsp;there are no complaints, charges or claims against
    Biogen or any of its Subsidiaries pending with or, to the
    Knowledge of Biogen, threatened by any Governmental Entity or
    arbitrator based on, arising out of, in connection with, or
    otherwise relating to the employment of any employees by Biogen
    and or any of its Subsidiaries, other than those occurring in
    the ordinary course of business, such as claims for
    workers&#146; compensation or unemployment benefits,
    (f)&nbsp;Biogen and each of its Subsidiaries have withheld
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">12
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">all amounts required by Applicable Law to be
    withheld from the wages, salaries, and other payments to
    employees, and is not liable for any arrears of wages or any
    Taxes (as defined in <I>Section&nbsp;3.1(j)(xi)</I>) or any
    penalty for failure to comply with any of the foregoing,
    (g)&nbsp;neither Biogen nor any of its Subsidiaries is liable
    for any payment to any trust or other fund or to any
    Governmental Entity, with respect to unemployment compensation
    benefits, social security or other benefits or obligations for
    employees (other than routine payments to be made in the
    ordinary course of business consistent with past practice),
    (h)&nbsp;no employee of Biogen or any of its Subsidiaries, at
    the officer level or above, has given notice to Biogen or any of
    its Subsidiaries that any such employee intends to terminate his
    or her employment with Biogen or any of its Subsidiaries, and
    (i)&nbsp;to the Knowledge of Biogen, no employee of Biogen or
    any of its Subsidiaries is in any respect in violation of any
    term of any employment contract, non-disclosure agreement,
    noncompetition agreement, or any restrictive covenant to a
    former employer relating to the right of any such employee to be
    employed by Biogen or any of its Subsidiaries because of the
    nature of the business conducted or presently proposed to be
    conducted by Biogen or any of its Subsidiaries or to the use of
    trade secrets or proprietary information of others.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;As of the date hereof,
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(A)&nbsp;neither Biogen nor any of its
    Subsidiaries is a party to, or otherwise bound by, any
    collective bargaining agreement or any other agreement with a
    labor union or labor organization, nor is any such agreement
    presently being negotiated;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(B)&nbsp;no labor organization or group of
    employees of Biogen or any of its Subsidiaries has made a
    pending demand for recognition or certification, and there are
    no representation or certification proceedings or petitions
    seeking a representation proceeding presently pending or, to the
    Knowledge of Biogen, threatened to be brought or filed with the
    National Labor Relations Board or any other labor relations
    tribunal or authority;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(C)&nbsp;to the Knowledge of Biogen, no labor
    union is seeking to organize any employees of Biogen or any of
    its Subsidiaries.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>Benefit Plans.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;With respect to each bonus, pension,
    profit sharing, deferred compensation, incentive compensation,
    stock ownership, stock purchase, stock option, phantom stock,
    stock-related or performance award, retirement, vacation,
    severance, disability, death benefit, hospitalization, medical,
    loan, fringe benefit, disability, sabbatical and other similar
    plan, arrangement or understanding, including, without
    limitation, each &#147;employee benefit plan&#148; within the
    meaning of Section&nbsp;3(3) of the Employee Retirement Income
    Security Act of 1974, as amended <I>(&#147;ERISA&#148;)</I> and
    any employment agreement, consulting agreement or severance
    agreement (such plans, agreements, arrangements or
    understandings, collectively, <I>&#147;Benefit Plans&#148;</I>)
    with or for the benefit of any current or former employee,
    officer or director of Biogen or any of its Subsidiaries or
    ERISA Affiliates (as defined in <I>Section&nbsp;3.1(i)(vi)</I>)
    (the <I>&#147;Biogen Benefit Plans&#148;</I>), no event has
    occurred and there exists no condition or set of circumstances,
    which could reasonably be likely to have a Material Adverse
    Effect on Biogen under ERISA, the Code or any other Applicable
    Law.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;Each Biogen Benefit Plan has been, in
    all material respects, administered and operated in accordance
    with its terms, with the applicable provisions of ERISA, the
    Code and other Applicable Law and the terms of all applicable
    collective bargaining agreements. Each Biogen Benefit Plan,
    including any material amendments thereto, that is capable of
    approval by, or registration or qualification for special tax
    status with, the appropriate taxation, social security or
    supervisory authorities in the relevant country, state,
    territory or the like (each, an <I>&#147;Approval&#148;</I>) has
    received such Approval (or there remains a period of time in
    which to obtain such Approval retroactive to the date of any
    material amendment that has not previously received such
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">13
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Approval) and no event has occurred which would
    be reasonably likely to result in the revocation of such
    Approval or the imposition of material sanctions by such
    authorities.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;To the Knowledge of Biogen, no oral or
    written representation or commitment with respect to any
    material aspect of any Biogen Benefit Plan has been made to an
    employee or former employee of Biogen or any of its Subsidiaries
    by an authorized Biogen employee that is not materially in
    accordance with the written or otherwise preexisting terms and
    provisions of such Biogen Benefit Plans. To the Knowledge of
    Biogen, neither Biogen nor any of its Subsidiaries has entered
    into any agreement, arrangement or understanding, whether
    written or oral, with any trade union, works council or other
    employee representative body or any material number or category
    of its employees which would prevent, restrict or materially
    impede the implementation of any lay-off, redundancy, severance
    or similar program within its or their respective workforces (or
    any part of them).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;There are no material unresolved claims
    or disputes under the terms of, or in connection with, any
    Biogen Benefit Plan (other than routine undisputed claims for
    benefits), and no action, legal or otherwise, has been commenced
    or threatened with respect to any material claim or otherwise in
    connection with a Biogen Benefit Plan.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;With respect to each Funded Retirement
    Plan (as defined below) of Biogen or its Subsidiaries, the
    aggregate value of the assets of such Funded Retirement Plan is
    equal to or greater than the aggregate value of its liabilities
    assessed on an ongoing and terminated basis and calculated in
    accordance with the actuarial methods and assumptions used in
    such valuation pursuant to such Funded Retirement Plan and
    Applicable Law and GAAP. For purposes of this Agreement,
    <I>&#147;Funded Retirement Plan&#148;</I> means, with respect to
    a party, a Benefit Plan that is a &#147;pension plan&#148;
    within the meaning of Section&nbsp;3(2) of ERISA (whether or not
    such Benefit Plan is subject to ERISA) and under which the
    assets to satisfy the benefit obligations are legally segregated
    from the general assets of such party or its Subsidiaries and
    are not subject to the creditors of such party or its
    Subsidiaries. None of Biogen or any other person or entity under
    common control within the meaning of Section&nbsp;414(b), (c),
    (m)&nbsp;or (o)&nbsp;of the Code (an <I>&#147;ERISA
    Affiliate&#148;</I>) with Biogen has incurred any liability to a
    Funded Retirement Plan under Title IV of ERISA (other than for
    contributions not yet due) or to the Pension Benefit Guaranty
    Corporation (other than for payment of premiums not yet due)
    that, when aggregated with other such liabilities, would result
    in a material liability of Biogen and its Subsidiaries taken as
    a whole, which liability has not been fully paid.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;At no time has Biogen or any ERISA
    Affiliate of Biogen participated in and/or been obligated to
    contribute to any Benefit Plan that is a &#147;multiemployer
    plan&#148; within the meaning of Section&nbsp;3(37) of ERISA.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;No Biogen Benefit Plan provides health
    benefits (whether or not insured), with respect to employees or
    former employees of Biogen or any Subsidiary of Biogen after
    retirement or other termination of service (other than coverage
    mandated by Applicable Law or benefits, the full cost of which
    is borne by the employee or former employee).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(viii)&nbsp;Neither the negotiation and execution
    of this Agreement nor the consummation of the transactions
    contemplated hereby will (either alone or upon the occurrence of
    any additional or subsequent events) constitute an event under
    any Biogen Benefit Plan that will or may result in any payment
    (whether of severance pay or otherwise), acceleration of
    payment, forgiveness of indebtedness, vesting, distribution,
    increase in benefits or obligation to fund benefits with respect
    to any employee or former employee of Biogen or any Subsidiary
    of Biogen. There is no contract, agreement, plan or arrangement
    with an employee or former employee of Biogen to which Biogen or
    any of its Subsidiaries is a party as of the date of this
    Agreement, that, individually or collectively and as a result of
    the transaction contemplated hereby (whether alone or upon the
    occurrence of any additional or subsequent events) or otherwise,
    would reasonably be likely to
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">14
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">give rise to the payment of any amount that would
    not be deductible pursuant to Sections&nbsp;280G or 162(m) of
    the Code.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(j)&nbsp;<I>Taxes.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;Each of Biogen and its Subsidiaries,
    including any predecessors thereof, has (A)&nbsp;duly and timely
    filed (or there have been filed on its behalf) all material Tax
    Returns (as defined below) required to be filed by it (taking
    into account all applicable extensions) with the appropriate Tax
    Authority (as defined below) and all such Tax Returns are true,
    correct and complete in all material respects, (B)&nbsp;duly
    paid in full or made provision in accordance with GAAP (or there
    has been paid or provision has been made on its behalf) for the
    payment of all material Taxes for all periods ending through the
    date hereof, and (C)&nbsp;complied in all material respects with
    all Applicable Laws relating to the payment and withholding of
    Taxes.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;There are no material Liens for Taxes
    upon any property or assets of Biogen or any of its
    Subsidiaries, except for liens for Taxes not yet due and payable
    and for which adequate reserves have been provided in accordance
    with GAAP in the most recent financial statements contained in
    the Biogen SEC Documents filed prior to the date of this
    Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;The unpaid Taxes of Biogen and its
    Subsidiaries (A)&nbsp;did not, as of the most recent financial
    statements contained in the Biogen SEC Documents filed prior to
    the date of this Agreement, exceed the reserve for Tax liability
    (rather than any reserve for deferred Taxes established to
    reflect timing differences between book and Tax income) set
    forth on the face of such financial statements (rather than in
    any notes thereto), and (B)&nbsp;do not exceed that reserve as
    adjusted for the passage of time since the date of such
    financial statements in accordance with the past custom and
    practice of Biogen and its Subsidiaries in filing their Tax
    Returns.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;There is no audit, examination,
    deficiency, refund litigation, proposed adjustment or matter in
    controversy with respect to any Taxes or Tax Return of Biogen or
    its Subsidiaries which if determined adversely would be expected
    to result in a material Tax deficiency. Neither Biogen nor any
    of its Subsidiaries has received notice of any claim made by a
    governmental authority in a jurisdiction where Biogen or any of
    its Subsidiaries, as applicable, does not file a Tax Return,
    that Biogen or such Subsidiary is or may be subject to taxation
    by that jurisdiction.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;The material income Tax Returns of
    Biogen and each of its Subsidiaries, including any predecessors
    thereof, have been examined by the applicable Tax Authority (or
    the applicable statutes of limitations for the assessment of
    income Taxes for such periods have expired) for all periods
    through and including December&nbsp;31, 1997, and no material
    deficiencies were asserted as a result of such examinations
    which have not been resolved and fully paid or accrued as a
    liability on the most recent financial statements contained in
    the Biogen SEC Documents.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;There are no outstanding requests,
    agreements, consents or waivers to extend the statutory period
    of limitations applicable to the assessment of any Taxes or
    deficiencies against Biogen or any of its Subsidiaries, and no
    power of attorney granted by either Biogen or any of its
    Subsidiaries with respect to any Taxes is currently in force.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;Neither Biogen nor any of its
    Subsidiaries is a party to any agreement providing for the
    allocation or sharing of Taxes imposed on or with respect to any
    individual or other Person, and neither Biogen nor any of its
    Subsidiaries (A)&nbsp;has been a member of an affiliated group
    (or similar state, local or foreign filing group) filing a
    consolidated income Tax Return (other than the group the common
    parent of which is Biogen) or (B)&nbsp;has any liability for the
    Taxes of any Person (other than Biogen or any of its
    Subsidiaries) under Treasury Regulation &#167;&nbsp;1.1502-6 (or
    any similar provision of state, local or foreign law), as a
    transferee or successor, by contract, or otherwise.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(viii)&nbsp;Biogen and each of its Subsidiaries
    has delivered or made available to IDEC complete copies of all
    material income Tax Returns of Biogen and each of its
    Subsidiaries, including any
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">15
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">predecessors thereof, for taxable years ending
    between January&nbsp;1, 1999 and December&nbsp;31, 2002,
    excepting such Tax Returns as have not been filed for the
    taxable year ending December&nbsp;31, 2002 pursuant to
    appropriate extensions with respect thereto.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ix)&nbsp;Neither Biogen nor any of its
    Subsidiaries has: (A) filed a consent under Section&nbsp;341(f)
    of the Code concerning collapsible corporations; (B)&nbsp;agreed
    to make nor is it required to make any material adjustment under
    Section&nbsp;481(a) of the Code by reason of a change in
    accounting method or otherwise; (C) constituted either a
    &#147;distributing corporation&#148; or a &#147;controlled
    corporation&#148; (within the meaning of
    Section&nbsp;355(a)(1)(A) of the Code) in a distribution of
    stock qualifying for tax-free treatment under Section&nbsp;355
    of the Code (I)&nbsp;in the two years prior to the date of this
    Agreement or (II)&nbsp;in a distribution which could otherwise
    constitute part of a &#147;plan&#148; or &#147;series of related
    transactions&#148; (within the meaning of Section&nbsp;355(e) of
    the Code) in connection with the Merger; or (D)&nbsp;taken any
    action or knows of any fact, agreement, plan or other
    circumstance that is reasonably likely to prevent the Merger
    from qualifying as a &#147;reorganization&#148; within the
    meaning of Section&nbsp;368(a) of the Code.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(x)&nbsp;Neither Biogen nor any of its
    Subsidiaries is, or has been, a United States real property
    holding corporation (as defined in Section&nbsp;897(c)(2) of the
    Code) during the applicable period specified in
    Section&nbsp;897(c)(1)(A)(ii) of the Code.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xi)&nbsp;For purposes of this Agreement,
    <I>&#147;Audit&#148;</I> means any examination, audit,
    assessment, action, proceeding, investigation, dispute or claim
    with respect to Taxes by any Tax Authority or any administrative
    or judicial proceedings or appeals of such proceedings relating
    to Taxes; <I>&#147;Taxes&#148;</I> means any and all federal,
    state, local, foreign or other taxes of any kind (together with
    any and all interest, penalties, additions to tax and additional
    amounts imposed with respect thereto) imposed by any
    governmental authority, including, without limitation, taxes or
    other charges on or with respect to income, franchises, windfall
    or other profits, gross receipts, property, sales, use, capital
    stock, payroll, employment, unemployment, social security,
    workers&#146; compensation, or net worth, and taxes or other
    charges in the nature of excise, withholding, ad valorem or
    value added; <I>&#147;Tax Authority&#148;</I> means the Internal
    Revenue Service and any other domestic or foreign governmental
    authority responsible for the administration or collection of
    any Taxes; and <I>&#147;Tax Return&#148;</I> means any return,
    report or similar statement (including the attached schedules)
    required to be filed with respect to Taxes, including, without
    limitation, any information return, claim for refund, amended
    return, or declaration of estimated Taxes.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(k)&nbsp;<I>Regulatory Compliance; Supply.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;All biological and drug products
    currently being manufactured, distributed or developed by Biogen
    or its Subsidiaries, or by any other Person pursuant to a
    development, commercialization, manufacturing, supply or other
    collaboration arrangement (other than an arrangement that is
    solely a license to market, distribute or sell products in a
    specified territory) with Biogen or any of its Subsidiaries (any
    such other Person acting under or in respect of such an
    arrangement, a <I>&#147;Biogen Collaboration Partner&#148;</I>
    and any such an arrangement with Biogen or any of its
    Subsidiaries, a <I>&#147;Biogen Collaboration&#148;</I>), that
    are subject to the jurisdiction of the FDA are, or, in the case
    of such manufacture, distribution or development by a Biogen
    Collaboration Partner pursuant to a Biogen Collaboration, to the
    Knowledge of Biogen are, being manufactured, labeled, stored,
    tested, distributed, and marketed in compliance with all
    applicable requirements under the FDCA, the Public Health
    Service Act, Biological Products, 21&nbsp;C.F.R.
    &#167;&#167;&nbsp;600-610 (the <I>&#147;Public Health Service
    Act&#148;</I>), and their applicable implementing regulations,
    except for such noncompliance which would not, individually or
    in the aggregate, reasonably be likely to have a Material
    Adverse Effect on Biogen. The biological and drug products
    described in this <I>Section&nbsp;3.1(k)(i)</I> are sometimes
    referred to herein as <I>&#147;Biogen Pharmaceutical
    Products.&#148;</I>
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;All clinical trials being conducted by
    Biogen or its Subsidiaries are, or, in the case of such trials
    being conducted by a Biogen Collaboration Partner pursuant to a
    Biogen Collaboration, to the Knowledge of Biogen are, being
    conducted in material compliance with the
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">16
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">applicable requirements of Good Clinical Practice
    (as defined in <I>Section&nbsp;8.3(g)</I>) and all applicable
    requirements relating to protection of human subjects contained
    in 21&nbsp;C.F.R. Parts 50, 54, and 56, except for such
    noncompliance which would not, individually or in the aggregate,
    reasonably be likely to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;The manufacture of Biogen
    Pharmaceutical Products is, or, in the case of any Biogen
    Pharmaceutical Products manufactured by a Biogen Collaboration
    Partner pursuant to a Biogen Collaboration, to the Knowledge of
    Biogen is, being conducted in compliance with the FDA&#146;s
    applicable current Good Manufacturing Practice (as defined in
    <I>Section&nbsp;8.3(h)</I>) regulations for drug and biological
    products, except for such noncompliance which would not,
    individually or in the aggregate, reasonably be likely to have a
    Material Adverse Effect on Biogen. In addition, Biogen and its
    Subsidiaries and, to the Knowledge of Biogen, their respective
    Biogen Collaboration Partners with respect to their activities
    pursuant to a Biogen Collaboration, are in compliance with all
    applicable registration and listing requirements set forth in 21
    U.S.C. Section&nbsp;360 and 21&nbsp;C.F.R. Part&nbsp;207 and all
    similar Applicable Laws, except for such noncompliance which
    would not, individually or in the aggregate, reasonably be
    likely to have a Material Adverse Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;No Biogen Pharmaceutical Product has
    been recalled, suspended or discontinued as a result of any
    action by the FDA or similar foreign Governmental Entity.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;Since January&nbsp;1, 2001, none of
    Biogen, its Subsidiaries nor, to the Knowledge of Biogen, their
    respective Collaboration Partners, has received any notice that
    the FDA or any other Governmental Entity has initiated or is
    considering initiating any steps, procedures or action to
    withdraw approval for or enjoin the production, sale, marketing
    or reimbursement of, or request the recall of, any Biogen
    Pharmaceutical Product.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;None of Biogen, any of its
    Subsidiaries, nor, to the Knowledge of Biogen, any of their
    respective Biogen Collaboration Partners with respect to their
    activities pursuant to a Biogen Collaboration, has committed any
    act, made any statement or failed to make any statement that
    would reasonably be likely to provide a basis for the FDA to
    invoke its policy with respect to &#147;Fraud, Untrue Statements
    of Material Facts, Bribery, and Illegal Gratuities&#148; set
    forth in 56 Fed. Reg. 46191 (September&nbsp;10, 1991) and any
    amendments thereto. Additionally, none of Biogen, its
    Subsidiaries nor, to the Knowledge of Biogen, any of their
    respective officers, key employees, agents, nor, to the
    Knowledge of Biogen, any Biogen Collaboration Partner nor any
    officer, key employee or agent thereof, has been convicted of
    any crime or engaged in any conduct (in the case of any Biogen
    Collaboration Partner or any officer, key employee or agent
    thereof, arising out of or in connection with acts or omissions
    pursuant to a Biogen Collaboration) that would reasonably be
    likely to result in (i)&nbsp;debarment under 21&nbsp;U.S.C.
    Section&nbsp;335a or any similar state law or regulation or
    (ii)&nbsp;exclusion under 42&nbsp;U.S.C. Section&nbsp;1320a-7 or
    any similar state law or regulation.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;Biogen has, or, to the Knowledge of
    Biogen, the Biogen Collaboration Partners that manufacture
    Biogen Pharmaceutical Products pursuant to a Biogen
    Collaboration have, sufficient manufacturing capacity and access
    to sufficient supply of materials to satisfy the reasonably
    anticipated clinical and commercial requirements for Biogen
    Pharmaceutical Products.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(l)&nbsp;<I>Environmental Matters.</I> As of the
    date hereof, except as would not, individually or in the
    aggregate, reasonably be likely to have a Material Adverse
    Effect on Biogen, (i)&nbsp;the operations of Biogen and its
    Subsidiaries are in compliance with all applicable Environmental
    Laws (as defined in <I>Section&nbsp;8.3(e)</I>), including
    possession and compliance with the terms of all licenses
    required by Environmental Laws, (ii)&nbsp;there are no pending,
    or to the Knowledge of Biogen, threatened suits, actions,
    investigations or proceedings under or pursuant to Environmental
    Laws against Biogen or its Subsidiaries or involving any real
    property currently or, to the Knowledge of Biogen, formerly
    owned, operated or leased by Biogen or its Subsidiaries,
    (iii)&nbsp;Biogen and its Subsidiaries are not subject to and
    have received no written allegations of any Environmental
    Liabilities (as defined in
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">17
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <I><FONT size="2">Section&nbsp;8.3(f)</FONT></I><FONT size="2">)
    and, to the Knowledge of Biogen, no facts, circumstances or
    conditions relating to, arising from, associated with or
    attributable to any real property currently or, to the Knowledge
    of Biogen, formerly owned, operated or leased by Biogen or its
    Subsidiaries or operations thereon has resulted in or would
    reasonably be likely to result in Environmental Liabilities, and
    (iv)&nbsp;all real property owned or operated by Biogen or its
    Subsidiaries is free of contamination from Hazardous Materials
    (as defined in <I>Section&nbsp;8.3(i)</I>) that would have an
    adverse effect on human health or the environment.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(m)&nbsp;<I>Intellectual Property.</I> Except as
    would not, individually or in the aggregate, reasonably be
    expected to have a Material Adverse Effect on Biogen,
    (i)&nbsp;Biogen and each of its Subsidiaries owns or has a
    legally enforceable right to use (in each case, free and clear
    of any Liens) all Intellectual Property used in or necessary for
    the conduct of its business as currently conducted, including
    without limitation all patents and patent applications and all
    trademark registrations and trademark applications; (ii)&nbsp;to
    the Knowledge of Biogen, the conduct of the business of Biogen
    and its Subsidiaries as currently conducted does not infringe on
    or misappropriate, either directly or indirectly, the
    Intellectual Property rights of any Person and the use by Biogen
    or its Subsidiaries of any Intellectual Property is, to the
    Knowledge of Biogen, in accordance with any applicable grant,
    license, agreement, instrument or other arrangement pursuant to
    which Biogen or any Affiliate acquired the right to use such
    Intellectual Property; (iii)&nbsp;to the Knowledge of Biogen, no
    Person has advised Biogen or any of its Subsidiaries in writing
    that it is challenging or threatening to challenge the
    ownership, use, validity or enforceability of any Intellectual
    Property owned or used by Biogen or its Subsidiaries;
    (iv)&nbsp;to the Knowledge of Biogen, no Person is
    misappropriating, infringing, diluting or otherwise violating
    any right of Biogen or any of its Subsidiaries with respect to
    any Intellectual Property owned or used by Biogen or its
    Subsidiaries; (v)&nbsp;to the Knowledge of Biogen, neither
    Biogen nor any of its Subsidiaries has received written notice
    of any pending or threatened claim, order or proceeding with
    respect to the validity, enforcement or maintenance of any
    Intellectual Property owned or used by Biogen or its
    Subsidiaries and, to the Knowledge of Biogen, no Intellectual
    Property owned or used by Biogen or its Subsidiaries is being
    used or enforced in a manner that would reasonably be expected
    to result in the abandonment, cancellation or unenforceability
    of such Intellectual Property; (vi)&nbsp;to the Knowledge of
    Biogen, the Intellectual Property owned or used by Biogen or its
    Subsidiaries has not expired, been cancelled or abandoned and
    all maintenance and renewal fees necessary to preserve the
    rights of Biogen in connection with such Intellectual Property
    have been paid in a timely manner; (vii)&nbsp;neither Biogen nor
    any of its Subsidiaries has entered into any consent,
    indemnification, forbearance to sue, settlement agreement,
    license or other arrangement which reasonably could be expected
    to provide a third party a defense to patent infringement in
    connection with any Intellectual Property owned or used by
    Biogen; (viii)&nbsp;to the Knowledge of Biogen, Biogen and each
    of its Subsidiaries has implemented commercially reasonable
    measures to maintain the confidentiality of the Intellectual
    Property and all other property used in the business of Biogen
    or its Subsidiaries as presently conducted; (ix)&nbsp;each
    current and former employee of Biogen or its Subsidiaries who
    has contributed to or participated in research and development
    activities has entered into an agreement with Biogen or a Biogen
    Subsidiary that has accorded Biogen or the Subsidiary full,
    effective and exclusive ownership rights in and to all tangible
    or intangible property created thereby; and (x)&nbsp;each
    employee, officer and director of Biogen or its Subsidiaries has
    entered into an agreement to maintain the confidential
    information of Biogen and its Subsidiaries and, to the Knowledge
    of Biogen, all consultants of Biogen or its Subsidiaries who
    have been in a position to receive any confidential information
    of Biogen or its Subsidiaries have entered into written
    agreements with Biogen or its Subsidiaries to maintain the
    confidentiality of all such information.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(n)&nbsp;<I>State Takeover Statutes.</I> The
    Board of Directors of Biogen has adopted a resolution or
    resolutions approving this Agreement, the Merger and the other
    transactions contemplated hereby, and, assuming the accuracy of
    IDEC&#146;s representation and warranty contained in
    <I>Section&nbsp;3.2(q)</I> (without giving effect to the
    Knowledge qualification contained therein), such approval
    constitutes approval of the Merger and the other transactions
    contemplated hereby by the Board of Directors of Biogen under
    the provisions of Chapter&nbsp;110F of the Massachusetts General
    Laws <I>(&#147;Chapter&nbsp;110F&#148;)</I>
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">18
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">such that Chapter&nbsp;110F does not apply to
    this Agreement, the Merger or the other transactions
    contemplated hereby. To the Knowledge of Biogen, no state
    takeover statute other than Chapter&nbsp;110F (which has been
    rendered inapplicable) is applicable to the Merger or the other
    transactions contemplated hereby.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(o)&nbsp;<I>Brokers.</I> Except for fees payable
    to Goldman, Sachs&nbsp;&#38; Co., no broker, investment banker,
    financial advisor or other Person, is entitled to any
    broker&#146;s, finder&#146;s, financial advisor&#146;s or other
    similar fee or commission in connection with the transactions
    contemplated by this Agreement based upon arrangements made by
    or on behalf of Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(p)&nbsp;<I>Opinion of Financial Advisor.</I>
    Biogen has received the opinion of its financial advisor,
    Goldman, Sachs&nbsp;&#38; Co., dated the date of this Agreement,
    to the effect that, as of such date, the Exchange Ratio is fair,
    from a financial point of view, to the holders of Biogen Common
    Stock.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(q)&nbsp;<I>Ownership of IDEC Common Stock.</I>
    None of Biogen, its Subsidiaries or, to the Knowledge of Biogen
    without independent investigation, any of their respective
    Affiliates, (i)&nbsp;beneficially owns (as defined in
    Rule&nbsp;13d-3 under the Exchange Act) directly or indirectly,
    or is party to any agreement, arrangement or understanding for
    the purpose of acquiring, holding, voting or disposing of,
    shares of capital stock of IDEC, or (ii)&nbsp;within the
    preceding thirty-six (36)&nbsp;months, beneficially owned
    directly or indirectly, or was party to any agreement,
    arrangement or understanding for the purpose of acquiring,
    holding, voting or disposing of, shares of capital stock of IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(r)&nbsp;<I>Material Contracts.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;For purposes of this Agreement,
    <I>&#147;Biogen Material Contract&#148;</I> shall mean:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(1)&nbsp;any &#147;material contracts&#148; (as
    such term is used in Item&nbsp;601(b)(10) of Regulation&nbsp;S-K
    of the SEC) with respect to Biogen and its Subsidiaries;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(2)&nbsp;any Contract to which Biogen or any of
    its Subsidiaries is a party, which is material to Biogen and its
    Subsidiaries, taken together, and which (A)&nbsp;contains any
    covenant limiting or restricting the right of Biogen or any of
    its Subsidiaries or that would, after the Effective Time, limit
    or restrict IDEC or any of its Subsidiaries (including the
    Surviving Corporation and its Subsidiaries) from
    (x)&nbsp;engaging or competing in any material line of business
    or in any geographic area or with any Person in any material
    line of business or (y)&nbsp;making use of any material
    Intellectual Property owned by or necessary for the conduct of
    the businesses of Biogen and its Subsidiaries in the manner
    described in the Biogen SEC Documents filed prior to the date
    hereof and as they are currently being conducted,
    (B)&nbsp;relates to the development, co-promotion,
    commercialization, manufacturing, supply or distribution of any
    material product, the out-licensing to third parties of
    Intellectual Property relating to any material product or the
    in-licensing from third parties of Intellectual Property
    relating to any material product, or (C)&nbsp;adversely affects
    the right of Biogen or any of its Subsidiaries to use, sell,
    distribute, manufacture or have manufactured or supply any
    material product;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(3)&nbsp;any Contract or group of Contracts with
    a Person (or group of affiliated Persons) to which Biogen or any
    of its Subsidiaries is a party, the termination or breach of
    which would be reasonably likely to have a Material Adverse
    Effect on Biogen.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;<I>Schedule.</I>
    <I>Section&nbsp;3.1(r)(ii)</I> of the Biogen Disclosure Schedule
    sets forth a list of all Biogen Material Contracts as of the
    date hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;<I>No Breach.</I> All Biogen Material
    Contracts are valid and in full force and effect and enforceable
    in accordance with their respective terms, subject to applicable
    bankruptcy, insolvency, reorganization, moratorium or other laws
    relating to or affecting the rights and remedies of creditors
    generally and to general principles of equity (regardless of
    whether considered in a proceeding in equity or at law), except
    to the extent that (A)&nbsp;they have previously expired in
    accordance with their terms or (B)&nbsp;the failure to be in
    full force and effect,
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">19
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">individually or in the aggregate, would not
    reasonably be likely to have a Material Adverse Effect on
    Biogen. Neither Biogen nor any of its Subsidiaries, nor, to
    Biogen&#146;s Knowledge, any counterparty to any Biogen Material
    Contract, has violated any provision of, or committed or failed
    to perform any act which, with or without notice, lapse of time
    or both would constitute a default under the provisions of, any
    Biogen Material Contract, except in each case for those
    violations and defaults which, individually or in the aggregate,
    would not reasonably be likely to have a Material Adverse Effect
    on Biogen.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(s)&nbsp;<I>Interested Party Transactions.</I>
    Since the date of the Biogen Balance Sheet, no event has
    occurred that would be required to be reported as a Certain
    Relationship or Related Transaction pursuant to Statement of
    Financial Accounting Standards No.&nbsp;57 or Item&nbsp;404 of
    Regulation&nbsp;S-K of the SEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(t)&nbsp;<I>Biogen Rights Agreement.</I> Biogen
    has taken all action so that the execution of this Agreement,
    the consummation of the Merger and the other transactions
    contemplated hereby do not and will not result in the grant of
    any rights to any Person under the Biogen Rights Agreement or
    enable, require or cause the Biogen Rights to be exercised,
    distributed or triggered.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations
and Warranties of IDEC and Merger Sub.</I> Except as set forth
in the disclosure schedule dated as of the date of this
Agreement and executed and delivered by IDEC and Merger Sub to
Biogen concurrently with or prior to the execution and delivery
by IDEC and Merger Sub of this Agreement (the <I>&#147;IDEC
Disclosure Schedule&#148;</I>), IDEC and Merger Sub represent
and warrant to Biogen as set forth below. Each exception set
forth in the IDEC Disclosure Schedule, and any other information
included in the IDEC Disclosure Schedule, is identified by
reference to, or has been grouped under a heading referring to,
a specific individual subsection of this Agreement and shall be
deemed to be disclosed solely for purposes of such subsection,
except to the extent that disclosure in one subsection of the
IDEC Disclosure Schedule is specifically referred to in another
subsection of the IDEC Disclosure Schedule by appropriate
cross-reference.
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Organization, Standing and Corporate
    Power; Charter Documents; Subsidiaries.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>Organization, Standing and Corporate
    Power.</I> IDEC and each of its Subsidiaries is a corporation or
    other legal entity duly organized, validly existing and in good
    standing (with respect to jurisdictions which recognize such
    concept) under the laws of the jurisdiction in which it is
    incorporated or otherwise organized and has the requisite
    corporate (or similar) power and authority to carry on its
    business as currently conducted, except for those jurisdictions
    in which the failure to be so organized, existing or in good
    standing would not, individually or in the aggregate, reasonably
    be likely to have a Material Adverse Effect on IDEC. Each of
    IDEC and its Subsidiaries is duly qualified or licensed to do
    business and is in good standing (with respect to jurisdictions
    which recognize such concept) in each jurisdiction in which the
    nature of its business or the ownership, leasing or operation of
    its properties makes such qualification or licensing necessary,
    except for those jurisdictions where the failure to be so
    qualified or licensed or to be in good standing would not,
    individually or in the aggregate, reasonably be likely to have a
    Material Adverse Effect on IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;<I>Charter Documents.</I> IDEC and
    Merger Sub have delivered or made available to Biogen prior to
    the execution of this Agreement complete and correct copies of
    (A)&nbsp;the Amended and Restated Certificate of Incorporation
    of IDEC (including any certificates of designation), as amended
    and currently in effect (the <I>&#147;IDEC Charter&#148;</I>),
    and the by-laws of IDEC, as amended and currently in effect (the
    <I>&#147;IDEC By-Laws,&#148;</I> and, together with the IDEC
    Charter, the <I>&#147;IDEC Organizational Documents&#148;</I>),
    and (B)&nbsp;the Articles of Organization and by-laws of Merger
    Sub in effect on the date of this Agreement and the like
    organizational documents of each of the IDEC Significant
    Subsidiaries (as defined in <I>Section&nbsp;3.2(a)(iii)</I>), as
    amended and currently in effect (collectively, the <I>&#147;IDEC
    Subsidiary Organizational Documents&#148;</I>), and each such
    instrument is in full force and effect. IDEC is not in violation
    of the IDEC Organizational Documents and no IDEC Significant
    Subsidiary is in violation of its IDEC
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">20
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Subsidiary Organizational Documents, except, in
    the case of such IDEC Significant Subsidiary, as would not
    reasonably be likely to have a Material Adverse Effect on IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;<I>Subsidiaries.</I>
    <I>Section&nbsp;3.2(a)(iii)</I> of the IDEC Disclosure Schedule
    lists all the Subsidiaries of IDEC which as of the date of this
    Agreement are significant subsidiaries (as defined in
    Rule&nbsp;102 of Regulation&nbsp;S-X of the SEC) (the
    <I>&#147;IDEC Significant Subsidiaries&#148;</I>). All the
    outstanding shares of capital stock of, or other equity
    interests in, each IDEC Significant Subsidiary have been validly
    issued and are fully paid and nonassessable and are owned
    directly or indirectly by IDEC, free and clear of all Liens and
    free of any other restriction (including any restriction on the
    right to vote, sell or otherwise dispose of such capital stock
    or other ownership interests).
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Capital Structure.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;The authorized capital stock of IDEC
    consists of 500,000,000&nbsp;shares of IDEC Common Stock and
    8,000,000&nbsp;shares of convertible preferred stock, par value
    $0.001&nbsp;per share <I>(&#147;IDEC Preferred Stock&#148;).</I>
    At the close of business on May&nbsp;31, 2003 (A)
    155,257,594&nbsp;shares of IDEC Common Stock were issued and
    outstanding; (B)&nbsp;2,209,493&nbsp;shares of IDEC Common Stock
    were held by IDEC in its treasury; (C)&nbsp;36,214&nbsp;shares
    of IDEC Preferred Stock were issued and outstanding, of which
    13,221&nbsp;shares were designated as
    Series&nbsp;A-2&nbsp;shares and 22,993&nbsp;shares were
    designated as Series&nbsp;A-3&nbsp;shares, and
    2,172,840&nbsp;shares of IDEC Common Stock were reserved for
    issuance upon conversion of the IDEC Preferred Stock;
    (D)&nbsp;13,934,774&nbsp;shares of IDEC Common Stock were
    reserved for issuance upon conversion of IDEC&#146;s
    subordinated convertible notes, due 2019;
    (E)&nbsp;8,661,301&nbsp;shares of IDEC Common Stock were
    reserved for issuance upon conversion of IDEC&#146;s senior
    convertible notes, due 2032; (F)&nbsp;1,001,680&nbsp;shares of
    IDEC Common Stock were reserved for issuance pursuant to IDEC
    1995 Employee Stock Purchase Plan, as amended and restated
    through February&nbsp;19, 2003 (the <I>&#147;IDEC Purchase
    Plan&#148;</I>); (G)&nbsp;57,256,742&nbsp;shares of IDEC Common
    Stock were reserved for issuance pursuant to the IDEC 1988 Stock
    Option Plan, as amended and restated through January&nbsp;16,
    2001 (the <I>&#147;IDEC 1988 Stock Option Plan&#148;</I>), and
    the IDEC 1993 Non-Employee Directors Stock Option Plan, as
    amended and restated through February&nbsp;19, 2003 (such plans,
    collectively, the <I>&#147;IDEC Stock Plans&#148;</I>), complete
    and correct copies of which, in each case as amended, have been
    filed as exhibits to the IDEC SEC Documents (as defined in
    <I>Section&nbsp;3.2(d)(i)</I>) prior to the date of this
    Agreement or delivered to Biogen; and
    (H)&nbsp;1,000,000&nbsp;shares of IDEC Preferred Stock were
    designated as Series&nbsp;X Junior Participating Preferred
    Stock, par value $0.001&nbsp;per share, and were reserved for
    issuance upon the exercise of preferred stock purchase rights
    (the <I>&#147;IDEC Rights&#148;</I>) issued pursuant to the
    Amended and Restated IDEC Rights Agreement dated July&nbsp;26,
    2001 between IDEC and Mellon Investor Services LLP, as amended
    by Amendment No.&nbsp;1 to Rights Agreement dated as of
    June&nbsp;20, 2003, between IDEC and Mellon Investor Services
    LLP (the <I>&#147;IDEC Rights Agreement&#148;</I>).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;As of the close of business on
    May&nbsp;31, 2003, 21,490,254&nbsp;shares of IDEC Common Stock
    were subject to issuance pursuant to outstanding options to
    acquire shares of IDEC Common Stock <I>(&#147;IDEC
    Options&#148;)</I> under the IDEC Stock Plans. All shares of
    IDEC Common Stock subject to issuance under the IDEC Stock Plans
    and the IDEC Purchase Plan, upon issuance on the terms and
    conditions specified in the instruments pursuant to which they
    are issuable, will be duly authorized, validly issued, fully
    paid and nonassessable. There are no commitments or agreements
    of any character to which IDEC is bound obligating IDEC to
    accelerate the vesting of any IDEC Option as a result of the
    Merger (whether alone or upon the occurrence of any additional
    or subsequent events). There are no outstanding or authorized
    stock appreciation, phantom stock, profit participation or other
    similar rights with respect to IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;No Voting Debt of IDEC is issued or
    outstanding as of the date hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;Except as otherwise set forth in this
    <I>Section&nbsp;3.2(b)</I>, as of May&nbsp;31, 2003, there are
    no securities, options, warrants, calls, rights, commitments,
    agreements, arrangements or undertak-
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">21
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">ings of any kind to which IDEC or any of its
    Subsidiaries is a party or by which any of them is bound
    obligating IDEC or any of its Subsidiaries to issue, deliver or
    sell, or cause to be issued, delivered or sold, additional
    shares of capital stock, Voting Debt or other voting securities
    of IDEC or any of its Subsidiaries, or obligating IDEC or any of
    its Subsidiaries to issue, grant, extend or enter into any such
    security, option, warrant, call, right, commitment, agreement,
    arrangement or undertaking. All outstanding shares of IDEC
    Common Stock, all outstanding IDEC Options, and all outstanding
    shares of capital stock of each Subsidiary of IDEC have been
    issued and granted in compliance in all material respects with
    (A)&nbsp;all applicable securities laws and all other Applicable
    Law and (B) all requirements set forth in applicable material
    Contracts.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;Since May&nbsp;31, 2003 and through the
    date hereof, other than (A) issuances of IDEC Common Stock
    pursuant to the exercise of IDEC Options granted under IDEC
    Stock Plans and outstanding as of May&nbsp;31, 2003, (B)
    issuances of IDEC Common Stock pursuant to the IDEC Purchase
    Plan, (C) repurchases of IDEC Common Stock from employees of
    IDEC following their termination pursuant to the terms of their
    pre-existing stock option or purchase agreements,
    (D)&nbsp;issuances of IDEC Common Stock (consisting of
    newly-issued shares or shares in treasury) as contributions of
    IDEC Common Stock to defined contribution plans sponsored by
    IDEC <I>(&#147;IDEC Defined Contribution Plans&#148;)</I> and
    (E)&nbsp;grants of IDEC Options under IDEC Stock Plans in the
    ordinary course of business consistent with past practice, there
    has been no change in (1)&nbsp;the outstanding capital stock of
    IDEC, (2)&nbsp;the number of IDEC Options outstanding, or
    (3)&nbsp;the number of other options, warrants or other rights
    to purchase IDEC capital stock.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;Neither IDEC nor any Subsidiary of IDEC
    is a party to any currently effective agreement restricting the
    purchase or transfer of, relating to the voting of, requiring
    registration of, or granting any preemptive or antidilutive
    rights with respect to, any capital stock of IDEC or any of its
    Subsidiaries or any securities of the type referred to in
    <I>Section&nbsp;3.2(b)(iv)</I> hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;Other than its Subsidiaries, as of the
    date hereof, IDEC does not directly or indirectly beneficially
    own any securities or other beneficial ownership interests in
    any other entity except for non-controlling investments made in
    the ordinary course of business consistent with past practice in
    entities which are not individually or in the aggregate material
    to IDEC and its Subsidiaries taken as a whole.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(viii)&nbsp;The authorized capital stock of
    Merger Sub consists of 1,000&nbsp;shares of common stock, par
    value $.01&nbsp;per share, all of which shares are issued and
    outstanding. IDEC is the legal and beneficial owner of all of
    the issued and outstanding shares of Merger Sub. Merger Sub was
    formed at the direction of IDEC on June&nbsp;11, 2003, solely
    for the purposes of effecting the Merger and the other
    transactions contemplated hereby. Except as required by or
    provided for in this Agreement, Merger Sub (x) does not hold,
    nor has it held, any assets, (y)&nbsp;does not have, nor has it
    incurred, any liabilities and (z)&nbsp;has not carried on any
    business activities other than in connection with the Merger and
    the transactions contemplated hereby. All of the outstanding
    shares of capital stock of Merger Sub have been duly authorized
    and validly issued, and are fully paid and nonassessable and not
    subject to any preemptive rights.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Authority; Board Approval; Voting
    Requirements; No Conflict; Required Filings and Consents.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>Authority.</I> Each of IDEC and
    Merger Sub has all requisite corporate power and authority to
    enter into this Agreement and to consummate the transactions
    contemplated hereby. The execution and delivery of this
    Agreement by IDEC and Merger Sub, and the consummation by IDEC
    and Merger Sub of the transactions contemplated hereby, have
    been duly authorized by all necessary corporate action on the
    part of IDEC and Merger Sub, and no other corporate proceedings
    on the part of IDEC or Merger Sub and no stockholder votes are
    necessary to authorize this Agreement or to consummate the
    transactions contemplated hereby, other than with respect to
    approval of the Share Issuance and the IDEC Charter Amendment,
    the IDEC Stockholder Approval. This Agreement has been duly
    executed and delivered by IDEC and
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">22
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Merger Sub. Assuming the due authorization,
    execution and delivery of this Agreement by Biogen, this
    Agreement constitutes the legal, valid and binding obligation of
    each of IDEC and Merger Sub, enforceable against IDEC and Merger
    Sub in accordance with its terms, subject to applicable
    bankruptcy, insolvency, reorganization, moratorium or other laws
    relating to or affecting the rights and remedies of creditors
    generally and to general principles of equity (regardless of
    whether considered in a proceeding in equity or at law).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;<I>Board Approval.</I> The Board of
    Directors of IDEC has (A) determined that this Agreement, the
    IDEC Charter Amendment, the Merger and the Share Issuance are
    advisable and fair to and in the best interest of IDEC and its
    stockholders, (B)&nbsp;approved and adopted this Agreement, the
    IDEC Charter Amendment, the Merger, the Share Issuance and the
    other transactions contemplated hereby, which adoption has not
    been rescinded or modified, (C)&nbsp;resolved (subject to
    <I>Section&nbsp;4.2(d)</I>) to recommend the IDEC Charter
    Amendment and the Share Issuance to its stockholders for
    approval and (D)&nbsp;directed that the IDEC Charter Amendment
    and the Share Issuance be submitted to its stockholders for
    consideration in accordance with this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;<I>Voting Requirements.</I> The
    affirmative vote in favor of approval of the IDEC Charter
    Amendment by the holders of a majority of the outstanding shares
    of IDEC Common Stock entitled to vote thereon and the
    affirmative vote in favor of approval of the Share Issuance by a
    majority of the votes cast thereon by holders of shares of IDEC
    Common Stock present in person or by proxy, in each case at a
    duly convened and held IDEC Stockholders&#146; Meeting
    (collectively, the <I>&#147;IDEC Stockholder
    Approval&#148;</I>), are the only votes of the holders of any
    class or series of IDEC&#146;s capital stock necessary to
    approve and adopt the IDEC Charter Amendment, the Share
    Issuance, this Agreement, the Merger and the other transactions
    contemplated hereby.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;<I>No Conflict.</I> The execution and
    delivery of this Agreement by IDEC and Merger Sub does not, and
    the consummation by IDEC and Merger Sub of the transactions
    contemplated hereby and compliance by IDEC and Merger Sub with
    the provisions of this Agreement will not, conflict with, or
    result in any violation of, or default (with or without notice
    or lapse of time, or both) under, require any consent, waiver or
    approval under, give rise to any right of termination or other
    right, or the cancellation or acceleration of any right or
    obligation or loss of a benefit under, or result in the creation
    of any Lien upon any of the properties or assets of IDEC or any
    of its Subsidiaries or any restriction on the conduct of
    IDEC&#146;s business or operations under, (A)&nbsp;the IDEC
    Organizational Documents or the IDEC Subsidiary Organizational
    Documents, (B)&nbsp;any Contract, permit, concession, franchise,
    license or authorization applicable to IDEC or any of its
    Subsidiaries or their respective properties or assets or (C)
    subject to the governmental filings and other matters referred
    to in <I>Section&nbsp;3.2(c)(v)</I>, any judgment, order,
    decree, statute, law, ordinance, rule or regulation applicable
    to IDEC or any of its Subsidiaries or their respective
    properties or assets, other than, in the case of
    clauses&nbsp;(B)&nbsp;and (C), any such conflicts, violations,
    defaults, rights, losses, restrictions or Liens, or failure to
    obtain consents, waivers or approvals, which, individually or in
    the aggregate, would not reasonably be likely to have a Material
    Adverse Effect on IDEC or Merger Sub.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;<I>Required Filings or Consents.</I> No
    consent, approval, order or authorization of, action by or in
    respect of, or registration, declaration or filing with, any
    Governmental Entity is required to be made or obtained by or
    with respect to IDEC or any of its Subsidiaries in connection
    with the execution and delivery of this Agreement by IDEC or
    Merger Sub, the approval of the IDEC Charter Amendment or the
    Share Issuance or the consummation by IDEC or Merger Sub of the
    transactions contemplated hereby, except for:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(A)&nbsp;the filing of a pre-merger notification
    and report form by IDEC and Merger Sub under the HSR Act and any
    applicable filings or notifications under the antitrust,
    competition or similar laws of any foreign jurisdiction;
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">23
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(B)&nbsp;the filing with the SEC of:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="13%"></TD>
    <TD width="87%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(1)&nbsp;the Form&nbsp;S-4 (including the Joint
    Proxy Statement);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(2)&nbsp;such reports under Section&nbsp;13(a),
    13(d), 15(d) or 16(a) of the Exchange Act as may be required in
    connection with this Agreement and the transactions contemplated
    hereby;
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(C)&nbsp;the filing of the Articles of Merger
    with the Secretary of State and appropriate documents with the
    relevant authorities of other states in which IDEC or Merger Sub
    are qualified to do business and such filings with state
    securities or other &#147;blue sky&#148; laws;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(D)&nbsp;the filing of the IDEC Charter Amendment
    with the Secretary of State of the State of Delaware;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(E)&nbsp;such consents, approvals, orders or
    authorizations, the failure of which to be made or obtained,
    individually or in the aggregate, would not reasonably be likely
    to have a Material Adverse Effect on IDEC or Merger Sub.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>SEC Documents; Financial
    Statements.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;IDEC has filed with the SEC all
    registration statements, prospectuses, reports, schedules,
    forms, statements, certifications and other documents (including
    exhibits and all other information incorporated by reference
    therein) required to be so filed by IDEC since January&nbsp;1,
    2001 (excluding the Joint Proxy Statement, the <I>&#147;IDEC SEC
    Documents&#148;</I>). As of their respective dates, the IDEC SEC
    Documents complied in all material respects with the
    requirements of the Securities Act or the Exchange Act, as the
    case may be, and the rules and regulations of the SEC
    promulgated thereunder applicable to such IDEC SEC Documents,
    and none of the IDEC SEC Documents, when filed, contained any
    untrue statement of a material fact or omitted to state a
    material fact required to be stated therein or necessary in
    order to make the statements therein, in light of the
    circumstances under which they were made, not misleading, except
    to the extent corrected by a subsequently filed IDEC SEC
    Document filed with the SEC prior to the date hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;The financial statements of IDEC
    included in the IDEC SEC Documents, including each IDEC SEC
    Document filed after the date hereof until the Effective Time,
    comply, as of their respective dates of filing with the SEC, in
    all material respects with applicable accounting requirements
    and the published rules and regulations of the SEC with respect
    thereto, have been prepared in accordance with GAAP (except, in
    the case of unaudited statements, as permitted by Form&nbsp;10-Q
    or 8-K of the SEC) applied on a consistent basis during the
    periods involved (except as may be indicated in the notes
    thereto) and fairly present the consolidated financial position
    of IDEC and its consolidated Subsidiaries as of the dates
    thereof and the consolidated results of their operations and
    cash flows for the periods then ended (subject, in the case of
    unaudited statements, to normal year-end audit adjustments which
    are not material).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;Except as reflected or reserved
    against in the balance sheet of IDEC dated March&nbsp;31, 2003
    included in the Form&nbsp;10-Q filed by IDEC with the SEC on
    May&nbsp;15, 2003 (including the notes thereto, the
    <I>&#147;IDEC Balance Sheet&#148;</I>), neither IDEC nor any of
    its Subsidiaries has any liabilities (absolute, accrued,
    contingent or otherwise) which are required by GAAP to be set
    forth on a consolidated balance sheet of IDEC and its
    consolidated Subsidiaries or in the notes thereto, other than
    (A)&nbsp;liabilities and obligations incurred since
    March&nbsp;31, 2003 in the ordinary course of business
    consistent with past practice which would not reasonably be
    likely to have a Material Adverse Effect on IDEC and
    (B)&nbsp;liabilities and obligations incurred in connection with
    this Agreement or the transactions contemplated hereby.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;Neither IDEC nor any of its
    Subsidiaries is a party to, or has any commitment to become a
    party to, any joint venture, partnership or any similar contract
    or arrangement (including without limitation any contract or
    arrangement relating to any transaction or
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">24
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">relationship between or among IDEC and any of its
    Subsidiaries, on the one hand, and any unconsolidated Affiliate,
    including without limitation any structured finance, special
    purpose or limited purpose entity or Person, on the other hand),
    where the result, purpose or intended effect of such contract or
    arrangement is to avoid disclosure of any material transaction
    involving, or material liabilities of, IDEC or any of its
    Subsidiaries in IDEC&#146;s or its Subsidiaries&#146; published
    financial statements.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>Information Supplied.</I> None of the
    information supplied or to be supplied by or on behalf of IDEC
    or Merger Sub for inclusion or incorporation by reference in
    (i)&nbsp;the Form&nbsp;S-4 will, at the time the Form&nbsp;S-4
    becomes effective under the Securities Act, contain any untrue
    statement of a material fact or omit to state any material fact
    required to be stated therein or necessary to make the
    statements therein not misleading or (ii)&nbsp;the Joint Proxy
    Statement will, at the date it is first mailed to IDEC&#146;s
    stockholders or at the time of the IDEC Stockholders&#146;
    Meeting, contain any untrue statement of a material fact or omit
    to state any material fact required to be stated therein or
    necessary in order to make the statements therein, in light of
    the circumstances under which they are made, not misleading. The
    Joint Proxy Statement and the Form&nbsp;S-4 will comply as to
    form in all material respects with the requirements of the
    Securities Act and the Exchange Act and the rules and
    regulations thereunder, except that no representation or
    warranty is made by IDEC with respect to information or
    statements with respect to Biogen or its Subsidiaries made or
    incorporated by reference therein supplied by or on behalf of
    Biogen for inclusion or incorporation by reference in the Joint
    Proxy Statement or the Form&nbsp;S-4.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>Absence of Certain Changes or
    Events.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;Since December&nbsp;31, 2002 through the
    date hereof, except as and to the extent disclosed in the IDEC
    SEC Documents filed prior to the date of this Agreement:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(A)&nbsp;IDEC and its Subsidiaries have conducted
    their business only in the ordinary course consistent with past
    practice;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(B)&nbsp;there has not been any split,
    combination or reclassification of any of IDEC&#146;s capital
    stock or any declaration, setting aside or payment of any
    dividend on, or other distribution (whether in cash, stock or
    property) in respect of, in lieu of, or in substitution for,
    shares of IDEC&#146;s capital stock;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(C)&nbsp;except as required by a change in GAAP,
    there has not been any change in accounting methods, principles
    or practices by IDEC;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(D)&nbsp;there has not been any action taken by
    IDEC or any of its Subsidiaries that, if taken during the period
    from the date of this Agreement through the Effective Time,
    would constitute a breach of <I>Section&nbsp;4.1(b)</I>, other
    than actions in connection with entering into this Agreement.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;Since December&nbsp;31, 2002 through
    the date hereof, there have not been any changes, circumstances
    or events that, individually or in the aggregate, have had, or
    would reasonably be likely to have, a Material Adverse Effect on
    IDEC.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(g)&nbsp;<I>Compliance with Applicable Laws;
    Permits; Litigation.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;IDEC, its Subsidiaries and employees
    hold all permits, licenses, easements, variances, exemptions,
    orders, consents, registrations and approvals of all
    Governmental Entities (including all authorizations under the
    FDCA and the regulations of the FDA promulgated thereunder)
    which are required for the operation of the businesses of IDEC
    and its Subsidiaries in the manner described in the IDEC SEC
    Documents filed prior to the date hereof or as they are being
    conducted as of the date hereof (the <I>&#147;IDEC
    Permits&#148;</I>), and all IDEC Permits are in full force and
    effect, except where the failure to have, or the suspension or
    cancellation of, or the failure to be valid or in full force and
    effect of, any such IDEC Permits individually or in the
    aggregate would not reasonably be likely to have a Material
    Adverse Effect on IDEC. As of the
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">25
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">date hereof, IDEC and its Subsidiaries are in
    compliance with the terms of the IDEC Permits and all Applicable
    Laws relating to IDEC and its Subsidiaries or their respective
    business or properties, except where the failure to be in
    compliance with the terms of the IDEC Permits or such Applicable
    Laws individually or in the aggregate would not reasonably be
    likely to have a Material Adverse Effect on IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;As of the date hereof, except as and to
    the extent disclosed in the IDEC SEC Documents filed prior to
    the date of this Agreement, including the notes to the financial
    statements included therein, no action, demand, suit,
    proceeding, requirement or investigation by any Governmental
    Entity and no suit, action, mediation, arbitration or proceeding
    by any Person, against or affecting IDEC or any of its
    Subsidiaries or any of their respective properties, including
    Intellectual Property, is pending or, to the Knowledge of IDEC,
    threatened which individually or in the aggregate would
    reasonably be likely to have a Material Adverse Effect on IDEC
    or Merger Sub.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;As of the date hereof, neither IDEC
    nor any of its Subsidiaries is subject to any outstanding order,
    injunction or decree which, individually or in the aggregate,
    has had or would reasonably be likely to have a Material Adverse
    Effect on IDEC.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(h)&nbsp;<I>Labor and Other Employment
    Matters.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;As of the date hereof, except as would
    not, individually or in the aggregate, reasonably be likely to
    have a Material Adverse Effect on IDEC, (a)&nbsp;no work
    stoppage, slowdown, lockout, labor strike, material arbitrations
    or other material labor disputes against IDEC or any of its
    Subsidiaries are pending or, to the Knowledge of IDEC,
    threatened, (b)&nbsp;no unfair labor practice charges,
    grievances or complaints are pending or, to the Knowledge of
    IDEC, threatened against IDEC or any of its Subsidiaries,
    (c)&nbsp;neither IDEC nor any of its Subsidiaries is delinquent
    in payments to any of its employees for any wages, salaries,
    commissions, bonuses or other direct compensation for any
    services performed for it or amounts required to be reimbursed
    to such employees, (d)&nbsp;IDEC and each of its Subsidiaries
    are in compliance with all Applicable Laws respecting labor and
    employment, including, but not limited to, terms and conditions
    of employment, workers&#146; compensation, occupational safety
    and health requirements, plant closings, wages and hours,
    employment discrimination, disability rights or benefits, equal
    opportunity, affirmative action, employee benefits, severance
    payments, labor relations, employee leave issues and
    unemployment insurance and related matters, (e)&nbsp;there are
    no complaints, charges or claims against IDEC or any of its
    Subsidiaries pending with or, to the Knowledge of IDEC,
    threatened by any Governmental Entity or arbitrator based on,
    arising out of, in connection with, or otherwise relating to the
    employment of any employees by IDEC and or any of its
    Subsidiaries, other than those occurring in the ordinary course
    of business, such as claims for workers&#146; compensation or
    unemployment benefits, (f)&nbsp;IDEC and each of its
    Subsidiaries have withheld all amounts required by Applicable
    Law to be withheld from the wages, salaries, and other payments
    to employees; and is not liable for any arrears of wages or any
    Taxes or any penalty for failure to comply with any of the
    foregoing, (g)&nbsp;neither IDEC nor any of its Subsidiaries is
    liable for any payment to any trust or other fund or to any
    Governmental Entity, with respect to unemployment compensation
    benefits, social security or other benefits or obligations for
    employees (other than routine payments to be made in the
    ordinary course of business consistent with past practice),
    (h)&nbsp;no employee of IDEC or any of its Subsidiaries, at the
    officer level or above, has given notice to IDEC or any of its
    Subsidiaries that any such employee intends to terminate his or
    her employment with IDEC or any of its Subsidiaries, and
    (i)&nbsp;to the Knowledge of IDEC, no employee of IDEC or any of
    its Subsidiaries is in any respect in violation of any term of
    any employment contract, non-disclosure agreement,
    noncompetition agreement, or any restrictive covenant to a
    former employer relating to the right of any such employee to be
    employed by IDEC or any of its Subsidiaries because of the
    nature of the business conducted or presently proposed to be
    conducted by IDEC or any of its Subsidiaries or to the use of
    trade secrets or proprietary information of others.
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">26
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;As of the date hereof,
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(A)&nbsp;neither IDEC nor any of its Subsidiaries
    is a party to, or otherwise bound by, any collective bargaining
    agreement or any other agreement with a labor union or labor
    organization, nor is any such agreement presently being
    negotiated;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(B)&nbsp;no labor organization or group of
    employees of IDEC or any of its Subsidiaries has made a pending
    demand for recognition or certification, and there are no
    representation or certification proceedings or petitions seeking
    a representation proceeding presently pending or, to the
    Knowledge of IDEC, threatened to be brought or filed with the
    National Labor Relations Board or any other labor relations
    tribunal or authority;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(C)&nbsp;to the Knowledge of IDEC, no labor union
    is seeking to organize any employees of IDEC or any of its
    Subsidiaries.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>Benefit Plans.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;With respect to each Benefit Plan with
    or for the benefit of any current or former employee, officer or
    director of IDEC or any of its Subsidiaries or ERISA Affiliates
    (the <I>&#147;IDEC Benefit Plans&#148;</I>), no event has
    occurred and there exists no condition or set of circumstances,
    which could reasonably be likely to have a Material Adverse
    Effect on IDEC under ERISA, the Code or any other Applicable Law.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;Each IDEC Benefit Plan has been, in all
    material respects, administered and operated in accordance with
    its terms, with the applicable provisions of ERISA, the Code and
    other Applicable Law and the terms of all applicable collective
    bargaining agreements. Each IDEC Benefit Plan, including any
    material amendments thereto, that is capable of Approval has
    received such Approval (or there remains a period of time in
    which to obtain such Approval retroactive to the date of any
    material amendment that has not previously received such
    Approval) and no event has occurred which would be reasonably
    likely to result in the revocation of such Approval or the
    imposition of material sanctions by such authorities.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;To the Knowledge of IDEC, no oral or
    written representation or commitment with respect to any
    material aspect of any IDEC Benefit Plan has been made to an
    employee or former employee of IDEC or any of its Subsidiaries
    by an authorized IDEC employee that is not materially in
    accordance with the written or otherwise preexisting terms and
    provisions of such IDEC Benefit Plans. To the Knowledge of IDEC,
    neither IDEC nor any of its Subsidiaries has entered into any
    agreement, arrangement or understanding, whether written or
    oral, with any trade union, works council or other employee
    representative body or any material number or category of its
    employees which would prevent, restrict or materially impede the
    implementation of any lay-off, redundancy, severance or similar
    program within its or their respective workforces (or any part
    of them).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;There are no material unresolved claims
    or disputes under the terms of, or in connection with, any IDEC
    Benefit Plan (other than routine undisputed claims for
    benefits), and no action, legal or otherwise, has been commenced
    or threatened with respect to any material claim or otherwise in
    connection with an IDEC Benefit Plan.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;With respect to each Funded Retirement
    Plan of IDEC or its Subsidiaries, the aggregate value of the
    assets of such Funded Retirement Plan is equal to or greater
    than the aggregate value of its liabilities assessed on an
    ongoing and terminated basis and calculated in accordance with
    the actuarial methods and assumptions used in such valuation
    pursuant to such Funded Retirement Plan and Applicable Law and
    GAAP. None of IDEC or any ERISA Affiliate of IDEC has incurred
    any liability to a Funded Retirement Plan under Title IV of
    ERISA (other than for contributions not yet due) or to the
    Pension Benefit Guaranty Corporation (other than for payment of
    premiums not yet due) that, when aggregated with other
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">27
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">such liabilities, would result in a material
    liability of IDEC and its Subsidiaries taken as a whole, which
    liability has not been fully paid.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;At no time has IDEC or any ERISA
    Affiliate of IDEC participated in and/or been obligated to
    contribute to any Benefit Plan that is a &#147;multiemployer
    plan&#148; within the meaning of Section&nbsp;3(37) of ERISA.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;No IDEC Benefit Plan provides health
    benefits (whether or not insured), with respect to employees or
    former employees of IDEC or any Subsidiary of IDEC after
    retirement or other termination of service (other than coverage
    mandated by Applicable Law or benefits, the full cost of which
    is borne by the employee or former employee).
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(viii)&nbsp;Neither the negotiation and execution
    of this Agreement nor the consummation of the transactions
    contemplated hereby will (either alone or upon the occurrence of
    any additional or subsequent events) constitute an event under
    any IDEC Benefit Plan that will or may result in any payment
    (whether of severance pay or otherwise), acceleration of
    payment, forgiveness of indebtedness, vesting, distribution,
    increase in benefits or obligation to fund benefits with respect
    to any employee or former employee of IDEC or any Subsidiary of
    IDEC. There is no contract, agreement, plan or arrangement with
    an employee or former employee of IDEC to which IDEC or any of
    its Subsidiaries is a party as of the date of this Agreement,
    that, individually or collectively and as a result of the
    transaction contemplated hereby (whether alone or upon the
    occurrence of any additional or subsequent events) or otherwise,
    would reasonably be likely to give rise to the payment of any
    amount that would not be deductible pursuant to
    Sections&nbsp;280G or 162(m) of the Code.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(j)&nbsp;<I>Taxes.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;Each of IDEC and its Subsidiaries,
    including any predecessors thereof, has (A)&nbsp;duly and timely
    filed (or there have been filed on its behalf) all material Tax
    Returns required to be filed by it (taking into account all
    applicable extensions) with the appropriate Tax Authority and
    all such Tax Returns are true, correct and complete in all
    material respects, (B)&nbsp;duly paid in full or made provision
    in accordance with GAAP (or there has been paid or provision has
    been made on its behalf) for the payment of all material Taxes
    for all periods ending through the date hereof, and
    (C)&nbsp;complied in all material respects with all Applicable
    Laws relating to the payment and withholding of Taxes.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;There are no material Liens for Taxes
    upon any property or assets of IDEC or any of its Subsidiaries,
    except for liens for Taxes not yet due and payable and for which
    adequate reserves have been provided in accordance with GAAP in
    the most recent financial statements contained in the IDEC SEC
    Documents filed prior to the date of this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;The unpaid Taxes of IDEC and its
    Subsidiaries (A)&nbsp;did not, as of the most recent financial
    statements contained in the IDEC SEC Documents filed prior to
    the date of this Agreement, exceed the reserve for Tax liability
    (rather than any reserve for deferred Taxes established to
    reflect timing differences between book and Tax income) set
    forth on the face of such financial statements (rather than in
    any notes thereto), and (B)&nbsp;do not exceed that reserve as
    adjusted for the passage of time since the date of such
    financial statements in accordance with the past custom and
    practice of IDEC and its Subsidiaries in filing their Tax
    Returns.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;There is no audit, examination,
    deficiency, refund litigation, proposed adjustment or matter in
    controversy with respect to any Taxes or Tax Return of IDEC or
    its Subsidiaries which if determined adversely would be expected
    to result in a material Tax deficiency. Neither IDEC nor any of
    its Subsidiaries has received notice of any claim made by a
    governmental authority in a jurisdiction where IDEC or any of
    its Subsidiaries, as applicable, does not file a Tax Return,
    that IDEC or such Subsidiary is or may be subject to taxation by
    that jurisdiction.
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">28
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;The material income Tax Returns of IDEC
    and each of its Subsidiaries, including any predecessors
    thereof, have been examined by the applicable Tax Authority (or
    the applicable statutes of limitations for the assessment of
    income Taxes for such periods have expired) for all periods
    through and including December&nbsp;31, 1997, and no material
    deficiencies were asserted as a result of such examinations
    which have not been resolved and fully paid or accrued as a
    liability on the most recent financial statements contained in
    the IDEC SEC Documents.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;There are no outstanding requests,
    agreements, consents or waivers to extend the statutory period
    of limitations applicable to the assessment of any Taxes or
    deficiencies against IDEC or any of its Subsidiaries, and no
    power of attorney granted by either IDEC or any of its
    Subsidiaries with respect to any Taxes is currently in force.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;Neither IDEC nor any of its
    Subsidiaries is a party to any agreement providing for the
    allocation or sharing of Taxes imposed on or with respect to any
    individual or other Person, and neither IDEC nor any of its
    Subsidiaries (A)&nbsp;has been a member of an affiliated group
    (or similar state, local or foreign filing group) filing a
    consolidated income Tax Return (other than the group the common
    parent of which is IDEC) or (B)&nbsp;has any liability for the
    Taxes of any Person (other than IDEC or any of its Subsidiaries)
    under Treasury Regulation &#167;&nbsp;1.1502-6 (or any similar
    provision of state, local or foreign law), as a transferee or
    successor, by contract, or otherwise.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(viii)&nbsp;IDEC and each of its Subsidiaries has
    delivered or made available to Biogen complete copies of all
    material income Tax Returns of IDEC and each of its
    Subsidiaries, including any predecessors thereof, for taxable
    years ending between January&nbsp;1, 1999 and December&nbsp;31,
    2002, excepting such Tax Returns as have not been filed for the
    taxable year ending December&nbsp;31, 2002 pursuant to
    appropriate extensions with respect thereto.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ix)&nbsp;Neither IDEC nor any of its
    Subsidiaries has: (A)&nbsp;filed a consent under
    Section&nbsp;341(f) of the Code concerning collapsible
    corporations; (B)&nbsp;agreed to make nor is it required to make
    any material adjustment under Section&nbsp;481(a) of the Code by
    reason of a change in accounting method or otherwise;
    (C)&nbsp;constituted either a &#147;distributing
    corporation&#148; or a &#147;controlled corporation&#148;
    (within the meaning of Section&nbsp;355(a)(1)(A) of the Code) in
    a distribution of stock qualifying for tax-free treatment under
    Section&nbsp;355 of the Code (I)&nbsp;in the two years prior to
    the date of this Agreement or (II)&nbsp;in a distribution which
    could otherwise constitute part of a &#147;plan&#148; or
    &#147;series of related transactions&#148; (within the meaning
    of Section&nbsp;355(e) of the Code) in connection with the
    Merger; or (D)&nbsp;taken any action or knows of any fact,
    agreement, plan or other circumstance that is reasonably likely
    to prevent the Merger from qualifying as a
    &#147;reorganization&#148; within the meaning of
    Section&nbsp;368(a) of the Code.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(x)&nbsp;Neither IDEC nor any of its Subsidiaries
    is, or has been, a United States real property holding
    corporation (as defined in Section&nbsp;897(c)(2) of the Code)
    during the applicable period specified in
    Section&nbsp;897(c)(1)(A)(ii) of the Code.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(k)&nbsp;<I>Regulatory Compliance; Supply.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;All biological and drug products
    currently being manufactured, distributed or developed by IDEC
    or its Subsidiaries, or by any other Person pursuant to a
    development, commercialization, manufacturing, supply or other
    collaboration arrangement (other than an arrangement that is
    solely a license to market, distribute or sell products in a
    specified territory) with IDEC or any of its Subsidiaries (any
    such other Person acting under or in respect of such an
    arrangement, an <I>&#147;IDEC Collaboration Partner&#148;</I>
    and any such an arrangement with IDEC or any of its
    Subsidiaries, an <I>&#147;IDEC Collaboration&#148;</I>), that
    are subject to the jurisdiction of the FDA are, or, in the case
    of such manufacture, distribution or development by an IDEC
    Collaboration Partner pursuant to an IDEC Collaboration, to the
    Knowledge of IDEC are, being manufactured, labeled, stored,
    tested, distributed, and marketed in compliance with all
    applicable requirements under the FDCA, the Public Health
    Service Act, and their applicable implementing regulations,
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">29
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">except for such noncompliance which would not,
    individually or in the aggregate, reasonably be likely to have a
    Material Adverse Effect on IDEC. The biological and drug
    products described in this <I>Section&nbsp;3.2(k)(i)</I> are
    sometimes referred to herein as <I>&#147;IDEC Pharmaceutical
    Products.&#148;</I>
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;All clinical trials being conducted by
    IDEC or its Subsidiaries are, or, in the case of such trials
    being conducted by an IDEC Collaboration Partner pursuant to an
    IDEC Collaboration, to the Knowledge of IDEC are, being
    conducted in material compliance with the applicable
    requirements of Good Clinical Practice and all applicable
    requirements relating to protection of human subjects contained
    in 21&nbsp;C.F.R. Parts 50, 54, and 56, except for such
    noncompliance which would not, individually or in the aggregate,
    reasonably be likely to have a Material Adverse Effect on IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;The manufacture of IDEC Pharmaceutical
    Products is, or, in the case of any IDEC Pharmaceutical Products
    manufactured by an IDEC Collaboration Partner pursuant to an
    IDEC Collaboration, to the Knowledge of IDEC is, being conducted
    in compliance with the FDA&#146;s applicable current Good
    Manufacturing Practice regulations for drug and biological
    products, except for such noncompliance which would not,
    individually or in the aggregate, reasonably be likely to have a
    Material Adverse Effect on IDEC. In addition, IDEC and its
    Subsidiaries and, to the Knowledge of IDEC, their respective
    IDEC Collaboration Partners with respect to their activities
    pursuant to an IDEC Collaboration, are in compliance with all
    applicable registration and listing requirements set forth in
    21&nbsp;U.S.C. Section&nbsp;360 and 21&nbsp;C.F.R. Part&nbsp;207
    and all similar Applicable Laws, except for such noncompliance
    which would not, individually or in the aggregate, reasonably be
    likely to have a Material Adverse Effect on IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;No IDEC Pharmaceutical Product has been
    recalled, suspended or discontinued as a result of any action by
    the FDA or similar foreign Governmental Entity.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;Since January&nbsp;1, 2001, none of
    IDEC, its Subsidiaries nor, to the Knowledge of IDEC, their
    respective Collaboration Partners, has received any notice that
    the FDA or any other Governmental Entity has initiated or is
    considering initiating any steps, procedures or action to
    withdraw approval for or enjoin the production, sale, marketing
    or reimbursement of, or request the recall of, any IDEC
    Pharmaceutical Product.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;None of IDEC, any of its Subsidiaries,
    nor, to the Knowledge of IDEC, any of their respective IDEC
    Collaboration Partners with respect to their activities pursuant
    to an IDEC Collaboration, has committed any act, made any
    statement or failed to make any statement that would reasonably
    be likely to provide a basis for the FDA to invoke its policy
    with respect to &#147;Fraud, Untrue Statements of Material
    Facts, Bribery, and Illegal Gratuities&#148; set forth in 56
    Fed. Reg. 46191 (September&nbsp;10, 1991) and any amendments
    thereto. Additionally, none of IDEC, its Subsidiaries nor, to
    the Knowledge of IDEC, any of their respective officers, key
    employees, agents, nor, to the Knowledge of IDEC, any IDEC
    Collaboration Partner nor any officer, key employee or agent
    thereof, has been convicted of any crime or engaged in any
    conduct (in the case of any IDEC Collaboration Partner or any
    officer, key employee or agent thereof, arising out of or in
    connection with acts or omissions pursuant to an IDEC
    Collaboration) that would reasonably be likely to result in
    (i)&nbsp;debarment under 21&nbsp;U.S.C. Section&nbsp;335a or any
    similar state law or regulation or (ii)&nbsp;exclusion under
    42&nbsp;U.S.C. Section&nbsp;1320a-7 or any similar state law or
    regulation.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;IDEC has, or, to the Knowledge of
    IDEC, the IDEC Collaboration Partners that manufacture IDEC
    Pharmaceutical Products pursuant to an IDEC Collaboration have,
    sufficient manufacturing capacity and access to sufficient
    supply of materials to satisfy the reasonably anticipated
    clinical and commercial requirements for IDEC Pharmaceutical
    Products.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(l)&nbsp;<I>Environmental Matters.</I> As of the
    date hereof, except as would not, individually or in the
    aggregate, reasonably be likely to have a Material Adverse
    Effect on IDEC, (i)&nbsp;the operations of IDEC and its
    Subsidiaries are in compliance with all applicable Environmental
    Laws, including
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">30
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">possession and compliance with the terms of all
    licenses required by Environmental Laws, (ii)&nbsp;there are no
    pending, or to the Knowledge of IDEC, threatened suits, actions,
    investigations or proceedings under or pursuant to Environmental
    Laws against IDEC or its Subsidiaries or involving any real
    property currently or, to the Knowledge of IDEC, formerly owned,
    operated or leased by IDEC or its Subsidiaries, (iii)&nbsp;IDEC
    and its Subsidiaries are not subject to and have received no
    written allegations of any Environmental Liabilities and, to the
    Knowledge of IDEC, no facts, circumstances or conditions
    relating to, arising from, associated with or attributable to
    any real property currently or, to the Knowledge of IDEC,
    formerly owned, operated or leased by IDEC or its Subsidiaries
    or operations thereon has resulted in or would reasonably be
    likely to result in Environmental Liabilities, and (iv)&nbsp;all
    real property owned or operated by IDEC or its Subsidiaries is
    free of contamination from Hazardous Materials that would have
    an adverse effect on human health or the environment.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(m)&nbsp;<I>Intellectual Property.</I> Except as
    would not, individually or in the aggregate, reasonably be
    expected to have a Material Adverse Effect on IDEC,
    (i)&nbsp;IDEC and each of its Subsidiaries owns or has a legally
    enforceable right to use (in each case, free and clear of any
    Liens) all Intellectual Property used in or necessary for the
    conduct of its business as currently conducted, including
    without limitation all patents and patent applications and all
    trademark registrations and trademark applications; (ii)&nbsp;to
    the Knowledge of IDEC, the conduct of the business of IDEC and
    its Subsidiaries as currently conducted does not infringe on or
    misappropriate, either directly or indirectly, the Intellectual
    Property rights of any Person and the use by IDEC or its
    Subsidiaries of any Intellectual Property is, to the Knowledge
    of IDEC, in accordance with any applicable grant, license,
    agreement, instrument or other arrangement pursuant to which
    IDEC or any Affiliate acquired the right to use such
    Intellectual Property; (iii)&nbsp;to the Knowledge of IDEC, no
    Person has advised IDEC or any of its Subsidiaries in writing
    that it is challenging or threatening to challenge the
    ownership, use, validity or enforceability of any Intellectual
    Property owned or used by IDEC or its Subsidiaries; (iv)&nbsp;to
    the Knowledge of IDEC, no Person is misappropriating,
    infringing, diluting or otherwise violating any right of IDEC or
    any of its Subsidiaries with respect to any Intellectual
    Property owned or used by IDEC or its Subsidiaries; (v)&nbsp;to
    the Knowledge of IDEC, neither IDEC nor any of its Subsidiaries
    has received written notice of any pending or threatened claim,
    order or proceeding with respect to the validity, enforcement or
    maintenance of any Intellectual Property owned or used by IDEC
    or its Subsidiaries and, to the Knowledge of IDEC, no
    Intellectual Property owned or used by IDEC or its Subsidiaries
    is being used or enforced in a manner that would reasonably be
    expected to result in the abandonment, cancellation or
    unenforceability of such Intellectual Property; (vi)&nbsp;to the
    Knowledge of IDEC, the Intellectual Property owned or used by
    IDEC or its Subsidiaries has not expired, been cancelled or
    abandoned and all maintenance and renewal fees necessary to
    preserve the rights of IDEC in connection with such Intellectual
    Property have been paid in a timely manner; (vii)&nbsp;neither
    IDEC nor any of its Subsidiaries has entered into any consent,
    indemnification, forbearance to sue, settlement agreement,
    license or other arrangement which reasonably could be expected
    to provide a third party a defense to patent infringement in
    connection with any Intellectual Property owned or used by IDEC;
    (viii)&nbsp;to the Knowledge of IDEC, IDEC and each of its
    Subsidiaries has implemented commercially reasonable measures to
    maintain the confidentiality of the Intellectual Property and
    all other property used in the business of IDEC or its
    Subsidiaries as presently conducted; (ix)&nbsp;each current and
    former employee of IDEC or its Subsidiaries who has contributed
    to or participated in research and development activities has
    entered into an agreement with IDEC or a IDEC Subsidiary that
    has accorded IDEC or the Subsidiary full, effective and
    exclusive ownership rights in and to all tangible or intangible
    property created thereby; and (x)&nbsp;each employee, officer
    and director of IDEC or its Subsidiaries has entered into an
    agreement to maintain the confidential information of IDEC and
    its Subsidiaries and, to the Knowledge of IDEC, all consultants
    of IDEC or its Subsidiaries who have been in a position to
    receive any confidential information of IDEC or its Subsidiaries
    have entered into written agreements with IDEC or its
    Subsidiaries to maintain the confidentiality of all such
    information.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(n)&nbsp;<I>State Takeover Statutes.</I> The
    Board of Directors of IDEC has adopted a resolution or
    resolutions approving this Agreement, the Merger, the Share
    Issuance, and the other transactions
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">31
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">contemplated hereby, and, assuming the accuracy
    of Biogen&#146;s representation and warranty contained in
    <I>Section&nbsp;3.1(q)</I>(without giving effect to the
    Knowledge qualification contained therein), such approval
    constitutes approval of the Merger, the Share Issuance and the
    other transactions contemplated hereby by the Board of Directors
    of IDEC under the provisions of Section&nbsp;203 of the Delaware
    General Corporation Law <I>(&#147;Section&nbsp;203&#148;)</I>
    such that Section&nbsp;203 does not apply to this Agreement, the
    Share Issuance and the other transactions contemplated hereby.
    To the Knowledge of IDEC, no state takeover statute other than
    Section&nbsp;203 (which has been rendered inapplicable) is
    applicable to the Merger, the Share Issuance or the other
    transactions contemplated hereby.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(o)&nbsp;<I>Brokers.</I> Except for fees payable
    to Merrill Lynch&nbsp;&#38; Co., no broker, investment banker,
    financial advisor or other Person is entitled to any
    broker&#146;s, finder&#146;s, financial advisor&#146;s or other
    similar fee or commission in connection with the transactions
    contemplated by this Agreement based upon arrangements made by
    or on behalf of IDEC or Merger Sub.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(p)&nbsp;<I>Opinion of Financial Advisor.</I>
    IDEC has received the opinion of its financial advisor, Merrill
    Lynch&nbsp;&#38; Co., dated the date of this Agreement, to the
    effect that, as of such date, the Exchange Ratio is fair, from a
    financial point of view, to holders of IDEC Common Stock.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(q)&nbsp;<I>Ownership of Biogen Common Stock.</I>
    None of IDEC, Merger Sub, their respective Subsidiaries or, to
    the Knowledge of IDEC without independent investigation, any of
    their respective Affiliates, (i)&nbsp;beneficially owns (as
    defined in Rule&nbsp;13d-3 under the Exchange Act) directly or
    indirectly, or is party to any agreement, arrangement or
    understanding for the purpose of acquiring, holding, voting or
    disposing of, shares of capital stock of Biogen, or
    (ii)&nbsp;within the preceding thirty-six (36)&nbsp;months,
    beneficially owned directly or indirectly, or was party to any
    agreement, arrangement or understanding for the purpose of
    acquiring, holding, voting or disposing of, shares of capital
    stock of Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(r)&nbsp;<I>Material Contracts.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;For purposes of this Agreement,
    <I>&#147;IDEC Material Contract&#148;</I> shall mean:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(1)&nbsp;any &#147;material contracts&#148; (as
    such term is used in Item&nbsp;601(b)(10) of Regulation&nbsp;S-K
    of the SEC) with respect to IDEC and its Subsidiaries;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(2)&nbsp;any Contract to which IDEC or any of its
    Subsidiaries is a party, which is material to IDEC and its
    Subsidiaries, taken together, and which (A)&nbsp;contains any
    covenant limiting or restricting the right of IDEC or any of its
    Subsidiaries or that would, after the Effective Time, limit or
    restrict IDEC or any of its Subsidiaries (including the
    Surviving Corporation and its Subsidiaries) from
    (x)&nbsp;engaging or competing in any material line of business
    or in any geographic area or with any Person in any material
    line of business or (y)&nbsp;making use of any material
    Intellectual Property owned by or necessary for the conduct of
    the businesses of IDEC and its Subsidiaries in the manner
    described in the IDEC SEC Documents filed prior to the date
    hereof and as they are currently being conducted,
    (B)&nbsp;relates to the development, co-promotion,
    commercialization, manufacturing, supply or distribution of any
    material product, the out-licensing to third parties of
    Intellectual Property relating to any material product or the
    in-licensing from third parties of Intellectual Property
    relating to any material product, or (C)&nbsp;adversely affects
    the right of IDEC or any of its Subsidiaries to use, sell,
    distribute, manufacture or have manufactured or supply any
    material product; and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(3)&nbsp;any Contract or group of Contracts with
    a Person (or group of affiliated Persons) to which IDEC or any
    of its Subsidiaries is a party, the termination or breach of
    which would be reasonably likely to have a Material Adverse
    Effect on IDEC.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;<I>Schedule.</I>
    <I>Section&nbsp;3.2(r)(ii)</I> of the IDEC Disclosure Schedule
    sets forth a list of all IDEC Material Contracts as of the date
    hereof.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;<I>No Breach.</I> All IDEC Material
    Contracts are valid and in full force and effect and enforceable
    in accordance with their respective terms, subject to applicable
    bankruptcy,
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">32
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">insolvency, reorganization, moratorium or other
    laws relating to or affecting the rights and remedies of
    creditors generally and to general principles of equity
    (regardless of whether considered in a proceeding in equity or
    at law), except to the extent that (A)&nbsp;they have previously
    expired in accordance with their terms or (B)&nbsp;the failure
    to be in full force and effect, individually or in the
    aggregate, would not reasonably be likely to have a Material
    Adverse Effect on IDEC. Neither IDEC nor any of its
    Subsidiaries, nor, to IDEC&#146;s Knowledge, any counterparty to
    any IDEC Material Contract, has violated any provision of, or
    committed or failed to perform any act which, with or without
    notice, lapse of time or both would constitute a default under
    the provisions of, any IDEC Material Contract, except in each
    case for those violations and defaults which, individually or in
    the aggregate, would not reasonably be likely to have a Material
    Adverse Effect on IDEC.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(s)&nbsp;<I>Interested Party Transactions.</I>
    Since the date of the IDEC Balance Sheet, no event has occurred
    that would be required to be reported as a Certain Relationship
    or Related Transaction pursuant to Statement of Financial
    Accounting Standards No.&nbsp;57 or Item&nbsp;404 of
    Regulation&nbsp;S-K of the SEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(t)&nbsp;<I>IDEC Rights Agreement.</I> IDEC has
    taken all action (including without limitation amending the IDEC
    Rights Agreement to clarify and confirm that, prior to the
    Effective Time, a Person shall not be deemed the
    &#147;Beneficial Owner&#148; or to have &#147;Beneficial
    Ownership&#148; of, or to &#147;Beneficially Own&#148; (as such
    terms are defined in the IDEC Rights Agreement), any shares of
    IDEC Common Stock into which, pursuant to
    <I>Section&nbsp;2.1(a)</I> of this Agreement, shares of Biogen
    Common Stock are convertible at the Effective Time) so that,
    prior to the Effective Time, the execution of this Agreement and
    the pending Merger and related transactions contemplated hereby
    do not and will not, in and of themselves, result in the grant
    of any rights to any Person under the IDEC Rights Agreement or
    enable, require or cause the IDEC Rights to be exercised,
    distributed (separately from shares of IDEC Common Stock) or
    triggered.
    </FONT></TD>
</TR>

</TABLE>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;IV</FONT></B>

<P align="center">
<B><FONT size="2">COVENANTS RELATING TO CONDUCT OF
BUSINESS</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Conduct
of Business.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Ordinary Course.</I> Except as
    otherwise expressly required by, or provided for, in this
    Agreement, or as consented to by the other party in writing,
    during the period from the date of this Agreement to the
    Effective Time, each of Biogen and IDEC shall, and shall cause
    each of their respective Subsidiaries to, carry on its business
    in the ordinary course consistent with past practice, maintain
    its existence in good standing under Applicable Law and use all
    commercially reasonable efforts to (i)&nbsp;preserve intact its
    current business organization, (ii)&nbsp;keep available the
    services of its current officers and key employees and
    (iii)&nbsp;preserve its relationships with its customers,
    suppliers and other persons with which it has significant
    business relations.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Required Consent.</I> Without
    limiting the generality of <I>Section&nbsp;4.1(a)</I>, except as
    otherwise expressly required by, or provided for in, this
    Agreement, or as set forth in <I>Section&nbsp;4.1(b)</I> of the
    Biogen Disclosure Schedule or <I>Section&nbsp;4.1(b)</I> of the
    IDEC Disclosure Schedule (as the case may be), without the prior
    consent of the other party hereto, during the period from the
    date of this Agreement to the Effective Time, neither Biogen nor
    IDEC shall do any of the following, and shall not permit any of
    their respective Subsidiaries to do any of the following:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;other than dividends and distributions
    by a direct or indirect wholly owned Subsidiary of a party
    hereto to its parent, or by a Subsidiary of a party hereto that
    is partially owned by such party or any of its Subsidiaries,
    <I>provided</I> that such party or such Subsidiary receives or
    is to receive its proportionate share thereof, (A)&nbsp;declare,
    set aside or pay any dividends on, make any other distributions
    in respect of, or enter into any agreement with respect to the
    voting of, any of its or any of its Subsidiary&#146;s capital
    stock, (B)&nbsp;split, combine or reclassify any of its or any
    of its
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">33
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Subsidiary&#146;s capital stock or issue or
    authorize the issuance of any other securities in respect of, in
    lieu of or in substitution for, shares of its or any of its
    Subsidiary&#146;s capital stock, or (C)&nbsp;purchase, redeem or
    otherwise acquire any shares of its or any of its
    Subsidiary&#146;s capital stock or any other securities thereof
    or any rights, warrants or options to acquire any such shares or
    other securities (except, in the case of clause&nbsp;(C), for
    (1)&nbsp;the deemed acceptance of shares upon cashless exercise
    of IDEC Options or Biogen Options outstanding on the date of
    this Agreement, (2)&nbsp;repurchases by Biogen or IDEC pursuant
    to a publicly announced repurchase program existing as of
    December&nbsp;31, 2002, or (3)&nbsp;purchases by Biogen for
    Biogen Defined Contribution Plans or purchases by IDEC for IDEC
    Defined Contribution Plans in the ordinary course of business
    consistent with past practice);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;issue, sell, deliver, pledge, or
    otherwise encumber or subject to any Lien, any shares of its or
    any of its Subsidiary&#146;s capital stock, any other voting
    securities or any securities convertible into, or exchangeable
    for, or any rights, warrants or options to acquire, any such
    shares, voting securities or convertible or exchangeable
    securities, other than (A)&nbsp;the issuance of IDEC Common
    Stock upon the exercise or conversion of IDEC Options or Biogen
    Common Stock upon the exercise or conversion of Biogen Options,
    as the case may be, in each case outstanding as of the date of
    this Agreement in accordance with their present terms,
    (B)&nbsp;the issuance of IDEC Options (and shares of IDEC Common
    Stock upon the exercise thereof) or Biogen Options (and shares
    of Biogen Common Stock upon the exercise thereof) granted after
    the date of this Agreement in the ordinary course of business
    consistent with past practice to employees (so long as such
    additional amount of IDEC Common Stock subject to IDEC Options
    or Biogen Common Stock subject to Biogen Options issued to such
    employees does not exceed a number of shares of IDEC Common
    Stock or Biogen Common Stock representing in the aggregate more
    than 0.75% of the shares of IDEC Common Stock or Biogen Common
    Stock outstanding on the date hereof, as applicable),
    (C)&nbsp;the issuance of shares of Biogen Common Stock or IDEC
    Common Stock in the ordinary course of business consistent with
    past practice to participants in the Biogen Purchase Plans or
    the IDEC Purchase Plan, respectively, or (D)&nbsp;the
    contribution of shares of Biogen Common Stock or IDEC Common
    Stock in the ordinary course of business consistent with past
    practice to a Biogen Defined Contribution Plan or an IDEC
    Defined Contribution Plan;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;amend any IDEC Organizational
    Document, IDEC Subsidiary Organizational Document, Biogen
    Organizational Document or Biogen Subsidiary Organizational
    Document;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;acquire or agree to acquire, by merging
    or consolidating with, or by purchasing any equity interest in
    or a portion of the assets of, or by any other manner, any
    Person or any business or division thereof, or otherwise acquire
    or agree to acquire any assets which are material individually
    or in the aggregate to its and its Subsidiaries&#146; business,
    taken as a whole, other than any (y)&nbsp;Permitted Acquisition
    or (z)&nbsp;any joint venture, development, commercialization,
    manufacturing, supply or other collaboration arrangement,
    strategic partnership, alliance, license or sublicense permitted
    by the exception in <I>Section&nbsp;4.1(b)(xiv)</I>. For
    purposes of this Agreement, a <I>&#147;Permitted
    Acquisition&#148;</I> by a party hereto shall mean any
    acquisition transaction (or series of acquisition transactions),
    (A)&nbsp;which is in the existing line of business of such party
    or any of its Subsidiaries, such existing line of business to be
    deemed to include research in immunology, neurology, dermatology
    and oncology, and the development, manufacturing, supply,
    marketing, distribution and sale of therapies for the treatment
    of cancer and autoimmune, inflammatory, neurogenerative and
    dermatologic diseases, or a related line of business,
    (B)&nbsp;in which the fair market value of the total
    consideration (including the value of indebtedness or other
    obligations assumed or acquired in connection with such
    transaction(s)) issued in exchange therefor, does not exceed
    fifteen million dollars ($15,000,000) in the aggregate and, when
    taken together with the fair market value of such total
    consideration issued in previously committed or consummated
    Permitted Acquisitions pursuant to the exception in (iv)(y)
    above, does not exceed thirty million dollars ($30,000,000) in
    the aggregate, (C)&nbsp;which does not present a
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">34
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">material risk of delaying the Merger or making it
    more difficult to obtain any required consents or approvals
    therefor, <I>and</I> (D) which does not require approval of such
    party&#146;s stockholders;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;sell, pledge, dispose of, transfer,
    lease, license or otherwise encumber, or authorize the sale,
    pledge, disposition, transfer, lease, license or other
    encumbrance of, any of its or any of its Subsidiary&#146;s
    property or assets (other than Intellectual Property), except
    (A)&nbsp;sales, pledges, dispositions, transfers, leases,
    licenses or encumbrances of such property or assets pursuant to
    and in compliance with binding Contracts in effect as of the
    date hereof, but not to exceed an aggregate value of ten million
    dollars ($10,000,000) for all sales, pledges, dispositions,
    transfers, leases, licenses or encumbrances made in reliance on
    this clause&nbsp;(A), (B)&nbsp;sales, pledges, dispositions,
    transfers, leases, licenses or encumbrances of such property or
    assets in the ordinary course of business consistent with past
    practice but not to exceed an aggregate value of five million
    dollars ($5,000,000) for all sales, pledges, dispositions,
    transfers, leases, licenses or encumbrances made in reliance
    upon this clause&nbsp;(B), (C)&nbsp;sales, pledges,
    dispositions, transfers, leases, licenses or encumbrances of
    such property or assets other than in the ordinary course of
    business which do not materially impair the conduct of the
    business of such party and its Subsidiaries, taken as a whole,
    but not to exceed an aggregate value of two million dollars
    ($2,000,000) for all such sales, pledges, dispositions,
    transfers, leases, licenses or encumbrances made in reliance
    upon this clause&nbsp;(C), (D)&nbsp;sales or dispositions of
    inventory in the ordinary course of business consistent with
    past practice, or (E)&nbsp;sales or dispositions of cash
    equivalents or marketable securities in furtherance of the
    reinvestment of the proceeds of such sale in the ordinary course
    of business consistent with past practice;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;sell, pledge, dispose of, transfer,
    encumber, abandon or fail to maintain, or authorize the sale,
    pledge, disposition, transfer, encumbrance, abandonment or
    failure to maintain of, any of its or any of its
    Subsidiary&#146;s Intellectual Property, except such sales,
    pledges, dispositions, transfers, encumbrances, abandonments or
    failures to maintain in the ordinary course of business
    consistent with past practice which do not individually or in
    aggregate materially impair the conduct of the business of such
    party and its Subsidiaries, taken as a whole;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;make any loans, advances or capital
    contributions to, or investments in, any other Person, other
    than: (A)&nbsp;in connection with any Permitted Acquisition (it
    being understood in each case that any such loans, advances,
    contributions or investments shall be considered obligations
    assumed or acquired in such transaction), (B)&nbsp;in connection
    with a joint venture, development, commercialization,
    manufacturing, supply or other collaboration arrangement,
    strategic partnership, alliance, license or sublicense permitted
    by the exception in clause&nbsp;(xiv) below, (C)&nbsp;loans or
    advances by it or any of its wholly owned Subsidiaries to it or
    any of its wholly owned Subsidiaries, (D) investments or capital
    contributions in any of its wholly owned Subsidiaries,
    (E)&nbsp;employee advances made in the ordinary course of
    business consistent with past practice, (F)&nbsp;as required by
    binding Contracts in effect as of the date hereof, all of which
    Contracts are listed on <I>Section&nbsp;4.1(b)(vii)</I> of the
    Biogen Disclosure Schedule or IDEC Disclosure Schedule, as
    applicable, or (G)&nbsp;in the ordinary course of business
    consistent with past practice (<I>provided</I> that, in the case
    of clause&nbsp;(G), the aggregate amount of all such loans,
    advances, capital contributions and investments made in reliance
    upon such clause, other than investments in cash equivalents and
    marketable securities made in the ordinary course of business
    consistent with past practice, is not more than two million
    dollars ($2,000,000), and the transactions do not present a
    material risk of delaying the Merger or making it more difficult
    to obtain any required consents or approvals therefor, or
    require approval of such party&#146;s stockholders);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(viii)&nbsp;incur any indebtedness for borrowed
    money or issue any debt securities or assume, guarantee or
    endorse, or otherwise as an accommodation become responsible for
    the obligations of any Person for borrowed money, other than in
    the ordinary course of business consistent with past practice,
    <I>provided</I> the aggregate amount of all such indebtedness
    for borrowed money, debt
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">35
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">securities and obligations outstanding at any
    time by such party and its Subsidiaries is not more than five
    million dollars ($5,000,000);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ix)&nbsp;settle any material claim (including
    any Tax claim), action or proceeding, except
    (A)&nbsp;settlements in the ordinary course of business
    consistent with past practice, or (B) settlements to the extent
    subject to reserves existing as of the date hereof in accordance
    with GAAP (<I>provided</I> that any settlement made in reliance
    upon clause&nbsp;(A)&nbsp;or (B)&nbsp;does not materially impair
    the conduct of the business of such party and its Subsidiaries,
    taken as a whole);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(x)&nbsp;make any material Tax election except in
    the ordinary course of business and consistent with past
    practice;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xi)&nbsp;except for increases in the ordinary
    course of business consistent with past practice, or as required
    by binding Contracts in effect as of the date hereof, all of
    which are listed on <I>Section&nbsp;4.1(b)(xi)</I> of the Biogen
    Disclosure Schedule or IDEC Disclosure Schedule, as applicable
    (the <I>&#147;Existing Benefits Commitments&#148;</I>), or as
    otherwise provided for in <I>Section&nbsp;4.1(b)(xi) </I>of the
    Biogen Disclosure Schedule or IDEC Disclosure Schedule, as
    applicable, (A)&nbsp;increase in any manner the compensation or
    fringe benefits of any of its officers or directors, or
    materially increase any of the foregoing in respect of other
    employees, or (B)&nbsp;enter into any commitment to pay any
    pension, retirement or severance benefit to any such officers or
    directors or make any material commitment to pay any of the
    foregoing to any other employees;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xii)&nbsp;commit itself to, or enter into, any
    employment agreement involving compensation in excess of two
    hundred seventy-five thousand dollars ($275,000) per year or
    other than on an at will basis (for U.S.&nbsp;employees) or a
    term of more than twelve (12)&nbsp;months (for
    non-U.S.&nbsp;employees), adopt or commit itself to any material
    new benefit, base salary or stock option plan or arrangement, or
    amend, supplement, or, except as required by the Existing
    Benefits Commitments, accelerate the timing of payments or
    vesting under, or otherwise materially amend or supplement, any
    existing benefit, stock option or compensation plan or
    arrangement (other than as may be required by Applicable Law);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xiii)&nbsp;change any of their respective
    methods or principles of accounting unless required by GAAP or
    the SEC as concurred in by its independent auditors;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xiv)&nbsp;enter into, modify or amend in any
    material respect, or terminate, or waive, release or assign any
    material benefit or claim under, any joint venture, development,
    commercialization, manufacturing, supply or other collaboration
    arrangement, strategic partnership, alliance, license or
    sublicense which is material to such party and its Subsidiaries
    taken as a whole, or any other material Contract, except for
    such joint ventures, collaborations, strategic partnerships,
    alliances, licenses or sublicenses or Contracts, and such
    modifications, amendments, terminations, waivers, releases or
    assignments, which (A)&nbsp;are in the ordinary course of
    business consistent with past practice, (B) do not confer,
    grant, license, transfer or assign to a third party, or agree
    that a third party has, the exclusive right (or co-exclusive
    right with such party) to sell, develop, offer for sale, market,
    promote, distribute or otherwise commercialize any product or
    material Intellectual Property of such party or any its
    Subsidiaries in any territory, (C)&nbsp;do not involve milestone
    or other payments of more than ten million dollars ($10,000,000)
    or adversely alter any existing financial terms, (D)&nbsp;do not
    materially impair the conduct of the business of such party and
    its Subsidiaries, taken as a whole, (E)&nbsp;do not present a
    material risk of delaying the Merger or making it more difficult
    to obtain any required consents or approvals therefor,
    <I>and</I> (F)&nbsp;do not require approval of such party&#146;s
    stockholders;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xv)&nbsp;subject to <I>Section&nbsp;4.2(c)</I>,
    modify or amend in any material respect or terminate, or waive,
    release or assign any material rights or claims under, any
    confidentiality or standstill agreement in connection with, or
    to facilitate, encourage or permit, an Alternative Transaction
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">36
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">(as defined in <I>Section&nbsp;8.3(b)</I>) or a
    possible Alternative Transaction involving such party or its
    Subsidiary;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xvi)&nbsp;enter into any new material line of
    business;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xvii)&nbsp;other than in the ordinary course of
    business consistent with past practice, subject such party or
    any of its Subsidiaries to any material non-compete or other
    similar material restriction on the conduct of any of their
    respective businesses that would be binding following the
    Closing;&nbsp;or
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(xviii)&nbsp;authorize, or commit or agree to
    take, any of the foregoing actions; <I>provided</I> that the
    limitations set forth in this <I>Section&nbsp;4.1(b)</I> (other
    than clause&nbsp;(iii)) shall not apply to any transaction
    solely between IDEC or Biogen and any of its wholly owned
    Subsidiaries or solely between any wholly owned Subsidiaries of
    IDEC or Biogen, respectively.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Consultation.</I> Without limiting
    the generality of <I>Section&nbsp;4.1(a)</I> or
    <I>Section&nbsp;4.1(b)</I>, to the extent permitted by
    Applicable Law, prior to taking any of the following actions, or
    entering into any agreement in principle, letter of intent or
    memorandum of understanding or Contract with respect thereto,
    the party seeking to do so shall use commercially reasonable
    efforts first to consult with the other party&#146;s Chief
    Executive Officer or a designee thereof, and to consider in good
    faith the advice of such party with respect to such action:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;any action permitted by the exception in
    <I>Section&nbsp;4.1(b)(iv)(y)</I>, if the Permitted Acquisition
    involves a consideration (including assumed or acquired
    obligations) in excess of five million dollars ($5,000,000);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;any action permitted by the exception
    in <I>Section&nbsp;4.1(b)(v)(A)</I>, <I>(B)</I> or <I>(C)</I>,
    if the sale, pledge, disposition, transfer, lease, license or
    encumbrance involves property or assets with an aggregate fair
    value in excess of (x)&nbsp;two million five hundred thousand
    dollars ($2,500,000) for an action permitted by
    <I>Section&nbsp;4.1(b)(v)(A)</I> or <I>(B)</I> and (y)&nbsp;one
    million dollars ($1,000,000) for an action permitted by
    <I>Section&nbsp;4.1(b)(v)(C)</I>;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;any action permitted by the exception
    in <I>Section&nbsp;4.1(b)(vi)</I>, if the sale, pledge,
    disposition, transfer, encumbrance, abandonment or failure to
    maintain involves consideration (including milestone payments)
    of more than three million dollars ($3,000,000);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;any action permitted by the exception
    in clauses <I>(E)</I> or <I>(G)</I> of
    <I>Section&nbsp;4.1(b)(vii)</I>, if the loan, advance or capital
    contribution is in an amount greater than one million dollars
    ($1,000,000);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(v)&nbsp;any action permitted by the exception in
    <I>Section&nbsp;4.1(b)(viii)</I>, if the amount of indebtedness,
    debt securities or obligations is greater than two million five
    hundred thousand dollars ($2,500,000);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vi)&nbsp;any settlement of any claim that
    involves a payment of greater than two million dollars
    ($2,000,000) or any royalty;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(vii)&nbsp;any action permitted by the exception
    in <I>Section&nbsp;4.1(b)(xiv)</I> or <I>(xvii)</I>;&nbsp;or
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(viii)&nbsp;any action described in the
    definition of Transaction Event (as defined in
    <I>Section&nbsp;8.3(r)</I>).
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>No Breach or Failure.</I>
    Notwithstanding anything in this Agreement to the contrary,
    <I>provided</I> that Biogen is in material compliance with
    <I>Section&nbsp;4.1(c)(viii)</I> hereof, no Transaction Event
    shall constitute, give rise to, or be deemed to contribute to, a
    breach by Biogen of any representation, warranty, covenant or
    other agreement, or a failure by Biogen to satisfy any closing
    condition, contained herein.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>Other Actions.</I> Except as required
    by law, IDEC, Biogen and Merger Sub shall not, and shall not
    permit any of their respective Subsidiaries to, voluntarily take
    any action that would, or that
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">37
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">would reasonably be likely to, result in
    (i)&nbsp;any of the representations and warranties of such party
    set forth in this Agreement that are qualified as to
    &#147;materiality&#148; or &#147;Material Adverse Effect&#148;
    becoming untrue as of the Closing (for this purpose, without
    giving effect to any limitation as to any such representation or
    warranty being made as of the date of this Agreement),
    (ii)&nbsp;any of such representations and warranties that are
    not so qualified becoming untrue in any material respect as of
    the Closing (for this purpose, without giving effect to any
    limitation as to any such representation or warranty being made
    as of the date of this Agreement), or (iii)&nbsp;any of the
    conditions to the Merger set forth in <I>Article VI</I> not
    being satisfied.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Solicitation.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;Neither Biogen nor IDEC shall, nor
    permit any of its Subsidiaries to, nor authorize or permit any
    of its officers, directors or employees or any investment
    banker, financial advisor, attorney, accountant or other
    representative retained by it or any of its Subsidiaries to,
    directly, or indirectly, (i)&nbsp;solicit, initiate or encourage
    (including by way of furnishing any information), or take any
    other action to, or which would be reasonably likely to,
    facilitate, induce or encourage, any inquiries with respect to,
    or the making, submission or announcement of, any Alternative
    Transaction Proposal (as defined in <I>Section&nbsp;8.3(c)</I>),
    (ii)&nbsp;participate in any discussions or negotiations
    regarding, or furnish to any Person any information with respect
    to, any, or any possible, Alternative Transaction Proposal
    (except to disclose the existence of the provisions of this
    <I>Section&nbsp;4.2</I>), (iii)&nbsp;approve, endorse or
    recommend any Alternative Transaction (except to the extent
    specifically permitted pursuant to <I>Section&nbsp;4.2(d)</I>),
    or (iv)&nbsp;enter into any letter of intent or similar document
    or any contract, agreement or commitment contemplating or
    otherwise relating to any possible or proposed Alternative
    Transaction Proposal. Each of Biogen and IDEC and each of their
    respective Subsidiaries will immediately cease, and will cause
    its officers, directors and employees and any investment banker,
    financial adviser, attorney, accountant or other representative
    retained by it to cease, any and all existing activities,
    discussions or negotiations with any third parties conducted
    heretofore with respect to any possible or proposed Alternative
    Transaction, and will use its best efforts to enforce (and not
    waive any provisions of) any confidentiality and standstill
    agreement (or any similar agreement) relating to any such
    possible or proposed Alternative Transaction.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Notification of Alternative
    Transactions.</I> As promptly as practicable (and in any event
    within twenty-four (24)&nbsp;hours) after receipt of any
    Alternative Transaction Proposal or any request for nonpublic
    information or any inquiry relating in any way to any, or any
    possible, Alternative Transaction Proposal, Biogen or IDEC, as
    the case may be, shall provide the other party with oral and
    written notice of the material terms and conditions of such
    Alternative Transaction Proposal, request or inquiry, and the
    identity of the Person or group making any such Alternative
    Transaction Proposal, request or inquiry and a copy of all
    written materials provided to it in connection with such
    Alternative Transaction Proposal, request or inquiry. In
    addition, Biogen or IDEC, as the case may be, shall provide the
    other party as promptly as practicable with oral and written
    notice setting forth all such information as is reasonably
    necessary to keep the other party informed in all material
    respects of all oral or written communications regarding, and
    the status and details (including material amendments or
    proposed material amendments) of, any such Alternative
    Transaction Proposal, request or inquiry, and, without
    limitation of the other provisions of this
    <I>Section&nbsp;4.2</I>, shall promptly provide to the other
    party a copy of all written materials (including written
    materials provided by email or otherwise in electronic format)
    subsequently provided by or to it in connection with such
    Alternative Transaction Proposal, request or inquiry. Biogen or
    IDEC, as the case may be, shall provide the other party with
    forty-eight (48)&nbsp;hours prior notice (or such lesser prior
    notice as is provided to the members of its Board of Directors)
    of any meeting of its Board of Directors at which its Board of
    Directors is reasonably likely to consider any Alternative
    Transaction Proposal or Alternative Transaction.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Superior Proposals.</I>
    Notwithstanding anything to the contrary contained in
    <I>Section&nbsp;4.2(a)</I>, in the event that Biogen or IDEC, as
    the case may be, receives an unsolicited, bona fide written
    Alternative Transaction Proposal which is determined (in
    accordance with <I>Section&nbsp;8.3(q)</I>) to be a
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">38
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Superior Proposal (as defined in
    <I>Section&nbsp;8.3(q)</I>), it may then take the following
    actions (but only (1)&nbsp;if and to the extent that
    (x)&nbsp;its Board of Directors concludes in good faith, after
    receipt of advice of its outside legal counsel, that the failure
    to do so is reasonably likely to result in a breach of its
    fiduciary obligations to its stockholders under Applicable Law,
    <I>and</I> (y)&nbsp;Biogen or IDEC, as the case may be, has
    given the other party at least one business day prior written
    notice of its intention to take any of the following actions and
    of the identity of the Person or group making such Superior
    Proposal and the material terms and conditions of such Superior
    Proposal and (2)&nbsp;if it shall not have breached in any
    material respect any of the provisions of this
    <I>Section&nbsp;4.2</I>):
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;Furnish nonpublic information to the
    Person or group making such Superior Proposal, <I>provided</I>
    that (A)&nbsp;prior to furnishing any such nonpublic
    information, it receives from such Person or group an executed
    confidentiality and standstill agreement containing terms at
    least as restrictive as the terms contained in the
    Confidentiality Agreement, dated as of February&nbsp;11, 2003,
    between IDEC and Biogen (the <I>&#147;CDA&#148;</I>) and (B)
    contemporaneously with furnishing any such nonpublic information
    to such Person or group, it furnishes such nonpublic information
    to the other party hereto (to the extent such nonpublic
    information has not been previously so furnished to such party);
    and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;Engage in negotiations with such Person
    or group with respect to such Superior Proposal.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>Changes of Recommendation.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;In response to the receipt of an
    unsolicited, bona fide written Alternative Transaction Proposal
    which is determined (in accordance with
    <I>Section&nbsp;8.3(q)</I>) to be a Superior Proposal, the Board
    of Directors of Biogen or IDEC, as the case may be, may
    withhold, withdraw, amend or modify its recommendation in favor
    of, in the case of Biogen, approval and adoption of this
    Agreement and the Merger and, in the case of IDEC, the IDEC
    Charter Amendment and the Share Issuance, and, in the case of a
    Superior Proposal that is a tender or exchange offer made
    directly to its stockholders, may recommend that its
    stockholders accept the tender or exchange offer (any of the
    foregoing actions, whether by a Board of Directors or a
    committee thereof, a <I>&#147;Change of
    Recommendation&#148;</I>), if all of the following conditions in
    clauses&nbsp;(1) through (5)&nbsp;are met:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(1)&nbsp;The Superior Proposal has been made and
    has not been withdrawn and continues to be a Superior Proposal;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(2)&nbsp;The Biogen Stockholders&#146; Meeting or
    IDEC Stockholders&#146; Meeting, as the case may be, has not
    occurred;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(3)&nbsp;Biogen or IDEC, as the case may be, has
    (A)&nbsp;provided to the other party hereto five
    (5)&nbsp;business days&#146; prior written notice which shall
    state expressly (x)&nbsp;that it has received a Superior
    Proposal, (y)&nbsp;the material terms and conditions of the
    Superior Proposal and the identity of the Person or group making
    the Superior Proposal, and (z)&nbsp;that it intends to effect a
    Change of Recommendation and the manner in which it intends to
    do so, (B) provided to the other party hereto a copy of all
    written materials delivered to the Person or group making the
    Superior Proposal in connection with such Superior Proposal,
    (C)&nbsp;made available to the other party hereto all materials
    and information made available to the Person or group making the
    Superior Proposal in connection with such Superior Proposal, and
    (D)&nbsp;during such five business day period, if requested by
    the other party hereto, engaged in good faith negotiations to
    amend this Agreement in such a manner that the Alternative
    Transaction Proposal which was determined to be a Superior
    Proposal no longer is a Superior Proposal;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(4)&nbsp;The Board of Directors of Biogen or
    IDEC, as the case may be, has concluded in good faith, after
    receipt of advice of its outside legal counsel, that, in light
    of such Superior Proposal, the failure of the Board of Directors
    to effect a Change of Recommendation is
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">39
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">reasonably likely to result in a breach of its
    fiduciary obligations to its stockholders under Applicable Law;
    and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(5)&nbsp;Biogen or IDEC, as the case may be,
    shall have complied with <I>Section&nbsp;4.2(c)</I> and shall
    not have breached in any material respect any of the other
    provisions set forth in this <I>Section&nbsp;4.2</I> or in
    <I>Sections&nbsp;5.1(b)</I> through <I>5.1(d).</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;Without limiting the foregoing,
    (1)&nbsp;provided no possible or proposed Alternative
    Transaction Proposal involving Biogen has been made public or is
    known to the Board of Directors or senior executives of Biogen,
    the Board of Directors of Biogen may effect a Change of
    Recommendation (but only insofar as the same involves
    withholding, withdrawing, amending or modifying its
    recommendation in favor of the Merger and no action with respect
    to or in connection with any Alternative Transaction Proposal),
    so long as (x)&nbsp;a Material Adverse Change (as defined in
    <I>Section&nbsp;8.3(l)</I>) of IDEC shall have occurred since
    the date of this Agreement and be continuing and (y)&nbsp;Biogen
    shall not have breached in any material respect any of the
    provisions set forth in this <I>Section&nbsp;4.2</I> or
    <I>Section&nbsp;5.1</I>; and (2)&nbsp;provided no possible or
    proposed Alternative Transaction Proposal involving IDEC has
    been made public or is known to the Board of Directors or senior
    executives of IDEC, the Board of Directors of IDEC may implement
    a Change of Recommendation (but only insofar as the same
    involves withholding, withdrawing, amending or modifying its
    recommendation in favor of the Merger and no action with respect
    to or in connection with any Alternative Transaction Proposal),
    so long as (x)&nbsp;a Material Adverse Change of Biogen shall
    have occurred since the date of this Agreement and be continuing
    and (y)&nbsp;IDEC shall not have breached in any material
    respect any of the provisions set forth in this
    <I>Section&nbsp;4.2</I> or <I>Section&nbsp;5.1.</I>
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;In the event a Superior Proposal that is
    a tender offer or exchange offer is made to the stockholders of
    IDEC or Biogen and the Board of Directors thereof has made a
    Change of Recommendation, the other party hereto shall be
    released from the obligations set forth in Section&nbsp;2.9 or
    3.9, respectively, of the CDA.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>Continuing Obligation to Hold
    Stockholders&#146; Meeting; No Other Vote.</I> Notwithstanding
    anything to the contrary contained in this Agreement, the
    obligation of Biogen or IDEC to call, give notice of, convene
    and hold the Biogen Stockholders&#146; Meeting or the IDEC
    Stockholders&#146; Meeting, as the case may be, shall not be
    limited or otherwise affected by the commencement, disclosure,
    announcement or submission to it of any Alternative Transaction
    Proposal with respect to it, or by any Change of Recommendation.
    Neither Biogen nor IDEC shall submit to the vote of its
    respective stockholders any Alternative Transaction, whether or
    not a Superior Proposal, or propose to do so.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(g)&nbsp;<I>Compliance with Tender Offer
    Rules.</I> Nothing contained in this Agreement shall prohibit
    Biogen or IDEC or their respective Boards of Directors from
    taking and disclosing to their stockholders a position
    contemplated by Rules&nbsp;14d-9 and 14e-2(a) promulgated under
    the Exchange Act; <I>provided</I> that neither Biogen nor IDEC
    shall effect, or disclose pursuant to such Rules or otherwise a
    position which constitutes, a Change of Recommendation unless
    specifically permitted pursuant to the terms of
    <I>Section&nbsp;4.2(d).</I>
    </FONT></TD>
</TR>

</TABLE>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;V</FONT></B>

<P align="center">
<B><FONT size="2">ADDITIONAL AGREEMENTS</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Preparation
of SEC Documents; Stockholders&#146; Meetings.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;As soon as practicable following the
    date of this Agreement, IDEC and Biogen shall prepare and file
    with the SEC the Joint Proxy Statement, and IDEC shall prepare
    and file with the SEC the Form&nbsp;S-4, in which the Joint
    Proxy Statement will be included as a prospectus. Each of IDEC
    and
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">40
</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Biogen shall use commercially reasonable efforts
    to have the Form&nbsp;S-4 declared effective under the
    Securities Act as promptly as practicable after such filing.
    IDEC will use all commercially reasonable efforts to cause the
    Joint Proxy Statement to be mailed to IDEC&#146;s stockholders,
    and Biogen will use all commercially reasonable efforts to cause
    the Joint Proxy Statement to be mailed to Biogen&#146;s
    stockholders, in each case as promptly as practicable after the
    Form&nbsp;S-4 is declared effective under the Securities Act.
    IDEC shall also take any action (other than qualifying to do
    business in any jurisdiction in which it is not now so qualified
    or to file a general consent to service of process) required to
    be taken under any applicable state securities laws in
    connection with the issuance of shares of IDEC Common Stock in
    the Merger and the conversion of Biogen Options into options to
    acquire IDEC Common Stock, and Biogen shall furnish all
    information concerning Biogen and the holders of Biogen Common
    Stock as may be reasonably requested in connection with any such
    action. No filing of, or amendment or supplement to, the
    Form&nbsp;S-4 or the Joint Proxy Statement will be made by IDEC
    without Biogen&#146;s prior consent (which shall not be
    unreasonably withheld) and without providing Biogen the
    opportunity to review and comment thereon. IDEC will advise
    Biogen promptly after it receives notice thereof, of the time
    when the Form&nbsp;S-4 has become effective or any supplement or
    amendment has been filed, the issuance of any stop order, the
    suspension of the qualification of the IDEC Common Stock
    issuable in connection with the Merger for offering or sale in
    any jurisdiction, or any request by the SEC for amendment of the
    Joint Proxy Statement or the Form&nbsp;S-4 or comments thereon
    and responses thereto or requests by the SEC for additional
    information. If at any time prior to the Effective Time any
    information (including any Change of Recommendation) relating to
    IDEC or Biogen, or any of their respective Affiliates, officers
    or directors, should be discovered by IDEC or Biogen which
    should be set forth in an amendment or supplement to any of the
    Form&nbsp;S-4 or the Joint Proxy Statement, so that any of such
    documents would not include any misstatement of a material fact
    or omit to state any material fact necessary to make the
    statements therein, in light of the circumstances under which
    they were made, not misleading, the party which discovers such
    information shall promptly notify the other parties hereto and
    an appropriate amendment or supplement describing such
    information shall be promptly filed with the SEC and, to the
    extent required by law, disseminated to the stockholders of IDEC
    and Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;Each of Biogen and IDEC shall, as
    promptly as practicable after the Form&nbsp;S-4 is declared
    effective under the Securities Act, take all action necessary in
    accordance with Applicable Law and the Biogen Organizational
    Documents, in the case of Biogen, and the IDEC Organizational
    Documents, in the case of IDEC, to duly give notice of, convene
    and hold a meeting of its stockholders to be held as promptly as
    practicable to consider, in the case of IDEC, the Share
    Issuance, the IDEC Charter Amendment and approval of the New
    IDEC Stock Plan (as defined in <I>Section&nbsp;8.3(n)</I>) and
    the New IDEC Annual Bonus Plan (as defined in
    <I>Section&nbsp;8.3(m)</I>) (the <I>&#147;IDEC
    Stockholders&#146; Meeting&#148;</I>) and, in the case of
    Biogen, the adoption and approval of this Agreement and the
    Merger (the <I>&#147;Biogen Stockholders&#146;
    Meeting&#148;</I>). Subject to <I>Section&nbsp;4.2(d)</I>, each
    of Biogen and IDEC will use all commercially reasonable efforts
    to solicit from its stockholders proxies in favor of, in the
    case of IDEC, the Share Issuance, the IDEC Charter Amendment and
    approval of the New IDEC Stock Plan and the New IDEC Annual
    Bonus Plan, and, in the case of Biogen, the adoption and
    approval of this Agreement and the Merger, and will take all
    other action necessary or advisable to secure the vote or
    consent of its stockholders required by the rules of the Nasdaq
    National Market or Applicable Law to obtain such approvals.
    Notwithstanding anything to the contrary contained in this
    Agreement, Biogen or IDEC may adjourn or postpone the Biogen
    Stockholders&#146; Meeting or IDEC Stockholders&#146; Meeting,
    as the case may be, to the extent necessary to ensure that any
    necessary supplement or amendment to the Joint Proxy Statement
    is provided to its respective stockholders in advance of a vote
    on, in the case of IDEC, the Share Issuance, the IDEC Charter
    Amendment and approval of the New IDEC Stock Plan and the New
    IDEC Annual Bonus Plan, and, in the case of Biogen, the approval
    and adoption of this Agreement and the Merger, or, if, as of the
    time for which the Biogen Stockholders&#146; Meeting or IDEC
    Stockholders&#146; Meeting, as the case may be, is originally
    scheduled, there are insufficient shares of Biogen Common Stock
    or IDEC Common Stock, as the case may be, represented (either in
    person or by proxy) to constitute a
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">41
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">quorum necessary to conduct the business of such
    meeting. Each of Biogen and IDEC shall ensure that the Biogen
    Stockholders&#146; Meeting and the IDEC Stockholders&#146;
    Meeting, respectively, is called, noticed, convened, held and
    conducted, and that all proxies solicited in connection with the
    Biogen Stockholders&#146; Meeting or IDEC Stockholders&#146;
    Meeting, as the case may be, are solicited in compliance with
    Applicable Law, the rules of the Nasdaq National Market and, in
    the case of Biogen, the Biogen Organizational Documents, and, in
    the case of IDEC, the IDEC Organizational Documents. Without the
    prior written consent of Biogen, the IDEC Charter Amendment, the
    Share Issuance and approval and adoption of the New IDEC Stock
    Plan and the New IDEC Annual Bonus Plan are the only matters
    which IDEC shall propose to be acted on by IDEC&#146;s
    stockholders at the IDEC Stockholders&#146; Meeting. Without the
    prior written consent of IDEC, approval and adoption of this
    Agreement and the Merger is the only matter which Biogen shall
    propose to be acted on by Biogen&#146;s stockholders at the
    Biogen Stockholders&#146; Meeting.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;Each of Biogen and IDEC will use
    commercially reasonable efforts to hold the Biogen
    Stockholders&#146; Meeting and IDEC Stockholders&#146; Meeting,
    respectively, on the same date as the other party and as soon as
    reasonably practicable after the date of this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;Except to the extent expressly permitted
    by <I>Section&nbsp;4.2(d)</I>: (i)&nbsp;the Board of Directors
    of each of Biogen and IDEC shall recommend that its stockholders
    vote in favor of, in the case of Biogen, the approval and
    adoption of this Agreement and the Merger at the Biogen
    Stockholders&#146; Meeting, and, in the case of IDEC, the Share
    Issuance, the IDEC Charter Amendment and approval and adoption
    of the New IDEC Stock Plan and the New IDEC Annual Bonus Plan at
    the IDEC Stockholders&#146; Meetings, (ii)&nbsp;the Joint Proxy
    Statement shall include a statement to the effect that the Board
    of Directors of (A)&nbsp;IDEC has recommended that IDEC&#146;s
    stockholders vote in favor of the Share Issuance, the IDEC
    Charter Amendment and approval and adoption of the New IDEC
    Stock Plan and the New IDEC Annual Bonus Plan at the IDEC
    Stockholders&#146; Meeting and (B)&nbsp;Biogen has recommended
    that Biogen&#146;s stockholders vote in favor of approval and
    adoption of this Agreement and the Merger at the Biogen
    Stockholders&#146; Meeting, and (iii)&nbsp;neither the Board of
    Directors of Biogen or IDEC nor any committee thereof shall
    withdraw, amend or modify, or propose or resolve to withdraw,
    amend or modify in a manner adverse to the other party, the
    recommendation of its respective Board of Directors that the
    respective stockholders of Biogen or IDEC vote in favor of, in
    the case of Biogen, the approval and adoption of this Agreement
    and the Merger, and, in the case of IDEC, the Share Issuance,
    the IDEC Charter Amendment and approval and adoption of the New
    IDEC Stock Plan and the New IDEC Annual Bonus Plan.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Accountant&#146;s
Letters.</I> Each of Biogen and IDEC shall use commercially
reasonable efforts to cause to be delivered to the other party
two letters from their respective independent accountants, one
dated approximately as of the date the Form&nbsp;S-4 is declared
effective and one dated approximately as of the Closing Date,
each addressed to the other party, in form and substance
reasonably satisfactory to the other party and customary in
scope and substance for comfort letters delivered by independent
public accountants in connection with registration statements
similar to the Form&nbsp;S-4.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Access
to Information; Confidentiality.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;Subject to the CDA and subject to
    Applicable Law, each of IDEC and Biogen shall, and shall cause
    each of its respective Subsidiaries to, afford to the other
    party and to the officers, employees, accountants, counsel,
    financial advisors and other representatives of such other
    party, reasonable access during normal business hours during the
    period prior to the Effective Time to all their respective
    properties, books, contracts, commitments, personnel and records
    (<I>provided</I> that such access shall not interfere with the
    business or operations of such party) and, during such period,
    each of IDEC and Biogen shall, and shall cause each of its
    respective Subsidiaries to, furnish promptly to the other party
    (a)&nbsp;a copy of each report, schedule, registration statement
    and other document filed by it during such period pursuant to
    the requirements of federal or state securities laws and
    (b)&nbsp;all other information concerning its business,
    properties and personnel as such other party may reasonably
    request. No review pursuant to this <I>Section&nbsp;5.3</I>
    shall affect or be deemed to modify any representation
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">42
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">or warranty contained herein, the covenants or
    agreements of the parties hereto or the conditions to the
    obligations of the parties hereto under this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;Each of IDEC and Biogen will hold, and
    will cause its respective officers, employees, accountants,
    counsel, financial advisors and other representatives and
    Affiliates to hold, any nonpublic information in accordance with
    the terms of the CDA.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Reasonable
Efforts.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;Upon the terms and subject to the
    conditions set forth in this Agreement, each of the parties
    agrees to use their commercially reasonable efforts to take, or
    cause to be taken, all actions, and to do, or cause to be done,
    and to assist and cooperate with the other parties in doing, all
    things necessary, proper or advisable to consummate and make
    effective, in the most expeditious manner practicable, the
    Merger and the other transactions contemplated by this
    Agreement, including (i)&nbsp;the obtaining of all necessary
    actions or nonactions, waivers, consents and approvals from
    Governmental Entities and the making of all necessary
    registrations and filings and the taking of all steps as may be
    necessary to obtain an approval or waiver from, or to avoid an
    action or proceeding by, any Governmental Entity, including all
    filings required by the HSR Act (the initial filing required by
    the HSR Act to be filed promptly within the meaning of the HSR
    Act) and any applicable antitrust, competition or similar laws
    of any foreign jurisdiction, (ii)&nbsp;the obtaining of all
    necessary consents, approvals or waivers from third parties,
    (iii)&nbsp;the defending of any lawsuits or other legal
    proceedings, whether judicial or administrative, challenging
    this Agreement or the consummation of the transactions
    contemplated by this Agreement, including seeking to have any
    stay or temporary restraining order entered by any court or
    other Governmental Entity vacated or reversed, and (iv)&nbsp;the
    execution and delivery of any additional instruments necessary
    to consummate the transactions contemplated by, and to fully
    carry out the purposes of, this Agreement. Subject to Applicable
    Laws relating to the exchange of information and in addition to
    <I>Section&nbsp;5.4(b)</I>, Biogen and IDEC shall have the right
    to review in advance, and to the extent practicable each will
    consult the other on, all the information relating to Biogen and
    its Subsidiaries or IDEC and its Subsidiaries, as the case may
    be, that appears in any filing made with, or written materials
    submitted to, any third party or any Governmental Entity in
    connection with the Merger and the other transactions
    contemplated by this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;Each of IDEC and Biogen shall keep the
    other reasonably apprised of the status of matters relating to
    the completion of the transactions contemplated hereby and work
    cooperatively in connection with obtaining all required
    approvals or consents of any Governmental Entity (whether
    domestic, foreign or supranational). In that regard, each party
    shall without limitation: (i)&nbsp;promptly notify the other of,
    and if in writing, furnish the other with copies of (or, in the
    case of material oral communications, advise the other orally
    of) any communications from or with any Governmental Entity
    (whether domestic, foreign or supranational) with respect to the
    Merger or any of the other transactions contemplated by this
    Agreement, (ii)&nbsp;permit the other to review and discuss in
    advance, and consider in good faith the views of the other in
    connection with, any proposed written (or any material proposed
    oral) communication with any such Governmental Entity,
    (iii)&nbsp;not participate in any meeting with any such
    Governmental Entity unless it consults with the other in advance
    and to the extent permitted by such Governmental Entity gives
    the other the opportunity to attend and participate thereat,
    (iv)&nbsp;furnish the other with copies of all correspondence,
    filings and communications (and memoranda setting forth the
    substance thereof) between it and any such Governmental Entity
    with respect to this Agreement and the Merger, and
    (v)&nbsp;furnish the other with such necessary information and
    reasonable assistance as IDEC or Biogen may reasonably request
    in connection with its preparation of necessary filings or
    submissions of information to any such Governmental Entity. Each
    of IDEC and Biogen may, as each deems advisable and necessary,
    reasonably designate any competitively sensitive material
    provided to the other under this <I>Section&nbsp;5.4</I> as
    &#147;outside counsel only.&#148; Such material and the
    information contained therein shall be given only to the outside
    legal counsel of the recipient and will not be disclosed by such
    outside counsel to employees, officers, or directors of
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">43
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">the recipient unless express permission is
    obtained in advance from the source of the materials (IDEC or
    Biogen, as the case may be) or its legal counsel.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;In connection with and without limiting
    the foregoing, IDEC and Biogen shall (i)&nbsp;take all action
    necessary to ensure that no state takeover statute or similar
    statute or regulation is or becomes applicable to this Agreement
    or any of the transactions contemplated hereby and (ii)&nbsp;if
    any state takeover statute or similar statute or regulation
    becomes applicable to this Agreement or any of the transactions
    contemplated hereby, take all action necessary to ensure that
    such transactions may be consummated as promptly as practicable
    on the terms required by, or provided for, in this Agreement and
    otherwise to minimize the effect of such statute or regulation
    on the Merger and the other transactions contemplated by this
    Agreement.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
and Insurance.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;From and after the Effective Time, IDEC
    will, and will cause the Surviving Corporation to, fulfill and
    honor in all respects the obligations of Biogen pursuant to any
    indemnification agreements between Biogen and its directors and
    officers in effect immediately prior to the Effective Time (the
    <I>&#147;Indemnified Parties&#148;</I>), subject to Applicable
    Law. The articles of organization and by-laws of the Surviving
    Corporation will contain provisions with respect to exculpation
    and indemnification that are at least as favorable to the
    Indemnified Parties as those contained in the Biogen Charter and
    the Biogen By-laws as in effect on the date hereof, which
    provisions will not be amended, repealed or otherwise modified
    for a period of six years from the Effective Time in any manner
    that would adversely affect the rights thereunder of individuals
    who, immediately prior to the Effective Time, were directors,
    officers, employees or agents of Biogen, unless such
    modification is required by law.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;For a period of six years after the
    Effective Time, the Surviving Corporation shall cause to be
    maintained in effect the current policies of directors&#146; and
    officers&#146; and fiduciary liability insurance maintained by
    Biogen (<I>provided</I> that the Surviving Corporation may
    substitute therefor policies of at least the same coverage and
    amounts containing terms and conditions which are no less
    advantageous to former officers and directors of Biogen) only
    with respect to claims arising from facts or events which
    occurred at or before the Effective Time.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Fees
and Expenses.</I> Except as set forth in this
<I>Section&nbsp;5.6</I> and in <I>Section&nbsp;7.3</I>, all fees
and expenses incurred in connection with the Merger, this
Agreement and the transactions contemplated by this Agreement
shall be paid by the party incurring such fees or expenses,
whether or not the Merger is consummated, except that each of
Biogen and IDEC shall bear and pay one-half of the costs and
expenses incurred by IDEC, Merger Sub or Biogen (other than
attorneys&#146; fees, accountants&#146; fees and related
expenses) in connection with (i)&nbsp;the filing, printing and
mailing of the Form&nbsp;S-4 (including financial statements and
exhibits), the Joint Proxy Statement (including SEC filing fees)
and any preliminary materials related thereto and (ii)&nbsp;the
filings of the premerger notification and report forms under the
HSR&nbsp;Act and any applicable antitrust, competition or
similar laws of any foreign jurisdiction (including filing fees).
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Public
Announcements.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;Biogen and IDEC will consult with each
    other before issuing, and will provide each other the
    opportunity to review, comment upon and concur with, and use
    commercially reasonable efforts to agree on, any press release
    or other public statements with respect to the transactions
    contemplated by this Agreement, including the Merger, and shall
    not issue any such press release or make any such public
    statement prior to such consultation, except as either party may
    determine is required by Applicable Law, court process or by
    obligations pursuant to any listing agreement with any national
    securities exchange or stock market. The parties agree that the
    initial press release to be issued with respect to the
    transactions contemplated by this Agreement shall be in the form
    heretofore agreed to by the parties.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;Notwithstanding anything to the contrary
    contained in this Agreement or the CDA, the parties (and each
    employee, representative or other agent of the parties) may
    disclose to any and all
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">44
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Persons, without limitation of any kind, the tax
    treatment and tax structure of the transactions contemplated
    hereby beginning on the earliest of (i)&nbsp;the date of the
    public announcement by the parties of discussions relating to
    the transactions contemplated hereby, (ii)&nbsp;the date of
    public announcement by the parties of the transactions
    contemplated hereby or (iii)&nbsp;the date of the execution of
    this Agreement; <I>provided, however,</I> that neither party
    (nor any employee, representative or agent thereof) may disclose
    any information that is not necessary to understand the tax
    treatment and tax structure of such transactions (including the
    identity of the parties and any information that could lead
    another to determine the identity of the parties), or any other
    information to the extent that such disclosure could result in a
    violation of any Applicable Law.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Listing.</I>
IDEC shall use all commercially reasonable efforts to cause the
IDEC Common Stock issuable under <I>Article&nbsp;II,</I> and
those shares of IDEC Common Stock required to be reserved for
issuance in connection with the Merger, to be authorized for
listing on the Nasdaq National Market, upon official notice of
issuance.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Tax-Free
Reorganization Treatment.</I> IDEC and Biogen intend that the
Merger will qualify as a reorganization within the meaning of
Section&nbsp;368(a) of the Code, and each shall, and shall cause
its respective subsidiaries to, use its reasonable best efforts
to cause the Merger to so qualify. Neither IDEC nor Biogen shall
knowingly take any action, or knowingly fail to take any action,
that would be reasonably likely to jeopardize the qualification
of the Merger as a reorganization within the meaning of
Section&nbsp;368(a) of the Code.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Post-Agreement
Operations.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;Promptly following execution of this
    Agreement, the parties shall establish a transition planning
    team (the <I>&#147;Transition Team&#148;</I>) consisting of an
    equal number of representatives of Biogen and IDEC. The
    Transition Team shall be responsible for facilitating a
    transition and integration planning process to ensure the
    successful combination of the operations of Biogen with those of
    IDEC. The Transition Team shall be responsible for developing,
    and monitoring the development of, and deliverables due under,
    an action plan for the combination of the businesses.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;The Board of Directors of IDEC shall
    take all actions necessary to cause the appointment, as of the
    Effective Time, of the individuals named on
    <I>Schedule&nbsp;5.10</I> hereto to the respective offices set
    forth therein.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;As of the Effective Time, IDEC shall
    take all steps necessary to cause the headquarters and the
    principal executive offices of IDEC to be located in Cambridge,
    Massachusetts.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Conveyance
Taxes.</I> Biogen and IDEC shall cooperate in the preparation,
execution and filing of all returns, questionnaires,
applications or other documents regarding any real property
transfer or gains, sales, use, transfer, value added, stock
transfer and stamp taxes, any transfer, recording, registration
and other fees or any similar taxes which become payable in
connection with the transactions contemplated by this Agreement
that are required or permitted to be filed on or before the
Effective Time.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Equity
Awards and Employee Benefits.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;At the Effective Time, each then
    outstanding Biogen Option, whether or not exercisable at the
    Effective Time, will be assumed by IDEC. Each Biogen Option so
    assumed by IDEC under this Agreement will continue to have, and
    be subject to, the same terms and conditions set forth in the
    applicable Biogen Option (including any applicable stock option
    agreement or other document evidencing such Biogen Option)
    immediately prior to the Effective Time (including any
    repurchase rights or vesting provisions), except that
    (i)&nbsp;each Biogen Option will be exercisable (or will become
    exercisable in accordance with its terms) for that number of
    whole shares of IDEC Common Stock equal to the product of the
    number of shares of Biogen Common Stock that were issuable upon
    exercise of such Biogen Option immediately prior to the
    Effective Time (disregarding any vesting schedule applicable to
    such option) multiplied by the Exchange Ratio, rounded down to
    the nearest whole number of shares of IDEC Common Stock and
    (ii)&nbsp;the per share exercise price for the shares
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">45
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">of IDEC Common Stock issuable upon exercise of
    such assumed Biogen Option will be equal to the quotient
    determined by dividing the exercise price per share of Biogen
    Common Stock of such Biogen Option by the Exchange Ratio,
    rounded up to the nearest whole cent. Each assumed Biogen Option
    shall be vested immediately following the Effective Time as to
    the same percentage of the total number of shares subject
    thereto as it was vested as to immediately prior to the
    Effective Time, except to the extent such Biogen Option (either
    by its terms or by the terms of another agreement) provides for
    acceleration of vesting. As soon as reasonably practicable, IDEC
    will issue to each holder of an assumed Biogen Option a document
    evidencing the foregoing assumption of such Biogen Option by
    IDEC. Immediately following the Effective Time, IDEC shall file
    a registration statement under the Securities Act on
    Form&nbsp;S-8 or another appropriate form (and use its
    commercially reasonable efforts to maintain the effectiveness
    thereof and maintain the current status of the prospectuses
    contained therein) with respect to the Biogen Options assumed by
    IDEC pursuant hereto and shall cause such registration statement
    to remain in effect for so long as such assumed Biogen Option
    remain outstanding. Prior to the Effective Time, IDEC shall take
    all corporate action necessary to reserve for issuance a
    sufficient number of shares of IDEC Common Stock for delivery in
    connection with the exercise of the converted Biogen Options.
    The parties shall use their commercially reasonable efforts to
    ensure that the conversion of any Biogen Options which are
    intended to be &#147;incentive stock options&#148; (as defined
    in Section&nbsp;422 of the Code) provided for in this
    <I>Section&nbsp;5.12(a)</I> shall be effected in a manner
    consistent with Section&nbsp;424(a) of the Code.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;Biogen shall terminate the Biogen
    Purchase Plans immediately prior to the Effective Time. To the
    extent any offering period under the Biogen Purchase Plans is in
    progress prior to such termination, Biogen shall ensure that
    such offering period ends immediately prior to such termination,
    and that each participant&#146;s accumulated contributions for
    such offering period are applied towards the purchase of Biogen
    Common Stock immediately prior to such termination unless the
    participant has previously withdrawn from such offering period
    in accordance with the terms of such plan. Effective as soon as
    practicable after the Effective Time, all Continuing Employees
    (as defined in <I>Section&nbsp;5.12(c)</I>) shall be permitted
    to participate in the IDEC Purchase Plan in accordance with the
    terms of such plan.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;For one year following the Effective
    Time, IDEC shall provide or cause to be provided to those of its
    employees and employees of the Surviving Corporation or any
    other Affiliate of IDEC who were employees of Biogen immediately
    prior to the Effective Time <I>(&#147;Continuing
    Employees&#148;),</I> employee welfare benefits that, in the
    aggregate, are no less favorable than the employee welfare
    benefits package provided to those Continuing Employees by
    Biogen or a Subsidiary of Biogen immediately prior to the
    execution of this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;Following the Effective Time, IDEC shall
    recognize (or cause to be recognized) the service of each
    Continuing Employee with Biogen or its Subsidiaries for purposes
    of (i)&nbsp;eligibility and vesting under any IDEC Benefit Plan,
    (ii)&nbsp;determination of benefits levels under any vacation or
    severance IDEC Benefit Plan and (iii)&nbsp;determination of
    &#147;retiree&#148; status under any IDEC Benefit Plan, for
    which the Continuing Employee is otherwise eligible and in which
    the Continuing Employee is offered participation, in each case
    except where such crediting would result in a duplication of
    benefits. To the extent IDEC establishes or designates an IDEC
    Benefit Plan to provide group health benefits to Continuing
    Employees, (i)&nbsp;each such IDEC Benefit Plan shall waive
    pre-existing condition limitations with respect to Continuing
    Employees to the same extent waived or no longer applicable
    under the applicable group health plan of Biogen and
    (ii)&nbsp;each Continuing Employee shall be given credit under
    the applicable IDEC Benefit Plan for amounts paid under the
    corresponding group health plan of Biogen or an Affiliate during
    the plan year in which the Effective Time occurs for purposes of
    applying deductibles, co-payments and out-of-pocket maximums for
    such plan year.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;As of the Effective Time, IDEC shall
    assume and agree to perform in accordance with their terms all
    employment, severance and other compensation agreements and
    arrangements existing as of the date hereof, and provided to
    IDEC by Biogen prior to the date hereof, between Biogen or any
    Biogen Subsidiary and any director, officer or employee thereof
    and any such agreements or
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">46
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">arrangements entered into after the date hereof
    and prior to the Effective Time by Biogen or any Biogen
    Subsidiary in compliance with the terms of this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;Notwithstanding anything in this
    Agreement to the contrary, no provision of this Agreement shall
    be deemed to (i)&nbsp;guarantee employment for any period of
    time for, or preclude the ability of either party to terminate,
    any Continuing Employee for any reason or (ii)&nbsp;require
    either party to continue any IDEC Benefit Plan or Biogen Benefit
    Plan or prevent the amendment, modification or termination
    thereof after the Effective Time.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Consents
of Accountants.</I> IDEC and Biogen will each use commercially
reasonable efforts to cause to be delivered to each other
consents from their respective independent auditors, dated the
date on which the Form&nbsp;S-4 shall become effective or a date
not more than two (2)&nbsp;days prior to such date, in form
reasonably satisfactory to the recipient and customary in scope
and substance for consents delivered by independent public
accountants in connection with registration statements on
Form&nbsp;S-4 under the Securities Act.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>IDEC
Board.</I> The Board of Directors of IDEC shall take all action
necessary so that:
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;immediately following the Effective
    Time, the Board of Directors of IDEC consists of 12 members,
    including William H. Rastetter,&nbsp;Ph.D., James C. Mullen,
    five (5)&nbsp;members named by IDEC (together with William H.
    Rastetter,&nbsp;Ph.D., the <I>&#147;IDEC Designated
    Directors&#148;</I>), and five (5)&nbsp;members named by Biogen
    (together with James C. Mullen, the <I>&#147;Biogen Designated
    Directors&#148;</I>);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;immediately following the Effective
    Time, each of the three (3) classes of the IDEC Board of
    Directors includes two (2)&nbsp;IDEC Designated Directors and
    two (2)&nbsp;Biogen Designated Directors and James C. Mullen and
    William H. Rastetter,&nbsp;Ph.D., are included in the class of
    directors with the longest remaining term;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;immediately following the Effective
    Time, (i)&nbsp;there shall be equal numbers of IDEC Designated
    Directors and Biogen Designated Directors on each committee of
    the Board of Directors of IDEC; (ii)&nbsp;William H.
    Rastetter,&nbsp;Ph.D., shall be the Executive Chairman of the
    Board of Directors of IDEC; (iii)&nbsp;James C. Mullen shall be
    the Chief Executive Officer of IDEC; (iv)&nbsp;the chairman of
    the Compensation and Management Resources committee of the Board
    of Directors of IDEC shall be an IDEC Designated Director named
    by IDEC prior to the Effective Time and (v)&nbsp;the respective
    chairmen of the Corporate Governance and Nominating and the
    Finance and Audit committees of the Board of Directors of IDEC
    shall be Biogen Designated Directors named by Biogen prior to
    the Effective Time;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;immediately following the Effective
    Time, the IDEC Bylaws are amended, effective at the Effective
    Time, to provide that, until the third anniversary of the
    Effective Time, the affirmative vote, at a duly convened meeting
    of IDEC&#146;s Board of Directors, of at least eighty percent
    (80%) of IDEC&#146;s entire Board of Directors (excluding for
    this purpose directors who are then serving as an officer or
    employee of IDEC) will be required to (i)&nbsp;remove William H.
    Rastetter,&nbsp;Ph.D., from his position as the Executive
    Chairman of the Board of Directors of IDEC or significantly
    diminish his position, authority, duties or responsibilities;
    (ii)&nbsp;remove James C. Mullen from his position as
    IDEC&#146;s Chief Executive Officer or significantly diminish
    his position, authority, duties or responsibilities; or
    (iii)&nbsp;amend or modify, or adopt any Bylaw inconsistent
    with, the Bylaw referred to in clauses&nbsp;(i) or (ii)&nbsp;of
    this <I>Section&nbsp;5.14(d).</I>
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Affiliate
Legends.</I> <I>Section&nbsp;5.15</I> of the Biogen Disclosure
Schedule sets forth a list of those Persons who are, in
Biogen&#146;s reasonable judgment, &#147;affiliates&#148; of
Biogen within the meaning of Rule&nbsp;145 promulgated under the
Securities Act <I>(&#147;Rule&nbsp;145 Affiliates&#148;).</I>
Biogen shall notify IDEC in writing regarding any change in the
identity of its Rule&nbsp;145 Affiliates prior to the Closing
Date. IDEC shall be entitled to place appropriate legends on the
certificates evidencing any shares of IDEC Common Stock to be
received by Rule&nbsp;145 Affiliates in the Merger reflecting
the restrictions set forth in Rule&nbsp;145 promulgated under
the Securities Act and to issue appropriate stop transfer
instructions to the transfer
</FONT>

<P align="center"><FONT size="2">47
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="left">
<FONT size="2">agent for IDEC Common Stock (<I>provided</I> that
such legends or stop transfer instructions shall be removed, one
year after the Effective Time, upon the request of any holder of
shares of IDEC Common Stock issued in the Merger if such holder
is not then a Rule&nbsp;145 Affiliate).
</FONT>
</DIV>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Notification
of Certain Matters.</I> IDEC shall give prompt notice to Biogen,
and Biogen shall give prompt notice to IDEC, of the occurrence,
or failure to occur, of any event, which occurrence or failure
to occur would be reasonably likely to cause (a)(i) any
representation or warranty of such party contained in this
Agreement that is qualified as to &#147;materiality&#148; or
&#147;Material Adverse Effect&#148; to be untrue or inaccurate
in any respect or (ii)&nbsp;any other representation or warranty
of such party contained in this Agreement to be untrue or
inaccurate in any material respect, in each case at any time
from and after the date of this Agreement until the Effective
Time, or (b)&nbsp;any material failure of IDEC and the Merger
Sub or Biogen, as the case may be, or of any officer, director,
employee or agent thereof, to comply with or satisfy any
covenant, condition or agreement to be complied with or
satisfied by it under this Agreement. In addition, IDEC shall
give prompt notice to Biogen and Biogen shall give prompt notice
to IDEC of any change or event having, or which would reasonably
be likely to have, a Material Adverse Effect on such party or
which would be reasonably likely to result in the failure of any
of the conditions set forth in <I>Article&nbsp;VI</I> to be
satisfied. Notwithstanding the above, the delivery of any notice
pursuant to this <I>Section&nbsp;5.16</I> will not limit or
otherwise affect the remedies available hereunder to the party
receiving such notice or the conditions to such party&#146;s
obligation to consummate the Merger.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Section&nbsp;16
Matters.</I> Prior to the Effective Time, each of IDEC and
Biogen shall take all such steps as may be required (to the
extent permitted under Applicable Law) to cause any dispositions
of Biogen Common Stock (including derivative securities) or
acquisitions of IDEC Common Stock (including derivative
securities with respect to IDEC Common Stock) resulting from the
transactions contemplated by this Agreement by each individual
who is subject to the reporting requirements of
Section&nbsp;16(a) of the Exchange Act with respect to Biogen to
be exempt under Rule&nbsp;16b-3 promulgated under the Exchange
Act, such steps to be taken in accordance with the No-Action
Letter dated January&nbsp;12, 1999, issued by the SEC to
Skadden, Arps, Slate, Meagher&nbsp;&#38; Flom LLP.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Rights
Plans; State Takeover Laws.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;Prior to the Effective Time, neither
    Biogen nor IDEC shall redeem the Biogen Rights or the IDEC
    Rights or amend, modify (other than to delay any
    &#147;distribution date&#148; therein or to render the Biogen
    Rights or the IDEC Rights inapplicable to the Merger or any
    action permitted under this Agreement) or terminate the Biogen
    Rights Agreement or the IDEC Rights Agreements unless
    (i)&nbsp;required to do so by order of a court of competent
    jurisdiction or (ii)&nbsp;IDEC&#146;s or Biogen&#146;s Board of
    Directors, as the case may be, has concluded in good faith,
    after receipt of advice of its outside legal counsel, that, in
    light of a Superior Proposal with respect to it, the failure to
    effect such amendment, modification or termination is reasonably
    likely to result in a breach of its Board of Directors&#146;
    fiduciary obligations to its stockholders under Applicable Law.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;Prior to the Effective Time, neither
    Biogen nor IDEC shall take any action to render inapplicable, or
    to exempt any third party from, any state takeover law or state
    law that purports to limit or restrict business combinations or
    the ability to acquire or vote shares of capital stock unless
    (i)&nbsp;required to do so by order of a court of competent
    jurisdiction or (ii)&nbsp;IDEC&#146;s or Biogen&#146;s Board of
    Directors, as the case may be, has concluded in good faith,
    after receipt of advice of its outside legal counsel, that, in
    light of a Superior Proposal with respect to it, the failure to
    take such action is reasonably likely to result in a breach of
    its Board of Directors&#146; fiduciary obligations to its
    stockholders under Applicable Law.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Reservation
of IDEC Common Stock.</I> Effective at or prior to the Effective
Time, IDEC shall reserve (free from preemptive rights) out of
its reserved but unissued shares of IDEC Common Stock, for the
purposes of effecting the conversion of the issued and
outstanding shares of Biogen Common Stock pursuant to this
Agreement, sufficient shares of IDEC Common Stock to provide for
such conversion as well as the issuance of IDEC Common Stock
upon the exercise of Biogen Options assumed by IDEC under
<I>Section&nbsp;5.12.</I>
</FONT>

<P align="center"><FONT size="2">48
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Actions
with Respect to the New IDEC Stock Plan and the New IDEC Annual
Bonus Plan.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Actions of IDEC.</I> Promptly
    following the date hereof, the Board of Directors of IDEC shall
    approve and adopt the New IDEC Stock Plan and the New IDEC
    Annual Bonus Plan, in each case subject to the approval of IDEC
    stockholders and the occurrence of the Effective Time. The Board
    of Directors of IDEC shall also, at the time at which it
    approves and adopts the New IDEC Stock Plan, adopt an amendment
    to the IDEC 1988 Stock Option Plan, which amendment shall be
    conditioned upon both the occurrence of the Effective Time and
    the approval by IDEC stockholders of the New IDEC Stock Plan,
    and which amendment shall provide that after the Effective Time,
    no new grants or awards shall be made under the IDEC 1988 Stock
    Option Plan.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Actions of Biogen.</I> The Board of
    Directors of Biogen shall, following the date hereof, adopt an
    amendment to each of the Biogen Stock Plans which amendments
    shall be conditioned upon both the occurrence of the Effective
    Time and the approval and adoption by the Board of Directors of
    IDEC, and approval by IDEC stockholders, of the New IDEC Stock
    Plan, and which amendment shall provide that after the Effective
    Time, no new grants or awards shall be made under the Biogen
    Stock Plans.
    </FONT></TD>
</TR>

</TABLE>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;VI</FONT></B>

<P align="center">
<B><FONT size="2">CONDITIONS PRECEDENT</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Conditions
to Each Party&#146;s Obligation to Effect The Merger.</I> The
obligation of each party to effect the Merger is subject to the
satisfaction or waiver at or prior to the Closing of the
following conditions:
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Stockholder Approvals.</I> Each of
    the IDEC Stockholder Approval and the Biogen Stockholder
    Approval shall have been obtained.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Antitrust Waiting Periods.</I> The
    waiting periods (and any extensions thereof) applicable to the
    Merger under the HSR Act and any applicable foreign antirust
    laws, rules or regulations shall have been terminated or shall
    have expired.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Governmental Consents and
    Approvals.</I> Other than as required by
    <I>Section&nbsp;6.1(b)</I>, all filings with, and all consents,
    approvals and authorizations of, any Governmental Entity
    required to be made or obtained by IDEC, Biogen or any of their
    Subsidiaries to consummate the Merger, the failure of which to
    be obtained would, individually or in the aggregate, have a
    Material Adverse Effect on IDEC (determined, for purposes of
    this clause, after giving effect to the Merger), shall have been
    made or obtained.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>No Injunctions or Restraints.</I> No
    judgment, order, decree, statute, law, ordinance, rule or
    regulation, or other legal restraint or prohibition, entered,
    enacted, promulgated, enforced or issued by any court or other
    Governmental Entity of competent jurisdiction (collectively,
    <I>&#147;Restraints&#148;</I>), shall be in effect which
    prohibits, materially restricts, makes illegal or enjoins the
    consummation of the transactions contemplated by this Agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>Form&nbsp;S-4.</I> The Form&nbsp;S-4
    shall have become effective under the Securities Act prior to
    the mailing of the Joint Proxy Statement by each of IDEC and
    Biogen to their respective stockholders, and no stop order or
    proceedings seeking a stop order shall be threatened by the SEC
    or shall have been initiated or, to the Knowledge of IDEC or
    Biogen, threatened by the SEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>Listing.</I> The shares of IDEC
    Common Stock issuable to the stockholders of Biogen as provided
    for in <I>Article&nbsp;II</I> shall have been authorized for
    listing on the Nasdaq National Market upon official notice of
    issuance.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(g)&nbsp;<I>Tax Opinions.</I> Biogen and IDEC
    shall have received an opinion of Skadden, Arps, Slate,
    Meagher&nbsp;&#38; Flom LLP and Pillsbury Winthrop LLP,
    respectively, dated as of the Effective Time, to
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">49
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">the effect that the Merger will qualify as a
    reorganization within the meaning of Section&nbsp;368(a) of the
    Code. The issuance of such opinion shall be conditioned upon the
    receipt by such counsel of customary representation letters from
    each of IDEC, Merger Sub, and Biogen, in each case, in form and
    substance reasonably satisfactory to such counsel. Each such
    representation letter shall be dated on or before the date of
    such opinion and shall not have been withdrawn or modified in
    any material respect. The opinion condition referred to in this
    <I>Section&nbsp;6.1(g)</I> shall not be waivable after receipt
    of the Biogen Stockholder Approval, unless further stockholder
    approval of Biogen stockholders is obtained with appropriate
    disclosure.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Conditions
to Obligations of Biogen.</I> The obligation of Biogen to effect
the Merger is further subject to satisfaction or waiver at or
prior to the Closing of the following conditions:
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Representations and Warranties.</I>
    The representations and warranties of IDEC and Merger Sub set
    forth herein shall be true and correct (without giving effect to
    any limitation as to &#147;materiality&#148; or &#147;Material
    Adverse Effect&#148; set forth therein) both when made and at
    and as of the Closing Date, as if made at and as of such time
    (except to the extent expressly made as of an earlier date, in
    which case as of such date), except where the failure of such
    representations and warranties to be so true and correct
    (without giving effect to any limitation as to
    &#147;materiality&#148; or &#147;Material Adverse Effect&#148;
    set forth therein) does not have, and is not reasonably likely
    to have, individually or in the aggregate, a Material Adverse
    Effect on IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Performance of Obligations of IDEC
    and Merger Sub.</I> Each of IDEC and Merger Sub shall have
    performed, or complied with, in all material respects all
    obligations required to be performed or complied with by it
    under this Agreement at or prior to the Closing Date.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>No Material Adverse Change.</I> No
    Material Adverse Change of IDEC shall have occurred since the
    date of this Agreement and be continuing.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>IDEC Rights Agreement.</I> The IDEC
    Rights issued pursuant to the IDEC Rights Agreement shall not
    have become non-redeemable, exercisable, distributed (separately
    from shares of IDEC Common Stock) or triggered pursuant to the
    terms of such agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>IDEC Charter Amendment.</I> The IDEC
    Certificate of Amendment shall have been duly filed with the
    Secretary of State of the State of Delaware and shall be in
    effect.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>Officer&#146;s Certificate.</I>
    Biogen shall have received an officer&#146;s certificate duly
    executed by each of the Chief Executive Officer and Chief
    Financial Officer of IDEC to the effect that the conditions set
    forth in <I>Sections&nbsp;6.2(a)</I>, <I>(b)</I>, <I>(c)</I>,
    <I>(d)</I> and <I>(e)</I> have been satisfied.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Conditions
to Obligations of IDEC and Merger Sub.</I> The obligations of
IDEC and Merger Sub to effect the Merger are further subject to
satisfaction or waiver at or prior to the Closing of the
following conditions:
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Representations and Warranties.</I>
    The representations and warranties of Biogen set forth herein
    shall be true and correct (without giving effect to any
    limitation as to &#147;materiality&#148; or &#147;Material
    Adverse Effect&#148; set forth therein) both when made and at
    and as of the Closing Date, as if made at and as of such time
    (except to the extent expressly made as of an earlier date, in
    which case as of such date), except where the failure of such
    representations and warranties to be so true and correct
    (without giving effect to any limitation as to
    &#147;materiality&#148; or &#147;Material Adverse Effect&#148;
    set forth therein) does not have, and is not reasonably likely
    to have, individually or in the aggregate, a Material Adverse
    Effect on Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Performance of Obligations of
    Biogen.</I> Biogen shall have performed, or complied with, in
    all material respects all obligations required to be performed
    or complied with by it under this Agreement at or prior to the
    Closing Date.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>No Material Adverse Change.</I> No
    Material Adverse Change of Biogen shall have occurred since the
    date of this Agreement and be continuing.
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">50
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>Biogen Rights Agreement.</I> The
    Biogen Rights issued pursuant to the Biogen Rights Agreement
    shall not have become non-redeemable, exercisable, distributed
    (separately from Biogen Common Stock) or triggered pursuant to
    the terms of such agreement.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>Officer&#146;s Certificate.</I> IDEC
    shall have received an officer&#146;s certificate duly executed
    by each of the Chief Executive Officer and Chief Operating
    Officer of Biogen to the effect that the conditions set forth in
    <I>Sections&nbsp;6.3(a), (b), (c)</I> and <I>(d)</I> have been
    satisfied.
    </FONT></TD>
</TR>

</TABLE>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;VII</FONT></B>

<P align="center">
<B><FONT size="2">TERMINATION, AMENDMENT AND WAIVER</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination.</I>
This Agreement may be terminated at any time prior to the
Effective Time by action taken or authorized by the Board of
Directors of the terminating party or parties, and (except in
the case of <I>Sections&nbsp;7.1(e)</I> or <I>7.1(f)</I>)
whether before or after the IDEC Stockholder Approval or the
Biogen Stockholder Approval:
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;by mutual written consent of Biogen and
    IDEC, if the Board of Directors of each so determines;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;by written notice of either Biogen or
    IDEC (as authorized by the Board of Directors of Biogen or IDEC,
    as applicable):
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;if the Merger shall not have been
    consummated by December&nbsp;15, 2003 (the <I>&#147;Outside
    Date&#148;</I>), <I>provided, however,</I> that if (x)&nbsp;the
    Effective Time has not occurred by such date by reason of
    nonsatisfaction of any of the conditions set forth in
    <I>Section&nbsp;6.1(b)</I> or <I>Section&nbsp;6.1(c)</I> and
    (y)&nbsp;all other conditions set forth in
    <I>Article&nbsp;VI</I> have heretofore been satisfied or waived
    or are then capable of being satisfied, then such date shall
    automatically be extended to January&nbsp;31, 2004 (which shall
    then be the <I>&#147;Outside Date&#148;</I>); <I>provided,
    however</I> that the right to terminate this Agreement under
    this <I>Section&nbsp;7.1(b)(i)</I> shall not be available to any
    party whose failure to fulfill in any material respect any
    obligation of such party, or satisfy any condition to be
    satisfied by such party, under this Agreement has caused or
    resulted in the failure of the Effective Time to occur on or
    before the Outside Date;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(ii)&nbsp;if a Governmental Entity of competent
    jurisdiction shall have issued an order, decree or ruling or
    taken any other action (including the failure to have taken an
    action), in any case having the effect of permanently
    restraining, enjoining or otherwise prohibiting the Merger,
    which order, decree, ruling or other action is final and
    nonappealable; <I>provided however,</I> that the right to
    terminate this Agreement under this
    <I>Section&nbsp;7.1(b)(ii)</I> shall not be available to a party
    which has not used commercially reasonable efforts to resist,
    resolve or lift as applicable (as contemplated by
    <I>Section&nbsp;5.4</I>) any such order, decree, ruling or other
    action;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iii)&nbsp;if the IDEC Stockholder Approval shall
    not have been obtained at the IDEC Stockholders&#146; Meeting,
    or at any adjournment or postponement thereof, at which the vote
    was&nbsp;taken; <I>provided, however,</I> that the right to
    terminate this Agreement under this
    <I>Section&nbsp;7.1(b)(iii)</I> shall not be available to IDEC
    if the failure to obtain the IDEC Stockholder Approval shall
    have been caused by the action or failure to act of IDEC and
    such action or failure to act constitutes a material breach by
    IDEC of this Agreement;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(iv)&nbsp;if the Biogen Stockholder Approval
    shall not have been obtained at the Biogen Stockholders&#146;
    Meeting, or at any adjournment or postponement thereof, at which
    the vote was taken; <I>provided, however,</I> that the right to
    terminate this Agreement under this
    <I>Section&nbsp;7.1(b)(iv)</I> shall not be available to Biogen
    if the failure to obtain the Biogen Stockholder Approval shall
    have been caused by the action or failure to act of Biogen and
    such action or failure to act constitutes a material breach by
    Biogen of this Agreement;
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">51
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;by Biogen (as authorized by its Board of
    Directors) upon a breach of any representation, warranty,
    covenant or agreement on the part of IDEC set forth in this
    Agreement, or if any representation or warranty of IDEC shall
    have become untrue, in either case such that the conditions set
    forth in <I>Section&nbsp;6.2(a)</I> or
    <I>Section&nbsp;6.2(b)</I> would not be satisfied as of the time
    of such breach or as of the time such representation or warranty
    shall have become untrue, <I>provided</I> that if such
    inaccuracy in IDEC&#146;s representations and warranties or
    breach by IDEC is curable by IDEC prior to December&nbsp;12,
    2003 through the exercise of its commercially reasonable
    efforts, then Biogen may not terminate this Agreement under this
    <I>Section&nbsp;7.1(c)</I> prior to December&nbsp;12, 2003,
    <I>provided</I> that IDEC continues to exercise its commercially
    reasonable efforts to cure such inaccuracy or breach through
    December&nbsp;11, 2003 (it being understood that Biogen may not
    terminate this Agreement pursuant to this
    <I>Section&nbsp;7.1(c)</I> if it shall have materially breached
    this Agreement (and such breach shall not have been cured) or if
    such inaccuracy or breach by IDEC is reasonably capable of being
    cured, and is in fact cured, prior to December&nbsp;12, 2003);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;by IDEC (or authorized by its Board of
    Directors) upon a breach of any representation, warranty,
    covenant or agreement on the part of Biogen set forth in this
    Agreement, or if any representation or warranty of Biogen shall
    have become untrue, in either case such that the conditions set
    forth in <I>Section&nbsp;6.3(a)</I> or
    <I>Section&nbsp;6.3(b)</I> would not be satisfied as of the time
    of such breach or as of the time such representation or warranty
    shall have become untrue, <I>provided</I> that if such
    inaccuracy in Biogen&#146;s representations and warranties or
    breach by Biogen is curable by Biogen prior to December&nbsp;12,
    2003 through the exercise of its commercially reasonable
    efforts, then IDEC may not terminate this Agreement under this
    <I>Section&nbsp;7.1(d)</I> prior to December&nbsp;12, 2003,
    <I>provided</I> that Biogen continues to exercise its
    commercially reasonable efforts to cure such inaccuracy or
    breach through December&nbsp;11, 2003 (it being understood that
    IDEC may not terminate this Agreement pursuant to this
    <I>Section&nbsp;7.1(d)</I> if it shall have materially breached
    this Agreement (and such breach shall not have been cured) or if
    such inaccuracy or breach by Biogen is reasonably capable of
    being cured, and is in fact cured, prior to December&nbsp;12,
    2003);
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;by Biogen (as authorized by its Board of
    Directors), at any time prior to IDEC Stockholder Approval, if
    IDEC, the IDEC Board of Directors or any committee thereof, for
    any reason, shall have (i)&nbsp;failed to hold the IDEC
    Stockholders&#146; Meeting in accordance with
    <I>Section&nbsp;5.1(b)</I> on or before December&nbsp;11, 2003,
    (ii)&nbsp;failed to include in the Joint Proxy Statement
    distributed to the stockholders of IDEC its recommendation
    without modification or qualification in favor of the IDEC
    Charter Amendment and the Share Issuance, (iii)&nbsp;withdrawn
    its recommendation in favor of the IDEC Charter Amendment or the
    Share Issuance, (iv)&nbsp;amended, modified or qualified such
    recommendation in a manner adverse to the interests of Biogen,
    (v)&nbsp;failed to reconfirm such recommendation within ten
    (10)&nbsp;calendar days of receipt of a written request from
    Biogen to do so, (vi)&nbsp;approved or recommended any
    Alternative Transaction, or (vii)&nbsp;failed, within ten
    (10)&nbsp;business days after any tender or exchange offer
    relating to IDEC Common Stock commenced by any third party shall
    have been first published, sent or given, to have sent to its
    security holders a statement disclosing that the Board of
    Directors of IDEC recommends rejection of such tender offer or
    exchange offer;&nbsp;or
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;by IDEC (as authorized by its Board of
    Directors), at any time prior to Biogen Stockholder Approval, if
    Biogen, the Biogen Board of Directors or any committee thereof,
    for any reason, shall have (i)&nbsp;failed to hold the Biogen
    Stockholders&#146; Meeting in accordance with
    <I>Section&nbsp;5.1(b)</I> on or before December&nbsp;11, 2003,
    (ii)&nbsp;failed to include in the Joint Proxy Statement
    distributed to the stockholders of Biogen its recommendation
    without modification or qualification that such stockholders
    adopt and approve this Agreement and approve the Merger,
    (iii)&nbsp;withdrawn its recommendation in favor of the adoption
    and approval of this Agreement or the Merger, (iv)&nbsp;amended,
    modified or qualified such recommendation in a manner adverse to
    the interests of IDEC, (v) failed to reconfirm such
    recommendation within ten (10)&nbsp;calendar days of receipt of
    a written request from IDEC to do so, (vi)&nbsp;approved or
    recommended any Alternative Transaction, or (vii)&nbsp;failed,
    within ten (10)&nbsp;business days after any tender or exchange
    offer relating to Biogen Common Stock commenced by any third
    party shall have been first published, sent or given, to have
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">52
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">sent to its security holders a statement
    disclosing that the Board of Directors of Biogen recommends
    rejection of such tender offer or exchange offer.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Effect
of Termination.</I> In the event of termination of this
Agreement as provided in <I>Section&nbsp;7.1</I> hereof, this
Agreement shall forthwith become void and there shall be no
liability on the part of any of the parties, except (i)&nbsp;as
set forth in <I>Sections&nbsp;5.3(b), 5.6</I>, this
<I>Section&nbsp;7.2</I> and <I>Section&nbsp;7.3</I>, as well as
<I>Article&nbsp;VIII</I> (other than <I>Section&nbsp;8.1</I>) to
the extent applicable to such surviving sections, each of which
shall survive termination of this Agreement, and (ii)&nbsp;that
nothing herein shall relieve any party from liability for any
willful breach of any representation or warranty of such party
contained herein or any breach of any covenant or agreement of
such party contained herein. No termination of this Agreement
shall affect the obligations of the parties contained in the
CDA, all of which obligations shall survive termination of this
Agreement in accordance with their terms.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Payments.</I>
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;<I>Payment by Biogen.</I> In the event
    that this Agreement is terminated by Biogen pursuant to any of
    <I>Sections&nbsp;7.1(b)(i)</I> or <I>7.1(b)(iv)</I>, or by IDEC
    pursuant to any of <I>Sections&nbsp;7.1(b)(i), 7.1(b)(iv),
    7.1(d)</I> or <I>7.1(f)</I>, Biogen shall promptly, but in no
    event later than two (2)&nbsp;business days after the date of
    such termination (subject to the further provisions of this
    <I>Section&nbsp;7.3(a)</I>), pay IDEC a fee equal to
    $230,000,000 in immediately available funds (the <I>&#147;Biogen
    Termination Fee&#148;</I>); <I>provided,</I> that
    (w)&nbsp;notwithstanding the foregoing, no Biogen Termination
    Fee shall be payable in the case of a termination by IDEC
    pursuant to <I>Section&nbsp;7.1(f)</I> if (1)&nbsp;IDEC&#146;s
    right to terminate this Agreement pursuant to such
    <I>Section&nbsp;7.1(f)</I> arises solely out of the Board of
    Directors of Biogen having effected a Change of Recommendation
    as permitted by and in compliance with clause&nbsp;(1) of
    <I>Section&nbsp;4.2(d)(ii)</I> and (2)&nbsp;following the date
    hereof and prior to such termination no Person shall have made
    to Biogen or its stockholders, or publicly announced, a
    proposal, offer or indication of interest relating to an
    Alternative Transaction with respect to Biogen, (x)&nbsp;in the
    case of a termination pursuant to <I>Section&nbsp;7.1(b)(i)</I>,
    the Biogen Termination Fee shall be payable only if following
    the date hereof and prior to such termination, any Person shall
    have made to Biogen or its stockholders, or publicly announced,
    a proposal, offer or indication of interest relating to any
    Acquisition (as defined in <I>Section&nbsp;7.3(d)</I>) with
    respect to Biogen and within twelve (12)&nbsp;months following
    termination of this Agreement, an Acquisition of Biogen is
    consummated or Biogen enters into an agreement providing for an
    Acquisition of Biogen, such fee payment to be made concurrently
    with the earlier of the consummation of such Acquisition or the
    execution of such agreement, as applicable, (y)&nbsp;in the case
    of termination pursuant to <I>Section&nbsp;7.1(b)(iv)</I>,
    unless, at the time of such termination, IDEC had the right to
    terminate this Agreement pursuant to <I>Section&nbsp;7.1(f)</I>
    (in which event the Biogen Termination Fee shall be payable (if
    applicable) as if this Agreement were terminated by IDEC
    pursuant to <I>Section&nbsp;7.1(f)</I>), fifty percent (50%) of
    the Biogen Termination Fee shall be payable (not later than two
    (2)&nbsp;business days after such termination) only if following
    the date hereof and prior to the Biogen Stockholders&#146;
    Meeting, any Person shall have made to Biogen or its
    stockholders, or publicly announced, a proposal, offer or
    indication of interest relating to an Acquisition with respect
    to Biogen, with the remaining fifty percent (50%) of the Biogen
    Termination Fee becoming payable only if the first fifty percent
    (50%) of the Biogen Termination Fee shall have become payable
    pursuant to this clause&nbsp;(y) and, within twelve
    (12)&nbsp;months following the termination of this Agreement, an
    Acquisition of Biogen is consummated or Biogen enters into an
    agreement providing for an Acquisition of Biogen, in which event
    such remaining fifty percent (50%) of the Biogen Termination Fee
    shall be payable concurrently with the earlier of the
    consummation of such Acquisition or the execution of such
    agreement, and (z)&nbsp;in the case of a termination under
    <I>Section&nbsp;7.1(d)</I>, the Biogen Termination Fee shall be
    payable only if following the date hereof and prior to such
    termination, any Person shall have made to Biogen or its
    stockholders, or publicly announced, a proposal, offer or
    indication of interest relating to an Alternative Transaction
    with respect to Biogen.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;<I>Payment by IDEC.</I> In the event
    that this Agreement is terminated by IDEC pursuant to any of
    <I>Sections&nbsp;7.1(b)(i)</I> or <I>7.1(b)(iii)</I>, or by
    Biogen pursuant to any of <I>Sections&nbsp;7.1(b)(i),
    7.1(b)(iii), 7.1(c)</I> or <I>7.1(e)</I>, IDEC shall promptly,
    but in no event later than two (2)&nbsp;business days
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">53
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">after the date of such termination (subject to
    the further provisions of this <I>Section&nbsp;7.3(b)</I>), pay
    Biogen a fee equal to $230,000,000 in immediately available
    funds (the <I>&#147;IDEC Termination Fee&#148;</I>);
    <I>provided,</I> that (w)&nbsp;notwithstanding the foregoing, no
    IDEC Termination Fee shall be payable in the case of a
    termination by Biogen pursuant to <I>Section&nbsp;7.1(e)</I> if
    (1)&nbsp;Biogen&#146;s right to terminate this Agreement
    pursuant to such <I>Section&nbsp;7.1(e)</I> arises solely out of
    the Board of Directors of IDEC having effected a Change of
    Recommendation as permitted by and in compliance with
    clause&nbsp;(2) of <I>Section&nbsp;4.2(d)(ii)</I> and
    (2)&nbsp;following the date hereof and prior to such termination
    no Person shall have made to IDEC or its stockholders, or
    publicly announced, a proposal, offer or indication of interest
    relating to an Alternative Transaction with respect to IDEC,
    (x)&nbsp;in the case of a termination pursuant to
    <I>Section&nbsp;7.1(b)(i)</I>, the IDEC Termination Fee shall be
    payable only if following the date hereof and prior to such
    termination, any Person shall have made to IDEC or its
    stockholders, or publicly announced, a proposal, offer or
    indication of interest relating to any Acquisition with respect
    to IDEC and within twelve (12)&nbsp;months following termination
    of this Agreement, an Acquisition of IDEC is consummated or IDEC
    enters into an agreement providing for an Acquisition of IDEC,
    such fee payment to be made concurrently with the earlier of the
    consummation of such Acquisition or the execution of such
    agreement, as applicable, (y)&nbsp;in the case of termination
    pursuant to <I>Section&nbsp;7.1(b)(iii)</I>, unless, at the time
    of such termination, Biogen had the right to terminate this
    Agreement pursuant to <I>Section&nbsp;7.1(e)</I> (in which event
    the IDEC Termination Fee shall be payable (if applicable) as if
    this Agreement were terminated by Biogen pursuant to
    <I>Section&nbsp;7.1(e)</I>), fifty percent (50%) of the IDEC
    Termination Fee shall be payable (not later than two
    (2)&nbsp;business days after such termination) only if following
    the date hereof and prior to the IDEC Stockholders&#146;
    Meeting, any Person shall have made to IDEC or its stockholders,
    or publicly announced, a proposal, offer or indication of
    interest relating to an Acquisition with respect to IDEC, with
    the remaining fifty percent (50%) of the IDEC Termination Fee
    becoming payable only if the first fifty percent (50%) of the
    IDEC Termination Fee shall have become payable pursuant to this
    clause&nbsp;(y) and, within twelve (12)&nbsp;months following
    the termination of this Agreement, an Acquisition of IDEC is
    consummated or IDEC enters into an agreement providing for an
    Acquisition of IDEC, in which event such remaining fifty percent
    (50%) of the IDEC Termination Fee shall be payable concurrently
    with the earlier of the consummation of such Acquisition or the
    execution of such agreement, and (z)&nbsp;in the case of a
    termination under <I>Section&nbsp;7.1(c)</I>, the IDEC
    Termination Fee shall be payable only if following the date
    hereof and prior to such termination, any Person shall have made
    to IDEC or its stockholders, or publicly announced, a proposal,
    offer or indication of interest relating to an Alternative
    Transaction with respect to IDEC.
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;<I>Interest and Costs; Other
    Remedies.</I> All payments under this <I>Section&nbsp;7.3</I>
    shall be made by wire transfer of immediately available funds to
    an account designated by the party to receive payment. Each of
    IDEC and Biogen acknowledges that the agreements contained in
    this <I>Section&nbsp;7.3</I> are an integral part of the
    transactions contemplated by this Agreement and that, without
    these agreements, the other party hereto would not enter into
    this Agreement; accordingly, if IDEC or Biogen, as the case may
    be, fails to pay in a timely manner the amounts due pursuant to
    this <I>Section&nbsp;7.3</I> and, in order to obtain such
    payment, the other party hereto makes a claim that results in a
    judgment against the party failing to pay for the amounts set
    forth in this <I>Section&nbsp;7.3</I>, the party so failing to
    pay shall pay to the other party its reasonable costs and
    expenses (including reasonable attorneys&#146; fees and
    expenses) in connection with such suit, together with interest
    on the amounts set forth in this <I>Section&nbsp;7.3</I> at the
    rate of interest per annum publicly announced by JP Morgan Chase
    Bank as its prime rate at its principal office in New York City,
    as in effect on the date such payment was required to be made.
    Payment of the fees described in this <I>Section&nbsp;7.3</I>
    shall not be in lieu of damages incurred in the event of breach
    of this Agreement, subject to <I>Section&nbsp;7.2.</I>
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>Certain Definitions.</I> For the
    purposes of this <I>Section&nbsp;7.3</I> only,
    <I>&#147;Acquisition,&#148;</I> with respect to a party hereto,
    shall mean any of the following transactions (other than the
    Merger or any Transaction Event): (i)&nbsp;a merger,
    consolidation, business combination, recapitalization,
    liquidation, dissolution or similar transaction involving the
    party pursuant to which the stockholders of the party
    immediately preceding such transaction hold less than sixty
    percent (60%) of the aggregate equity
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">54
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">interests in the surviving or resulting entity of
    such transaction or any direct or indirect parent thereof,
    (ii)&nbsp;a sale or other disposition by the party or its
    Subsidiaries of assets representing in excess of forty percent
    (40%) of the aggregate fair market value of the consolidated
    assets of the party and its Subsidiaries immediately prior to
    such sale, or (iii)&nbsp;the acquisition by any Person or group
    (including by way of a tender offer or an exchange offer or
    issuance by the party or such Person or group), directly or
    indirectly, of beneficial ownership or a right to acquire
    beneficial ownership of shares representing in excess of forty
    percent (40%) of the voting power of the then outstanding shares
    of capital stock of the party.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendment.</I>
Subject to compliance with Applicable Law, this Agreement may be
amended by the parties at any time before or after the IDEC
Stockholder Approval or the Biogen Stockholder Approval;
<I>provided, however,</I> that after the Biogen Stockholder
Approval, there may not be, without further approval of the
stockholders of Biogen, any amendment of this Agreement that
changes the amount or the form of the consideration to be
delivered to the holders of Biogen Common Stock hereunder, or
which by law otherwise expressly requires the further approval
of such stockholders. This Agreement may not be amended except
by an instrument in writing signed on behalf of each of the
parties hereto and duly approved by the parties&#146; respective
Boards of Directors or a duly designated committee thereof.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Extension;
Waiver.</I> At any time prior to the Effective Time, a party
may, subject to the proviso of <I>Section&nbsp;7.4</I> (and for
this purpose treating any waiver referred to below as an
amendment), (a)&nbsp;extend the time for the performance of any
of the obligations or other acts of the other parties,
(b)&nbsp;waive any inaccuracies in the representations and
warranties of the other parties contained in this Agreement or
in any document delivered pursuant to this Agreement or
(c)&nbsp;waive compliance by the other party with any of the
agreements or conditions contained in this Agreement. Any
agreement on the part of a party to any such extension or waiver
shall be valid only if set forth in an instrument in writing
signed on behalf of such party. Any extension or waiver given in
compliance with this <I>Section&nbsp;7.5</I> or failure to
insist on strict compliance with an obligation, covenant,
agreement or condition shall not operate as a waiver of, or
estoppel with respect to, any subsequent or other failure.
</FONT>

<P align="center">
<B><FONT size="2">ARTICLE&nbsp;VIII</FONT></B>

<P align="center">
<B><FONT size="2">GENERAL PROVISIONS</FONT></B>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Nonsurvival
of Representations and Warranties.</I> None of the
representations and warranties in this Agreement or in any
instrument delivered pursuant to this Agreement shall survive
the Effective Time. This <I>Section&nbsp;8.1</I> shall not limit
the survival of any covenant or agreement of the parties in the
Agreement which by its terms contemplates performance after the
Effective Time.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Notices.</I>
All notices, requests, claims, demands and other communications
under this Agreement shall be in writing and shall be deemed
given if delivered personally, sent via facsimile (receipt
confirmed) or sent by a nationally recognized overnight courier
(providing proof of delivery) to the parties at the following
addresses (or at such other address for a party as shall be
specified by like notice):
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;if to Biogen to:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Biogen, Inc.
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">14 Cambridge Center
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Cambridge, Massachusetts 02142
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Fax No: 617-679-2838
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Attention: General Counsel
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">55
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">with a copy to:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Skadden, Arps, Slate, Meagher&nbsp;&#38; Flom LLP
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">One Beacon Street
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Boston, MA 02108
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Fax No.: (617)&nbsp;573-4822
    </FONT></TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="7%"></TD>
    <TD width="83%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD><FONT size="2">Attention:</FONT></TD>
    <TD align="left">
    <FONT size="2">Louis A. Goodman,&nbsp;Esq.
    </FONT></TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Kent A. Coit,&nbsp;Esq.
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;if to IDEC or Merger Sub, to it at:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">IDEC Pharmaceuticals Corporation
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">3030 Callan Road
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">San&nbsp;Diego, California 92121
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Fax No: (858)&nbsp;431-8786
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Attention: Office of the General Counsel
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">with a copy to:
    </FONT></TD>
</TR>

</TABLE>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Pillsbury Winthrop LLP
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">101 West Broadway, Suite&nbsp;1800
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">San&nbsp;Diego, CA 92101
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Fax No: (619)&nbsp;236-1995
    </FONT></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">Attention: David R. Snyder,&nbsp;Esq.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Definitions.</I>
For purposes of this Agreement:
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(a)&nbsp;An <I>&#147;Affiliate&#148;</I> of any
    Person means another Person that directly, or indirectly through
    one or more intermediaries, controls, is controlled by, or is
    under common control with, such first Person, where
    &#147;control&#148; means the possession, directly or
    indirectly, of the power to direct or cause the direction of the
    management policies of a Person, whether through the ownership
    of voting securities, by contract, as trustee or executor, or
    otherwise;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(b)&nbsp;An <I>&#147;Alternative
    Transaction&#148;</I> with respect to a party hereto, shall mean
    any of the following transactions (other than any Transaction
    Event): (i)&nbsp;any transaction or series of related
    transactions with one or more third Persons involving:
    (A)&nbsp;any purchase from such party or acquisition by any
    Person or &#147;group&#148; (as defined under Section&nbsp;13(d)
    of the Exchange Act and the rules and regulations thereunder) of
    more than a ten percent (10%) interest in the total outstanding
    voting securities of such party or any of its Subsidiaries or
    any tender offer or exchange offer that if consummated would
    result in any Person or group beneficially owning ten percent
    (10%) or more of the total outstanding voting securities of such
    party or any of its Subsidiaries or any merger, consolidation,
    business combination or similar transaction involving such party
    or any of its Subsidiaries, or (B)&nbsp;any sale, lease (other
    than in the ordinary course of business consistent with past
    practice), exchange, transfer, license (other than in the
    ordinary course of business consistent with past practice),
    acquisition or disposition of more than ten percent (10%) of the
    assets of such party or any of its Subsidiaries, taken as a
    whole, or (ii)&nbsp;any liquidation or dissolution of such party;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(c)&nbsp;An <I>&#147;Alternative Transaction
    Proposal&#148;</I> shall mean any offer or proposal relating to
    an Alternative Transaction;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(d)&nbsp;<I>&#147;Contract&#148;</I> shall mean
    any written, oral or other agreement, contract, subcontract,
    settlement agreement, lease, binding understanding, instrument,
    note, option, bond, mortgage, indenture, trust document, loan or
    credit agreement, warranty, purchase order, license, sublicense,
    insurance policy, benefit plan or legally binding commitment or
    undertaking of any nature, as in effect as of the date hereof or
    as may hereinafter be in effect;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(e)&nbsp;<I>&#147;Environmental Laws&#148;</I>
    means any and all federal, state, foreign, interstate, local or
    municipal laws, rules, orders, regulations, statutes,
    ordinances, codes, decisions, injunctions, orders,
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">56
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">decrees, requirements of any Governmental Entity,
    any and all common law requirements, rules and bases of
    liability regulating, relating to or imposing liability or
    standards of conduct concerning pollution, Hazardous Materials
    or protection of human health, safety or the environment, as
    currently in effect and includes the Comprehensive Environmental
    Response, Compensation and Liability Act, 42&nbsp;U.S.C.
    &#167;&nbsp;9601 <I>et&nbsp;seq</I>., the Hazardous Materials
    Transportation Act, 49&nbsp;U.S.C. &#167;&nbsp;1801
    <I>et&nbsp;seq</I>., the Resource Conservation and Recovery Act,
    42&nbsp;U.S.C. &#167;&nbsp;6901 <I>et&nbsp;seq</I>., the Clean
    Water Act, 33&nbsp;U.S.C. &#167;&nbsp;1251 <I>et&nbsp;seq</I>.,
    the Clean Air Act, 42&nbsp;U.S.C. &#167;&nbsp;7401
    <I>et&nbsp;seq</I>., the Toxic Substances Control Act,
    15&nbsp;U.S.C. &#167;&nbsp;2601 <I>et&nbsp;seq</I>., the Federal
    Insecticide, Fungicide and Rodenticide Act, 7&nbsp;U.S.C.,
    &#167;&nbsp;136 <I>et&nbsp;seq</I>., Occupational Safety and
    Health Act 29&nbsp;U.S.C. &#167;&nbsp;651 <I>et&nbsp;seq.</I>
    and the Oil Pollution Act of 1990, 33&nbsp;U.S.C.
    &#167;&nbsp;2701 <I>et&nbsp;seq</I>., as such laws have been
    amended or supplemented, and the regulations promulgated
    pursuant thereto, and all analogous state or local statutes;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(f)&nbsp;<I>&#147;Environmental
    Liabilities&#148;</I> with respect to any Person means any and
    all liabilities of or relating to such Person or any of its
    Subsidiaries (including any entity which is, in whole or in
    part, a predecessor of such Person or any of such Subsidiaries),
    which (i)&nbsp;arise under or relate to matters covered by
    Environmental Laws and (ii)&nbsp;relate to actions occurring or
    conditions existing on or prior to the Closing Date;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(g)&nbsp;<I>&#147;Good Clinical
    Practice&#148;</I> shall mean the then current standards for
    clinical trials for pharmaceuticals, as set forth in the FDCA
    and applicable regulations promulgated thereunder, as amended
    from time to time, and such standards of good clinical practice
    as are required by the regulatory authorities of the European
    Union and other organizations and governmental agencies in any
    other countries in which the products of Biogen or IDEC, as the
    case may be, are sold or intended to be sold, to the extent such
    standards are not less stringent than in the United States;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(h)&nbsp;<I>&#147;Good Manufacturing
    Practice&#148;</I> shall mean the regulatory requirements for
    current good manufacturing practices promulgated by the FDA
    under the FDCA and under the Public Health Service Act and the
    regulations promulgated thereunder, as the same may be amended
    from time to time, and such standards of good manufacturing
    practice as are required by the applicable regulatory
    authorities of the European Union and other organizations and
    governmental agencies in countries in which the products of
    Biogen or IDEC, as the case may be, are manufactured or sold, or
    intended to be manufactured or sold, to the extent such
    standards are not less stringent than in the United States;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(i)&nbsp;<I>&#147;Hazardous Materials&#148;</I>
    means any materials or wastes, defined, listed, classified or
    regulated as hazardous, toxic, a pollutant, a contaminant or
    dangerous in or under any Environmental Laws which include
    petroleum, petroleum products, friable asbestos, urea
    formaldehyde, radioactive materials and polychlorinated
    biphenyls;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(j)&nbsp;<I>&#147;Intellectual Property&#148;</I>
    shall mean trademarks, service marks, brand names, certification
    marks, logos and slogans, commercial symbols, business name
    registrations, domain names, trade dress and other indications
    of origin, the goodwill associated with the foregoing and
    registrations in any domestic or foreign jurisdiction of, and
    applications in any such jurisdiction to register, the
    foregoing, including any extension, modification or renewal of
    any such registration or application; inventions, discoveries,
    ideas and biological materials, whether patentable or not, in
    any domestic or foreign jurisdiction; patents, applications for
    patents (including, without limitation, divisions, continuations
    in part and renewal applications), and any renewals, extensions,
    supplementary protection certificates or reissues thereof, in
    any such jurisdiction; research and development data (including
    without limitation the results of research into and development
    of drug or biologic-based products and drug delivery systems),
    formulae, know-how, technical information, designs, procedures,
    laboratory notebooks, trade secrets and confidential information
    and rights in any domestic or foreign jurisdiction to limit the
    use or disclosure thereof by any Person; writings and other
    works, whether copyrightable or not, in any such jurisdiction;
    computer software; and registrations or applications for
    registration of copyrights in any domestic or foreign
    jurisdiction, and any renewals or extensions thereof; and any
    similar intellectual property or proprietary rights;
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">57
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(k)&nbsp;<I>&#147;Knowledge&#148;</I> of any
    Person which is not an individual means, with respect to a
    specified matter, the actual knowledge of any of such
    Person&#146;s executive officers, general counsel or any other
    officer having primary responsibility for such matter and, in
    the case of IDEC, includes the actual knowledge of IDEC in-house
    IP counsel and, in the case of Biogen, includes the actual
    knowledge of Biogen in-house IP counsel;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(l)&nbsp;<I>&#147;Material Adverse
    Change&#148;</I> or <I>&#147;Material Adverse Effect&#148;</I>
    means, when used with respect to IDEC or Biogen, any change,
    event, violation, inaccuracy, circumstance or effect (any such
    item, an <I>&#147;Effect&#148;</I>) that, individually or when
    taken together with all other Effects that have occurred prior
    to the date of determination of the occurrence of the Material
    Adverse Change or Material Adverse Effect, is or is reasonably
    likely (i)&nbsp;to be materially adverse to the business, assets
    (including intangible assets), capitalization, financial
    condition or results of operations of such party and its
    Subsidiaries taken as a whole or (ii)&nbsp;to impair in any
    material respect the ability of such party to perform its
    obligations under this Agreement or prevent or materially delay
    the consummation by such party of any of the transactions
    contemplated hereby; <I>provided, however,</I> that, in no event
    shall any of the following, alone or in combination, be deemed
    to constitute, nor shall any of the following be taken into
    account in determining whether there has been or will be, a
    Material Adverse Change with respect to, or a Material Adverse
    Effect on, any party: (A) any change in such party&#146;s stock
    price or trading volume, in and of itself, (B) any failure by
    such party to meet published revenue or earnings projections, in
    and of itself, (C)&nbsp;any Effect that results from changes
    affecting the biotechnology or pharmaceutical industries
    generally (to the extent such Effect is not disproportionate
    with respect to such party in any material respect) or the
    United States economy generally (to the extent such Effect is
    not disproportionate with respect to such party in any material
    respect), (D)&nbsp;any Effect that results from changes
    affecting general worldwide economic or capital market
    conditions (to the extent such Effect is not disproportionate
    with respect to such party in any material respect), or
    (E)&nbsp;any stockholder class action litigation arising from
    allegations of a breach of fiduciary duty relating to this
    Agreement;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(m)&nbsp;<I>&#147;New IDEC Annual Bonus
    Plan&#148;</I> means an annual cash incentive bonus plan in a
    form to be agreed to by Biogen and IDEC following the date
    hereof, approved by the Board of Directors of IDEC and submitted
    to IDEC stockholders in accordance with the provisions of
    <I>Sections&nbsp;5.1</I> and <I>5.20</I> hereof, which plan is
    intended to allow the grant of awards by IDEC which qualify as
    performance based compensation under the provisions of
    Section&nbsp;162(m) of the Code;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(n)&nbsp;<I>&#147;New IDEC Stock Plan&#148;</I>
    means an omnibus equity plan in a form to be agreed to by Biogen
    and IDEC following the date hereof, approved by the Board of
    Directors of IDEC and submitted to IDEC stockholders in
    accordance with the provisions of <I>Sections&nbsp;5.1</I> and
    <I>5.20</I> hereof, pursuant to which 22,500,000&nbsp;shares of
    IDEC Common Stock shall be reserved for issuance;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(o)&nbsp;<I>&#147;Person&#148;</I> means an
    individual, corporation, partnership, limited liability company,
    joint venture, association, trust, unincorporated organization
    or other entity;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(p)&nbsp;a <I>&#147;Subsidiary&#148;</I> of any
    Person means another Person, an amount of the voting securities,
    other voting ownership or voting partnership interests of which
    is sufficient to elect at least a majority of its Board of
    Directors or other governing body is (or, if there are no such
    voting interests, more than fifty percent (50%) of the equity
    interests of which are) owned directly or indirectly by such
    first Person;
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(q)&nbsp;a <I>&#147;Superior Proposal&#148;</I>
    with respect to a party, means an unsolicited, bona fide written
    Alternative Transaction Proposal made by a third party to
    acquire, directly or indirectly, pursuant to a tender offer,
    exchange offer, merger, consolidation or other business
    combination, (A)&nbsp;all or substantially all of the assets of
    such party or (B)&nbsp;all of the outstanding voting securities
    of such party and as a result of which the stockholders of such
    party immediately preceding such transaction would hold less
    than fifty percent (50%) of the aggregate equity interests in
    the surviving or resulting entity of such transaction (or its
    ultimate parent), which the Board of Directors of such party has
    in good faith determined (taking into account, among other
    things, (1)&nbsp;the advice of its outside legal counsel
    </FONT></TD>
</TR>

</TABLE>

<P align="center"><FONT size="2">58
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    <FONT size="2">and its financial adviser, (2)&nbsp;all terms of
    such Alternative Transaction Proposal and this Agreement (as it
    may be proposed to be amended by the other party hereto), and
    (3)&nbsp;the relative impact of the transaction contemplated by
    such Alternative Transaction Proposal and this Agreement (as it
    may be proposed to be amended by the other party hereto) on the
    other Persons whose interests the Board may consider under
    Applicable Law) to be more favorable, from a financial point of
    view, to such party&#146;s stockholders (in their capacities as
    stockholders) than the terms of this Agreement (as it may be
    proposed to be amended by the other party hereto) and to be
    reasonably capable of being consummated on the terms proposed,
    taking into account, all other legal, financial, regulatory and
    other aspects of such Alternative Transaction Proposal and the
    Person making such Alternative Transaction Proposal;
    <I>provided, however,</I> that no Alternative Transaction
    Proposal will be deemed to be a Superior Proposal if
    consummation of the transaction contemplated thereby is subject
    to a financing condition and the financing required to satisfy
    such condition is not fully committed pursuant to a commitment
    letter or similar instrument from one or more institutions which
    are capable of providing such financing;&nbsp;and
    </FONT></TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(r)&nbsp;<I>&#147;Transaction Event&#148;</I>
    means any (i) (A)&nbsp;amendment, modification or termination
    of, or waiver, release, consent or other action under or in
    respect of, any agreement listed in <I>Section&nbsp;8.3(r)</I>
    of the Biogen Disclosure Schedule (each, a
    <I>&#147;Section&nbsp;8.3(r) Agreement&#148;</I>), or
    (B)&nbsp;any agreement or transaction (including any transaction
    described in <I>Section&nbsp;4.1(b)</I>) involving Biogen or any
    of its Subsidiaries, to the extent such amendment, modification,
    termination, waiver, release, consent or other action, or such
    agreement or transaction, is in connection with (x)&nbsp;Biogen
    or any of its Subsidiaries obtaining a waiver or consent with
    respect to the Merger under any Section&nbsp;8.3(r) Agreement or
    (y)&nbsp;Biogen or any of its Subsidiaries acquiring or
    disposing of any asset, right or license which is the subject of
    any Section&nbsp;8.3(r) Agreement, or (ii)&nbsp;any act, failure
    to act, event, effect, change, violation, termination, breach,
    circumstance, occurrence or state of facts in connection with,
    or resulting or arising from, any Transaction Event as defined
    in clause&nbsp;(i) above.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Terms
Defined Elsewhere.</I> The following terms are defined elsewhere
in this Agreement, as indicated below:
</FONT>

<CENTER>
<TABLE width="60%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="82%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="7%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="7%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="center" nowrap><B><FONT size="1">Term</FONT></B></TD>
    <TD></TD>
    <TD colspan="3" align="center" nowrap><B><FONT size="1">Section</FONT></B></TD>
</TR>

<TR>
    <TD align="center" nowrap><HR size="1" noshade></TD>
    <TD></TD>
    <TD colspan="3" align="center" nowrap><HR size="1" noshade></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Acquisition
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">7.3(d)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Affiliate
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Agreement
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Preamble</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Alternative Transaction
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(b)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Alternative Transaction Proposal
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(c)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Applicable Laws
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(g)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Approval
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(i)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Articles of Merger
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.3</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Audit
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(j)(xi)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Benefit Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(i)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Preamble</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Balance Sheet
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(d)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Benefit Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(i)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen By-Laws
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Charter
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Collaboration
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(k)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Collaboration Partner
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(k)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Common Stock
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Defined Contribution Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(b)(v)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Designated Directors
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.14(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="center"><FONT size="2">59
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<CENTER>
<TABLE width="60%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="78%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="9%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="9%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="center" nowrap>&nbsp;</TD>
    <TD></TD>
    <TD colspan="3" align="center" nowrap>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Disclosure Schedule
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Material Contract
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(r)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Option
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.1(d)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Organizational Documents
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Permits
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(g)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Pharmaceutical Products
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(k)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Preferred Stock
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Purchase Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.1(d)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Rights
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Rights Agreement
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen SEC Documents
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(d)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Significant Subsidiaries
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(a)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Stock Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Stockholder Approval
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(c)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Stockholders&#146; Meeting
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.1(b)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Subsidiary Organizational Documents
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Biogen Termination Fee
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">7.3(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Certificates
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.2(b)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">CDA
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">4.2(c)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Chapter&nbsp;110F
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(n)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Change of Recommendation
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">4.2(d)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Closing
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Closing Date
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Code
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Recitals</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Continuing Employees
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.12(c)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Contract
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(d)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Dissenting Holder
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.1(g)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Effect
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(l)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Effective Time
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.3</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Environmental Laws
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(e)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Environmental Liabilities
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(f)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">ERISA
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(i)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">ERISA Affiliate
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(i)(v)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Exchange Act
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(c)(v)(B)(2)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Exchange Agent
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.2(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Exchange Fund
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.2(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Exchange Ratio
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.1(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Existing Benefits Commitments
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">4.1(b)(xi)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">FDA
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(g)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">FDCA
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(g)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Form&nbsp;S-4
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(e)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Funded Retirement Plan
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(i)(v)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">GAAP
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(d)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Good Clinical Practice
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(g)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Good Manufacturing Practice
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(h)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="center"><FONT size="2">60
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<CENTER>
<TABLE width="60%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="78%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="9%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="9%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="center" nowrap>&nbsp;</TD>
    <TD></TD>
    <TD colspan="3" align="center" nowrap>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Governmental Entity
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(c)(v)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Hazardous Materials
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">HSR Act
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(c)(v)(A)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Indemnified Parties
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.5(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Intellectual Property
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(j)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Preamble</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC 1988 Stock Option Plan
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Balance Sheet
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(d)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Benefit Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(i)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC By-Laws
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Certificate of Amendment
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.8</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Charter
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Charter Amendment
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.8</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Collaboration
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(k)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Collaboration Partner
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(k)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Common Stock
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.1(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Defined Contribution Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(v)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Designated Directors
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.14(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Disclosure Schedule
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Material Contract
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(r)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Options
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Organizational Documents
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Preferred Stock
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Permits
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(g)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Pharmaceutical Products
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(k)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Purchase Plan
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Rights
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Rights Agreement
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC SEC Documents
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(d)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Significant Subsidiaries
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(a)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Stock Plans
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Stockholder Approval
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(c)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Stockholders&#146; Meeting
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.1(b)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Subsidiary Organizational Documents
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(a)(ii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">IDEC Termination Fee
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">7.3(b)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Joint Proxy Statement
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(c)(v)(B)(1)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Knowledge
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(k)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Liens
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(a)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Material Adverse Change
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(l)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Material Adverse Effect
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(l)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">MBCL
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Recitals</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Merger
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Recitals</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Merger Consideration
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">2.1(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Merger Sub
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Preamble</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">New IDEC Annual Bonus Plan
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(m)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="center"><FONT size="2">61
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<CENTER>
<TABLE width="60%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="82%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="7%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="7%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="center" nowrap>&nbsp;</TD>
    <TD></TD>
    <TD colspan="3" align="center" nowrap>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">New IDEC Stock Plan
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(n)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Outside Date
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">7.1(b)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Permitted Acquisition
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">4.1(b)(iv)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Person
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(o)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Public Health Service Act
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(k)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Restraints
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">6.1(d)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Rule&nbsp;145 Affiliates
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.15</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">SEC
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(a)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Secretary of State
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.3</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Section&nbsp;8.3(r) Agreement
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(r)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Section&nbsp;203
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.2(n)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Securities Act
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(d)(i)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Share Issuance
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">Recitals</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Subsidiary
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(p)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Superior Proposal
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(q)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Surviving Corporation
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">1.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Tax Authority
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(j)(xi)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Tax Return
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(j)(xi)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Taxes
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(j)(xi)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Transaction Event
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">8.3(r)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom" bgcolor="#EEEEEE">
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Transition Team
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">5.10(a)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left:10px; text-indent:-10px">
    <FONT size="2">Voting Debt
    </FONT></DIV>
    </TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="right" valign="bottom" nowrap><FONT size="2">3.1(b)(iii)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Interpretation.</I>
When a reference is made in this Agreement to an Article,
Section or Exhibit, such reference shall be to an Article or
Section of, or an Exhibit to, this Agreement unless otherwise
indicated. Whenever the words &#147;include,&#148;
&#147;includes&#148; or &#147;including&#148; are used in this
Agreement, they shall be deemed to be followed by the words
&#147;without limitation.&#148; The words &#147;hereof,&#148;
&#147;herein&#148; and &#147;hereunder&#148; and words of
similar import when used in this Agreement shall refer to this
Agreement as a whole and not to any particular provision of this
Agreement. All terms defined in this Agreement shall have the
defined meanings when used in any certificate or other document
made or delivered pursuant hereto unless otherwise defined
therein. The definitions contained in this Agreement are
applicable to the singular as well as the plural forms of such
terms and to the masculine as well as to the feminine and neuter
genders of such term. Any agreement, instrument or statute
defined or referred to herein or in any agreement or instrument
that is referred to herein means such agreement, instrument or
statute as from time to time amended, modified or supplemented,
including (in the case of agreements or instruments) by waiver
or consent and (in the case of statutes) by succession of
comparable successor statutes and references to all attachments
thereto and instruments incorporated therein. References to a
Person are also to its permitted successors and assigns.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Counterparts.</I>
This Agreement may be executed in two or more counterparts, all
of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been
signed by each of the parties and delivered to the other parties.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Entire
Agreement; No Third-Party Beneficiaries.</I> This Agreement
(including the CDA and the documents and instruments referred to
herein) (a)&nbsp;constitutes the entire agreement, and
supersedes all prior agreements and understandings, both written
and oral, among the parties with respect to the subject matter
of this Agreement and (b)&nbsp;except for the provisions of
<I>Section&nbsp;5.5</I> (which are
</FONT>

<P align="center"><FONT size="2">62
</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="left">
<FONT size="2">intended to benefit the Indemnified Parties,
including Indemnified Parties who or which are not parties
hereto), is not intended to confer upon any Person other than
the parties any rights or remedies.
</FONT>
</DIV>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Governing
Law.</I> This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable
principles of conflict of laws thereof, <I>provided,
however,</I> that the Merger shall be governed by the MBCL.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Assignment.</I>
Neither this Agreement nor any of the rights, interests or
obligations under this Agreement shall be assigned, in whole or
in part, by operation of law or otherwise by either of the
parties hereto without the prior written consent of the other
party. Any assignment in violation of the preceding sentence
shall be void. Subject to the preceding two sentences, this
Agreement will be binding upon, inure to the benefit of, and be
enforceable by, the parties and their respective successors and
assigns.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Consent
to Jurisdiction.</I> Each of the parties hereto
(a)&nbsp;consents to submit itself to the personal jurisdiction
of any federal court located in the State of Delaware or any
Delaware state court in the event any dispute arises out of this
Agreement or any of the transactions contemplated by this
Agreement, (b)&nbsp;agrees that it will not attempt to deny or
defeat such personal jurisdiction by motion or other request for
leave from any such court, and (c)&nbsp;agrees that it will not
bring any action relating to this Agreement or any of the
transactions contemplated by this Agreement in any court other
than a federal court sitting in the State of Delaware or a
Delaware state court.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Headings,
etc.</I> The headings and table of contents contained in this
Agreement are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severability.</I>
If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule of law or
public policy, all other conditions and provisions of this
Agreement shall nevertheless remain in full force and effect,
insofar as the foregoing can be accomplished without materially
affecting the economic benefits anticipated by the parties to
this Agreement. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced,
the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as
closely as possible to the fullest extent permitted by
Applicable Law in an acceptable manner to the end that the
transactions contemplated hereby are fulfilled to the extent
possible.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Failure
or Indulgence Not Waiver; Remedies Cumulative.</I> No failure or
delay on the part of any party hereto in the exercise of any
right hereunder shall impair such right or be construed to be a
waiver of, or acquiescence in, any breach of any representation,
warranty or agreement herein, nor shall any single or partial
exercise of any such right preclude any other or further
exercise thereof or of any other right. All rights and remedies
existing under this Agreement are cumulative to, and not
exclusive of, any rights or remedies otherwise available.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Waiver
of Jury Trial.</I> EACH OF IDEC, MERGER SUB AND BIOGEN HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR
OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HERBY OR THE ACTIONS OF IDEC, MERGER
SUB OR BIOGEN IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE
AND ENFORCEMENT OF THIS AGREEMENT.
</FONT>

<P align="center"><FONT size="2">63
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">SECTION&nbsp;8.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Specific
Performance.</I> The parties agree that irreparable damage would
occur and that the parties would not have any adequate remedy at
law in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms or
were otherwise breached. It is accordingly agreed that the
parties shall be entitled to an injunction or injunctions to
prevent breaches of this Agreement and to enforce specifically
the terms and provisions of this Agreement in any federal court
located in the State of Delaware or in Delaware state court,
this being in addition to any other remedy to which they are
entitled at law or in equity.
</FONT>

<P align="center">
<FONT size="2">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
</FONT>

<P align="center"><FONT size="2">64
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">IN WITNESS WHEREOF, Biogen, IDEC and Merger Sub
have caused this Agreement to be executed under seal by their
respective officers thereunto duly authorized, all as of the
date first written above.
</FONT>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="53%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="29%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="2%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="5" align="left" valign="top">
    <FONT size="2">BIOGEN, INC.
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">By:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left" valign="top">
    <FONT size="2">/s/ James C. Mullen
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left"><HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>

</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Name:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">James C. Mullen
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Title:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Chairman, Chief Executive Officer<BR>
    and President
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">By:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left" valign="top">
    <FONT size="2">/s/ Michael Phelps
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left"><HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>

</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Name:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Michael Phelps
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Title:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Vice President and Treasurer
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="5" align="left" valign="top">
    <FONT size="2">IDEC PHARMACEUTICALS<BR>
    CORPORATION
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left" valign="top">
    <FONT size="2">By:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">/s/ William H. Rastetter
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left"><HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>

</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Name:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">William H. Rastetter, Ph.D.
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Title:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Chairman of the Board and<BR>
    Chief Executive Officer
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="5" align="left" valign="top">
    <FONT size="2">BRIDGES MERGER CORPORATION
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left" valign="top">
    <FONT size="2">By:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">/s/ William H. Rastetter
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left"><HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>

</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Name:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">William H. Rastetter, Ph.D.
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Title:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">President
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left" valign="top">
    <FONT size="2">By:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">/s/ John M. Dunn
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left"><HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>

</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Name:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">John M. Dunn
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Title:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Treasurer
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="center"><FONT size="2">65
</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="right">
<B><FONT size="2">EXHIBIT A</FONT></B>
</DIV>

<P align="center">
<U><FONT size="2">FORM OF IDEC CERTIFICATE OF
AMENDMENT</FONT></U>

<P align="center">
<FONT size="2">CERTIFICATE OF AMENDMENT
</FONT>

<DIV align="center">
<FONT size="2">TO THE
</FONT>
</DIV>

<DIV align="center">
<FONT size="2">CERTIFICATE OF INCORPORATION
</FONT>
</DIV>

<DIV align="center">
<FONT size="2">OF
</FONT>
</DIV>

<DIV align="center">
<FONT size="2">IDEC PHARMACEUTICALS CORPORATION
</FONT>
</DIV>

<P align="center">
<HR size="1" width="78%" align="center" noshade>

<P align="center">
<FONT size="2">Pursuant to Section&nbsp;242 of the General
</FONT>

<DIV align="center">
<FONT size="2">Corporation Law of the State of Delaware
</FONT>
</DIV>

<P align="center">
<HR size="1" width="78%" align="center" noshade>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">IDEC Pharmaceuticals Corporation, a Delaware
corporation (hereinafter called the &#147;Corporation&#148;),
does hereby certify as follows:
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U><FONT size="2">FIRST</FONT></U><FONT size="2">:
Article&nbsp;I of the Corporation&#146;s Amended and Restated
Certificate of Incorporation is hereby amended to read in its
entirety as set forth below:
</FONT>

<P align="center">
<FONT size="2">ARTICLE&nbsp;I
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">The name of this corporation is &#147;BIOGEN
    IDEC, INC.&#148;
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U><FONT size="2">SECOND</FONT></U><FONT size="2">:
Article&nbsp;IV(A) of the Corporation&#146;s Amended and
Restated Certificate of Incorporation is hereby amended to read
in its entirety as set forth below:
</FONT>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT size="2">(A)&nbsp;Classes of Stock. The Corporation is
    authorized to issue two classes of stock to be designated,
    respectively, &#147;Common Stock&#148; and &#147;Preferred
    Stock.&#148; The total number of shares which the Corporation is
    authorized to issue is One Billion Eight Million (1,008,000,000)
    shares. One Billion (1,000,000,000) shares shall be Common
    Stock, par value $0.0005&nbsp;per share, and Eight Million
    (8,000,000) shares shall be Preferred Stock, par value
    $0.001&nbsp;per share.
    </FONT></TD>
</TR>

</TABLE>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U><FONT size="2">THIRD</FONT></U><FONT size="2">: The foregoing
amendments were duly adopted in accordance with Section&nbsp;242
of the General Corporation Law of the State of Delaware.
</FONT>

<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT size="2">IN WITNESS WHEREOF, the Corporation has caused
this Certificate to be duly executed in its corporate name this
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2003.
</FONT>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0">

<TR>
    <TD width="57%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="25%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="2%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="5" align="left" valign="top">
    <FONT size="2">IDEC PHARMACEUTICALS<BR>
    CORPORATION
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD colspan="9"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left" valign="top">
    <FONT size="2">By:&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="left" valign="top">
    <HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Name:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">William H. Rastetter, Ph.D.
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Title:
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top">
    <FONT size="2">Chairman of the Board and<BR>
    Chief Executive Officer
    </FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>

</TABLE>
</CENTER>

<P align="center"><FONT size="2">A-1
</FONT>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
